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ABSTRACT 
Background.  The extraordinary variability of HIV poses a major obstacle to HIV vaccine 
development. The effectiveness of a vaccine is likely to vary in different populations infected 
with different HIV subtypes, unless innovative vaccine immunogens are developed to protect 
against the range of HIV diversity. Artificial sequences such as group M consensus have been 
designed to reduce the genetic distance between a vaccine strain and contemporary circulating 
viruses. Recently developed vaccine immunogens, mosaic sequences, extend this concept to 
additionally contain potential T cell epitope (PTE) variants. The degree to which peptides 
based on these immunogens are recognised in HIV-infected populations with a high degree of 
viral diversity has not been evaluated. An example of such a country is Cameroon, which is 
home to multiple HIV subtypes and recombinants. Given the potential impact of HIV 
diversity on vaccine development, it is particularly important that molecular epidemiological 
surveillance is continued in HIV diversity hotspots such as Cameroon. 
Methods. HIV-1 genetic diversity was characterised in 59 plasma samples from HIV-infected 
blood donors from Cameroon. HIV gag (n=50) and nef (n=55) sequences, as well as near full 
length sequences of virus genomes (n=9) were generated, and phylogenetic analyses were 
performed. Maximum likelihood phylogenetic trees were constructed from these sequences, 
following either complete removal of recombinant sequence fragments or the division of 
recombinant sequences into their constituent fragments by a blinded fully exploratory screen 
for recombination using RDP3 for gag and nef sequences. To investigate the extent of the 
diversity on T cell immune response magnitude, breadth, specificity and immunodominance 
patterns, peptides based on HIV-1 group M consensus Gag and Nef were used in IFN-γ 
ELISPOT assays in (i) Cameroonians, where individuals infected with the predominant 
CRF02_AG subtype (n=24) were compared with those infected with diverse non-CRF02_AG 
subtypes (n=22); and (ii) in a multiclade epidemic, namely Cameroon, compared with a 
monoclade C epidemic, South Africa (n=44). In addition, HIV-specific responses to PTE Gag 
and Nef in HIV-infected individuals from Cameroon (n=32) were investigated to determine 
whether the detection of responses differed compared to consensus M responses.  
Results. All gag and nef sequences clustered within HIV-1 group M. Thirteen subtypes were 
identified, with circulating recombinant form CRF02_AG dominating the epidemic, 
Abstract Page xv 
 
accounting for 50% of the studied infections. In addition, 22% of the studied viruses had gag 
and nef genes from viruses belonging to different subtypes. Interestingly, five gag sequences 
(10%) and three (5%) nef sequences were neither obviously recombinant nor easily 
classifiable into any of the known HIV-1 group M subtypes. Of the full genome sequences 
generated, three were too divergent to be placed within any existing subtype or CRF grouping 
and therefore remain unclassified. IFN-γ ELISPOT data showed that there were no 
differences in the magnitude and breadth of responses to peptides based on HIV-1 group M 
consensus Gag and Nef for CRF02_AG and non-CRF02_AG-infected individuals. In contrast, 
the specificity of epitope targeting was markedly different between the two groups, with less 
than one third of peptides (11/28) commonly recognised. Furthermore, only one peptide was 
commonly recognised by at least three individuals from both AG and non-CRF02_AG 
groups, indicating poor immunodominance. For Nef, more than half of all targeted peptides 
(14/27) were recognised by both groups, and four peptides were commonly targeted by at 
least three individuals. Similar results were obtained when South Africa, representing a 
monoclade C epidemic, and Cameroon, a multiclade epidemic, were compared. The 
magnitude of responses was significantly higher (p=0.0045) for Gag when detectable 
responses to PTE peptides were compared to consensus peptides, although this was not the 
case for Nef. The breadth of responses was, however, similar when the two set of reagents 
were compared, both in Gag and Nef. Further analyses in Nef revealed that the magnitude and 
breadth of responses were similar in CRF02_AG and non-CRF02_AG-infected individuals. 
Finally, recognition of multiple variants was detected with the PTE peptide set, with up to 
five variants being recognised for particular peptides. 
Conclusion. This study confirms the widespread existence of highly divergent HIV lineages 
in Cameroon. While the genetic complexity of the Cameroonian HIV-1 epidemic has 
potentially serious implications for the design of biomedical interventions, detailed analyses 
of divergent Cameroonian HIV-1 group M lineages could be crucial for dissecting the earliest 
evolutionary steps in the emergence of HIV-1 group M. In addition, the central nature of 
HIV-1 consensus M sequences resulted in their broad recognition, but failed to identify highly 
immunodominant peptides between homogeneous and diverse HIV epidemics. Further 
refinement of these immunogens may contribute to the development of a globally relevant 
vaccine. Finally, the use of PTE peptides did not increase the breadth of T cell recognition in 
Abstract Page xvi 
 
this divergent population when compared to consensus M peptides. This underlies the need to 
include more mosaic peptides representing the variety of viruses that circulate in the region. 
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1.1 INTRODUCTION 
The Acquired Immunodeficiency Syndrome (AIDS) pandemic is more than 30 years 
old. The causative agent, human immunodeficiency virus type one (HIV-1), was discovered 
in 1983 (Barre-Sinoussi et al., 1983) and is responsible of the global epidemic. A second, 
closely-related virus was identified in 1986 in an individual in west Africa and was termed 
HIV-2 (Clavel et al., 1986). The first antiretroviral (ARV) drug, zidovudine, was used in 1986 
(Davtyan et al., 1987) and effective combination therapy in 1996 (Hogg et al., 1997). 
According to the UNAIDS 2013 report, the global face of HIV/AIDS has changed in recent 
years. The number of people living with HIV in late 2012 was estimated at 35.3 million, an 
increase of 18% compared to 2001, primarily as a result of an increase in the number of 
infected people taking antiretroviral therapy (ART), and not due to an increased infection rate, 
since the number of new infections continues to decline. There were 2.3 million new HIV 
infections in 2012, 33% fewer than in 2001. Much of this success has been recorded in the 
last four years, and can be attributed to the rapid improvement in access to ART. At the same 
time the number of AIDS deaths is also declining, with 1.6 million AIDS deaths in 2012, 
down from 2.3 million in 2005 (UNAIDS 2013). The number of newly-infected people 
continues to decline also in sub-Saharan Africa (SSA), the worst-affected region, with over 
70% of all people living with HIV in 2012, while this region accounts for only 12% of the 
world’s population (UNAIDS, 2013). Whilst differences in HIV prevalence still exist in 
different African regions, no country saw an increase in the incidence of HIV/AIDS in 2012 
(UNAIDS, 2013). Mother to child transmission (MTCT) in developing countries represents 
about 90% of HIV infections amongst children, and most of them (90%) live in SSA. Despite 
the overall reduction of HIV infections, AIDS continues to heavily influence maternal and 
infant mortality (UNAIDS, 2013). 
Besides the success in access to ARVs, there have been a number of other successes in 
the goal to reduce the burden of HIV/AIDS. Several prevention methods have proved 
efficacious in recent years. The latest data from Kisumu (Kenya) and Orange Farm (South 
Africa), sites of two randomised trials on voluntary medical male circumcision (MMC), 
demonstrated long term efficacy of this practice against HIV acquisition (Mehta et al., 2013; 
Lissouba et al., 2011). Pre-exposure prophylaxis (PrEP), which involves HIV-uninfected 
persons taking the same HIV drugs as those used to treat infected people, also showed very 
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encouraging results for HIV prevention. The first evidence that PrEP might work when 
applied locally at the site of exposure came from a clinical trial conducted in South Africa, 
which found that vaginal tenofovir gel was safe, well tolerated, and decreased the risk of 
contracting HIV by 39% in women (Abdool Karim et al., 2010). The efficacy exceeded 50% 
among participants who used the gel more consistently. The iPrEx trial subsequently revealed 
that oral tenofovir and emtricitabine, taken daily, reduced the risk of HIV infection among 
men who have sex with men by 44% (Grant et al., 2010). Furthermore, the HPTN052 study 
showed a 96% prevention of sexual transmission of HIV in heterosexual discordant couples 
when the infected sexual partner was on ART (Cohen et al., 2011). These results are 
extremely promising, as they showed that oral or local vaginal application of ARVs on a 
sustained basis, before and after exposure, may reduce the risk of HIV acquisition. 
Although full implementation of these preventive measures has the potential to 
drastically reduce the spread of HIV, they invariably face the huge challenges of cost and 
social behaviour change, including adherence. Therefore, a highly efficacious vaccine that 
would prevent HIV infection and/or progression to AIDS is urgently needed. The 
development of such a vaccine faces many challenges, including the huge genetic diversity 
the virus exhibits, the incomplete knowledge of immune correlates of an effective immune 
response against the virus, and how to generate such a response with a vaccine. 
Understanding all these challenges are of great importance in the design of an effective HIV 
vaccine. This chapter provides an overview of the key concepts in HIV biology, diversity, 
immunity and vaccine design and testing pertinent to the studies described in this thesis. 
 
1.2 HIV-1 STRUCTURE AND GENOMIC ORGANISATION 
HIV-1 is an RNA virus from the family of retroviridae which uses DNA as an 
intermediary for its replication (Coffin, 1992). The virus itself belongs to the group 
lentiviruses. [In this chapter, when mentioning HIV, we will in most cases be referring to 
HIV-1, the type responsible for the global pandemic. HIV-2 is less pathogenic than HIV-1 
and largely restricted to west Africa, with limited spread to other countries.] A number of 
other lentiviruses have been isolated from primates. For historical reasons, all lentiviruses 
isolated from humans are HIV and those isolated from simian primates are called simian 
Chapter 1: Literature review  Page 5 
 
immunodeficiency viruses or SIVs. Each viral particle, or virion, is made of a lipid bilayer 
envelope of 80-120 nm in diameter and contains two copies of the viral genome (Wain-











Figure 1.1 Structure of an HIV-1 virion. Envelope glycoproteins gp120 and gp41 are protruded 
from a lipid bilayer originated from the host cell plasma membrane. The viral core consists of two 
copies of positive single stranded RNA enclosed by the viral capsid protein p24 together with the 
reverse transcriptase and integrase enzymes required for the formation of new HIV particles (taken 
from Rubbert et al., 2011). 
 
The HIV-1 genome consists of nine genes that code for 15 proteins (Figure 1.2). Like 
other retroviruses, it has three major genes that code for the structural proteins, and in contrast 
to other retroviruses, HIV encodes six genes that are regulatory and accessory proteins, 
involved in the regulation of the viral life cycle or virion infectivity.  
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1.2.1 Structural proteins 
1.2.1.1 Gag 
The gag (group of antigen) gene codes for the 55 kD Gag protein, a molecule that 
associates with the cell membrane, and during viral assembly recruits all the viral proteins to 
form the building block of the viral particle core (Bryant et al., 1990). After budding, the Gag 
precursor is cleaved by the viral protease during the maturation of the virus into four small 
proteins called matrix (MA or p17), capsid (CA or p24), nucleocapsid (NC or p9), and p6 




Figure 1.2 A diagrammatic representation of the genetic organisation of HIV genome. The 
proviral genome is composed of nine genes that are flanked by two long terminal repeats (LTR, 5’ and 
3’). The nine open reading frames code for at least 15 proteins. The gag gene is translated into the 
structural Gag precursor that is cleaved into matrix (MA), capsid (CA), nucleocapsid (NC). The pol 
gene is translated by a -1 ribosomal frameshift as a Gag-Pol precursor polypeptide that yields the four 
enzymes Reverse Transcriptase (RT), Integrase (IN), Protease (PR) and Ribonuclease H (RNaseH) 
upon cleavage. The env gene encodes the anchor structural precursor Env, gp160, which is cleaved 
into the surface SU (gp120) and trans-membrane TM (gp41) glycoproteins. The Gag-Pol mRNAs are 
spliced to encode the regulatory (Rev, Tat) and accessory (Nef, Vpr, Vpu and Vif) proteins (taken 
from Yasutsugu and Youichi, 2011). 
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The matrix is derived from the N-terminal, myristoylated end of p55. The inner 
surface of the virion lipid bilayer is where most MA molecules remain attached and this aids 
in stabilising the particle (Gallay et al. 1995). This region of Gag also contains a nuclear 
localisation domain that facilitates the nuclear transport of the viral genome and allows HIV 
to infect non-dividing cells (Lewis et al., 1992, Fassati, 2006).  
The CA protein or p24 interacts with cellular cyclophilin A and this leads to its 
incorporation into HIV particles (Franke et al., 1994; Thali et al., 1994). Cyclophilin A is a 
cytosolic human protein involved in protein folding (Zydowsky et al., 1992). It has been 
shown that decreased levels of virion-associated cyclophilin A result in reduced virion 
infectivity (Thali et al., 1994) and decreased HIV replication (Franke and Luban, 1996). CA 
also plays a role in the incorporation of viral enzymes into the capsid via the Gag-Pol 
precursor (Bukovsky and Gottlinger, 1996; Huang and Martin, 1997).  
The NC region of Gag, also referred to as p9, is important for transmission and 
pathogenesis of the virus. It is responsible for specifically recognising the packaging signal of 
the genome, and introducing two copies of the viral genome into progeny virions (Heath et 
al., 2003; Dussupt et al., 2011). In addition, NC protein, a highly basic protein with two zinc 
fingers (Harrison and Lever, 1992), is indispensable for RNA dimerization, encapsidation and 
the initiation of reverse transcription (Lapadat-Tapolsky et al., 1993). 
The p6 protein, one of the most variable regions of Gag, is situated at its C-terminal 
domain; it mediates interactions between Gag and the accessory protein Vpr, leading to the 
incorporation of Vpr into assembling virions (Paxton et al., 1993). It has additional roles in 
the viral cycle, including binding to Tsg101 and ALIX, cellular factors important for viral 
budding from infected cells (Heath et al., 2003).  
The p24 region of Gag is relatively conserved compared to the p17 and nucleocapsid, 
and targeting of epitopes within p24 region of the HIV Gag protein have been shown to be 
associated with viral control (Zuniga et al., 2006). Overall, CD8+ T cell escape mutations in 
the Gag protein, particularly p24 epitopes, have been associated with a fitness costs to the 
virus (Ammaranond et al., 2011; Martinez-Picado et al.. 2006; Troyer et al., 2009), 
suggesting that Gag is a good target for inclusion in a vaccine. 
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1.2.1.2 Pol 
The pol (polymerase) gene codes for the expression of enzymes involved in viral 
replication (reverse transcriptase or RT), integration (integrase or INT) and maturation 
(protease or Pro) of the virion. It is expressed as a Gag-Pol precursor (Jacks et al., 1988) 
which is then cleaved to release the Pol polypeptide; the latter is then cleaved into three 
enzymes. This occurs during viral maturation and is performed by the virally-encoded 
protease (Parkin et al., 1992). Reverse transcriptase is an RNA-dependent polymerase that 
synthesises DNA from viral RNA (Zack et al., 1990). The newly formed DNA is then 
integrated into the host genome by the viral integrase (Craigie et al., 2001). The pol gene 
encodes Pro and RT, which are two major targets of ARVs (Esnouf et al., 1995; Spence et al., 
1995). In addition, pol is one the more conserved genes of HIV and is frequently targeted by 
the host immune system (Gea-Banacloche et al., 2000; Haas et al., 1998).   
1.2.1.3 Env 
The env gene encodes a 90 kDa precursor protein that undergoes post-translational 
modifications including glycosylation, to give rise to a 160 kDa glycoprotein. This protein is 
cleaved by cellular proteases to give rise to two mature proteins, the transmembrane 
glycoprotein gp41 and the surface envelope protein gp120 (Capon et al., 1991). Env is present 
on the surface of infected cells and virions as a trimer, a complex of three molecules 
(Bernstein et al., 1995). Gp120, by interacting with CD4 cell receptors and the main co-
receptors CCR5 or CXCR4, initiates the fusion process which allows the virus to enter into 
the cell (Feng et al., 1996; Deng et al., 1996). Five constant domains (C1-C5) have been 
identified in the protein, including the CD4 binding site, a target of neutralising antibodies, 
and five variable domains (V1-V5). These variable regions are the result of errors made by 
the RT enzyme and are highly immunogenic. The mutations are predominantly single base 
substitutions (Vartarian et al., 1991), suggesting that they arose as a result of 
misincorporations during RNA or DNA synthesis (Preston et al., 1988). One of these regions, 
the V3 loop, determines when HIV-1 preferentially targets T cells or macrophages (Hwang et 
al., 1991). The V3 loop also contains major neutralisation epitopes (Moore and Nara, 1991; 
Zolla-Pazner et al., 2007), along with the V1-V2 loop (Moore et al., 2013). The gp41 protein 
plays an essential role in the fusion of the virus and target cells; through this action, it 
facilitates the release of the viral contents into the cytoplasm (Camerini et al., 1990). The Env 
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protein is of particular interest in the design of an effective HIV vaccine as neutralising 
antibodies target specific regions of Env, and will likely be required to be elicited for an 
effective HIV vaccine.  
1.2.2 Regulatory Proteins 
1.2.2.1 Tat 
Tat or transactivator (p15) protein is essential for viral replication (Ruben et al., 1989). 
Tat is a transcriptional transactivator and binds to the transactivation response element (TAR) 
region of the newly formed mRNA LTR and this activates transcription (Roy et al., 1990). In 
the absence of Tat, transcription is prematurely terminated by an interruption of elongation of 
mRNA (Herrmann and Rice, 1995; Wei, et al., 1998). Tat requires a cellular co-factor, cyclin 
T, which facilitates the binding of Tat to the TAR (Wei et al., 1998).  
1.2.2.2 Rev 
Rev or regulator of viral expression, is a 13 kDa sequence-specific RNA binding 
protein (reviewed by Zapp, 1989), and functions in the cell nucleus. Like Tat and Nef, Rev is 
translated during the early phase of viral replication (Malim et al., 1989). It facilitates the 
export of mRNA which codes for Gag, Pol and Env from the nucleus to the cytoplasm (Felber 
et al., 1990), and therefore increases the expression of these proteins. It also down-regulates 
small mRNAs coding for regulatory proteins, including itself and Tat (Felber et al., 1990). 
Rev is absolutely required for HIV-1 replication; proviruses that lack Rev function are 
transcriptionally active but do not express viral late genes and thus do not produce viable 
virions (Hope et al., 1992). 
1.2.3 Accessory Proteins 
1.2.3.1 Vpr 
Vpr or viral protein regulatory (p15) is a late-synthesised protein of 96 amino acids 
that is incorporated into viral particles in approximately the same amount as Gag (Nitahara-
Kasahara et al., 2007). It plays a role in the ability of HIV to infect target cells, particularly 
non-dividing cells (Heinzinger et al., 1994). Vpr can also stop the viral cycle in G phase when 
viral replication is very active (Jowett et al., 1995). 
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1.2.3.2 Vpu 
  Vpu or viral protein unknown (p16) is a membrane protein consisting of 81 amino 
acids and is not incorporated into viral particles (Federau et al., 1996; Willbold et al., 1997). 
Vpu and Env are expressed from the same mRNA, but Vpu is translated much less efficiently 
than Env (Schwartz et al., 1990). Unlike other accessory proteins, Vpu protein is only found 
in HIV-1 and in SIV (simian immunodeficiency virus) infecting chimpanzees and gorillas 
(Gao et al., 1999). In HIV-2 and other SIVs, it is replaced by the Vpx protein (Courgnaud et 
al., 2003). Vpu forms an oligomeric complex on the membrane of the cell where it 
downregulates the expression of CD4 (Willey et al., 1992; 1992). Unlike Nef, Vpu does not 
directly downregulate CD4 from the cell surface (rather, it targets newly-made CD4 in the 
endoplasmic reticulum for degradation). It also inhibits the expression of MHC class I 
molecules (Derrien et al., 2004). Vpu can also help HIV-1 to overcome the restriction 
imposed by tetherin by antagonising its activities (Neil et al., 2008; Van Damme et al., 2008). 
Tetherin is an antiviral protein that can inhibit the cellular release of HIV (Neil et al., 2008; 
Van Damme et al., 2008).  
1.2.3.3 Vif 
Vif or virion infectivity factor is a 23 kDa protein produced late under Rev 
dependence. It is essential for viral infectivity as a deletion of this gene appears to decrease 
the virus infectivity (Kishi et al., 1992). HIV Vif counteracts the action of the antiviral 
restriction factor APOBEC3G, and prevents its incorporation into viral particles (Simon et al., 
1998). APOBEC3G is an intracellular antiviral protein that results in defective virions by 
deaminating the minus-strand of the viral genome, inducing numerous G to A mutations (Fan 
et al., 2010; Yu et al., 2004). Vif-deficient viruses incorporate APOBEC3G, making them 
non-infectious (Mariani et al., 2003). This activity is very specific as SIV Vif does not have 
the same effect in human cells (Simon et al., 1998).  
1.2.3.4 Nef    
Nef, or negative factor, is a 27 kDa protein that contains a myristol residue at its N-
terminal and is associated with the cell membrane (Welker et al., 1998). Nef is expressed in 
the early stage of viral infection and is the first viral protein to accumulate to detectable levels 
in a cell following HIV-1 infection ( Kim et al., 1989). Its plays an important role in the 
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pathogenesis of HIV-1; this has been well established in humans where individuals infected 
with a virus harbouring deletions in Nef remained asymptomatic for 10-14 years after sero-
conversion (Rhodes et al., 2000; Salvi et al., 1998; Tolstrup et al., 2006). The same 
observations were also seen in macaques where an SIV mutant with a deleted Nef had a very 
long incubation period before developing AIDS (Kirchhoff et al., 1992). Nef has multiple 
activities, including the downregulation of cell surface expression of CD4 and the activation 
of T cells, a cellular state required for optimal viral replication and the stimulation of HIV 
infectivity. Nef increases the rate of CD4 endocytosis and lysosomal degradation and 
therefore inhibits the expression of CD4 (Aiken et al., 1994; Luo et al., 1996). In addition to 
this, Nef also down-regulates CCR5 and CXCR4, to avoid superinfection of cells (Michel et 
al., 2005). Nef also downregulates surface expression of MHC class I and II molecules in 
infected cells (Schwartz et al., 1996) and this hampers antigen presentation. Nef also 
stimulates the infectivity of HIV virions. HIV-1 particles produced in the presence of Nef can 
be up to ten times more infectious than virions produced in the absence of Nef (Miller et al., 
1994). Finally, another major activity of Nef is to induce apoptosis in both infected and 
uninfected T cells. Nef induces the expression of both Fas (CD95) and the Fas ligand 
(CD95L) in infected cells, with CD95L aiding immune evasion by inducing the apoptosis of 
HIV-specific T cells (Peterlin and Trono, 2003).  
The HIV genome contains two non-coding regions located at the 5' and 3' end, which 
form the long terminal repeats (LTR; Verhoef et al., 1999; Montano et al., 1998). This region 
plays a role in the replication of the virus by regulating the expression of viral genes. The 5' 
region contains the initiation site for transcription, and binding sites for several transcription 
factors, including the TAR which allows Tat to bind to viral RNA (Verhoef et al., 1999; 
Montano et al., 1998). 
 
1.3 HIV DIVERSITY 
1.3.1 Origin of HIV 
SIVs have been identified in many species of non-human primates in Africa. Only 
African non-human primates are naturally infected with SIV, and no natural SIV infection has 
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been detected to date in monkeys living in Asia or in the new world (Aghokeng et al., 2005; 
Apetrei et al., 2005), with only one exception, isolated from a captive rhesus macaque (Hirsch 
et al., 1989). This macaque is thought to have acquired SIV in captivity by cross-species 
transmission from a SIV-infected African primate (Hirsch et al., 1989). Thus far, 40 different 
primate species present serological evidence of SIV infection (Klatt et al., 2011). Most of the 
primate hosts harbour a single SIV strain, however cross transmissions have occurred 
between species (Jin et al., 1994; Van Rensburg et al., 1998), which has given rise to new 
circulating SIV lineages (Van Heuverswyn et al., 2006). Five equidistant phylogenetic 
lineages based on phylogenetic analysis of full-length Pol protein sequences have been 
described (Hahn et al., 2000). These lentiviruses appear to cause no adverse effects in the 
majority of these primates (Hahn et al., 2000).  
The first SIV full length genome observed to have the same genetic structure as HIV-1 
was referred to as SIVcpz-gab (Huet et al., 1990). The organisation of the genome showed the 
presence of a vpu gene and the absence of the vpx gene, common to HIV-2 and most other 
SIVs. A second complete genome of a chimpanzee SIV, referred to as SIVcpz-ant, was 
characterised and found to have a similar genetic organisation to SIVcpz-gab (Vanden 
Haesevelde et al., 1996). From protein sequence comparisons, SIVcpz-ant was found to be a 
closer relation to SIVcpz-gab and to HIV-1 isolates than to members of the other four major 
phylogenetic lineages of these primate lentiviruses. After isolation of a third full length SIV 
strain, SIVcpz-us, and determining by mitochondrial DNA analysis the subspecies identity of 
all known infected chimpanzees, Gao et al. (1999) observed that one subspecies of 
chimpanzee, P.t. troglodytes, was the most probable natural ancestral host for HIV-1. 
Recently, Keele et al. (2006) confirmed that P. t. troglodytes is in fact the reservoir host of 
HIV-1 groups M and N (Figure 1.3). Using newly developed sampling techniques, up to 35% 
of individuals in some communities of wild living P. t. troglodytes were infected by the virus 
(Keele et al., 2006). 
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Figure 1.3 Cross species transmission. Maximum likelihood tree displaying the relationship between 
the four groups of HIV-1 and their SIV relatives across viral pol gene of the genome. All SIVcpz and 
SIVgor sequences are shown in black and green, respectively. The four groups of HIV-1, each of 
which represents an independent cross-species transmission, are shown in different colours. Black 
circles indicate the four branches where cross-species transmission-to-humans has occurred. White 
circles indicate two possible alternative branches on which chimpanzee-to-gorilla transmission 
occurred (taken from Sharp and Hahn, 2011). 
 
The predecessor to group M (SIVcpzptt) appears to have been a recombinant strain 
between two primate SIVs, namely red-capped mangabeys (SIVrcm) and greater spot-nosed 
monkeys (SIVgsn; reviewed by Holmes, 2001; Bailes et al., 2003). Both SIV from red-
capped mangabeys and greater spot-nosed monkeys could have infected a single chimpanzee 
host, as it is known that chimpanzees hunt smaller monkeys for food in overlapping 
geographical locations within central Africa (reviewed by Mitani and Watts, 1999). 
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Another SIV was later described in a second species of ape, western gorillas (Gorilla 
gorilla) in Cameroon. Surprisingly, this new virus (SIVgor) formed a monophyletic group 
closely related to HIV-1 group O and P (Figure 1.3), but chimpanzees were also shown to be 
the reservoir of SIV found in these gorillas (Van Heuverswyn et al., 2006). It is unclear how 
gorillas became infected, since they are strictly herbivores and are not known to have close 
contacts with other primates, especially chimpanzees (Van Heuverswyn et al., 2006). 
HIV-1 group M (Main or Major) is responsible for the global epidemic (Robertson et 
al., 2000; Hemelaar et al., 2011). For unknown reasons the group O (Outlier) has largely 
remained endemic to Cameroon where it is responsible for 1-5% of HIV-1 infections 
(Mauclere et al., 1997; Yamaguchi et al., 2004; Ayouba et al., 2001). Despite the low 
prevalence, cases have been isolated in Gabon, Equatorial Guinea, Nigeria, Benin, Ivory 
Coast, Togo, Senegal, Niger, Chad, Kenya and Zambia, as well as in France, Germany, 
Belgium, Spain, Norway and the United States, where it is thought that immigration is 
responsible for its introduction (reviewed by Quinones-Mateu et al., 2000; Roques et al., 
2002; Mauclere et al., 1997; Peeters et al., 1997). Group N (Non-M and non-O) is only found 
in Cameroon or in Cameroonian individuals (Roques et al., 2004; Simon et al., 1998; Bodelle 
et al., 2004). Group P has also only been isolated in two patients from Cameroon (Plantier et 
al., 2009; Vallari et al., 2011).  
The discovery and characterisation of SIVsmm, a SIV naturally infecting sooty 
mangabeys in west Africa (Fultz et al., 1986; Hirsch et al., 1989; Apetrei et al., 2005), and its 
remarkable identity with HIV-2, led to the hypothesis that it was the simian origin of HIV-2. 
The similarities of the organisation of the genome of these viruses, including the presence of a 
vpx gene, the geographic overlap between the epicentre of the HIV-2 epidemic and the 
habitation of the sooty mangabey (Gao et al., 1994; Hirsch et al., 1989), and the fact that 
these monkeys are regularly hunted or kept as pets (Marx et al., 1991), identified SIVsmm as 
the origin of HIV-2 (Santiago et al., 2005). 
It was largely believed that SIV was non-pathogenic in its natural host, primarily 
because the most-studied primates (sooty mangabeys and african green monkey) showed no 
signs of AIDS-related disease (Paiardini et al., 2009). However, it was found that SIVcpz, the 
progenitor of HIV-1, was pathogenic in wild chimpanzees, from a nine year study in Gombe 
National Park, Tanzania (Keele et al., 2009).  In a population of 94 individuals belonging to 
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two groups, mortality in SIV-infected chimpanzees was 10 to 16 times higher than that of 
uninfected chimpanzees, with a concomitant loss of CD4 cells in lymphatic tissues. A female 
who died less than three years after SIVcpz infection had histopathological disorders similar 
to the terminal stage of AIDS (Keele et al., 2009). Although based on limited samples, the 
results suggest that SIVcpz, like HIV-1 in humans, can cause disease in its host.  
1.3.2 Cross-species transmission from monkey to humans  
Although we do not know exactly how transmission of SIVcpz and SIVsmm to 
humans occurred, exposure to blood or secretions from infected monkeys during hunting and 
handling of bush meat represents the most likely cause of human infection (Hahn et al., 
2000). Bites from captive monkeys may also have been another possible source of 
contamination (Hahn et al., 2000). The factors that led to the emergence of the virus in 
humans are likely to be different from those that favoured its epidemic spread, such as 
behavioural and environmental factors. However, cross-species  transmission of other SIVs 
have not been identified thus far in humans, although the presence of antibodies against 
SIVmnd and SIVcol (from Colobus guereza) have been described in two individuals living in 
Cameroon, but with no virus isolated (Kalish et al., 2005; Souquiere et al., 2001). In addition, 
the transfer from apes to humans of other retroviruses has also been observed, as is the case 
for simian foamy virus (SFV) or simian T-lymphocyte virus (STLV) (Meertens et al., 2001; 
Switzer et al., 2004; Vandamme et al., 1997; Wolfe et al., 2005). Therefore, new occurrences 
of interspecies transmission by other known or even unknown SIV to humans are a distinct 
possibility (Aghokeng et al., 2006; Peeters et al., 2002). 
1.3.3 Timing of cross-species transmission to humans 
Timing of the epidemic to date reveals that HIV-1 group M is the oldest HIV lineage; 
its common ancestor can be traced to 1930, with a confidence interval ranging from 1915-
1941 (Korber et al., 2000, Salemi et al., 2001). A similar period is also estimated for HIV-1 
group O (1920, with a confidence interval from 1891-1940; Lemey et al., 2004). It is 
surprising that group O did not undergo the same spread as group M, despite their progenitors 
jumping into humans at approximately the same time. Reasons for the success of group M in 
relation to group O are poorly understood, but initial studies suggest that group O may have a 
reduced replicative and transmission fitness (Arien et al., 2005). The diversity within HIV-1 
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group N is significantly lower than for groups M and O (Roques et al., 2004; Simon et al., 
1998; Bodelle et al., 2004) , suggesting a more recent occurrence of this virus in humans, with 
its common ancestor traced to 1963 (range 1948-1977; Wertheim et al., 2009). Molecular 
clock studies traced the emergence of the HIV-2 groups A and B to 1940 and 1945, 
respectively (Lemey et al., 2003). With only two sequences to date, the common ancestor of 
HIV-1 group P cannot be accurately determined.  
1.3.4 Phylogeny of HIV 
Group M HIV can be subdivided into subtypes based on their phylogenetic 
relatedness. Currently there are nine described subtypes named A, B, C, D, F, G, H, J and K 
(Robertson et al., 2000).  Two of these, subtypes A and F, have been further subdivided into 
sub – subtypes (referred to as A1, A2 and F1, F2 respectively; Robertson et al., 2000). They 
are consistent in their phylogenetic topology in relation to each other, regardless of the section 
of their genome being compared (Archer and Robertson, 2007). Other significant clusters are 
formed by circulating recombinant forms (CRFs). These have arisen as a result of 
recombination events between divergent HIV strains within individual hosts. To qualify as a 
CRF, three epidemiologically unlinked viruses with the same mosaic genome and consistent 
phylogenetic clustering must be characterised (Robertson et al., 2000). Their number is 
constantly changing, and there are currently more than 50 CRFs (http://hiv-web.lanl.gov). 
When CRFs are found in isolated individuals, they are termed unique recombinant forms 
(URFs). 
The nine HIV group M subtypes are often referred to as being pure, recombinant-free 
lineages. However, this is misleading, as recombination is an important part of the life cycle 
of HIV (Jetzt et al., 2000; Robertson et al., 1995). The subtypes have emerged through a 
unique epidemiological history (Archer and Robertson, 2007), and their classification has 
been largely based on global sampling bias. Recently, one study observed that subtype G is 
actually a recombinant lineage involving subtypes A and J, as well as the designated 
recombinant lineage CRF02_AG (Abecasis et al., 2007). Thus, despite the rigid classification 
system, the phylogeny of HIV should be viewed as being highly dynamic in nature. The 
currently classified HIV subtypes and CRFs are representative of the viruses primarily 
responsible for the AIDS epidemic. They do not give a complete view of HIV diversity. There 
are presently many fully sequenced group M HIVs that are too divergent to be placed within 
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any existing subtype or CRF grouping, and these have remained unclassified (Carr et al., 
2010). In addition, certain inter-subtype recombinant viruses contain sequences that are of 
indeterminate origin, providing further evidence that HIV diversity is not fully represented 
under the current classification system (Carr et al., 2010). This implies that there is potentially 
far more diverse pool of HIV sequences circulating amongst humans than the classified 
subtypes and CRFs might suggest. 
1.3.5 Mechanisms of HIV diversification 
One of the most important characteristics of HIV-1 is its extreme genetic diversity. 
There are two viral mechanisms that generate HIV diversity: (1) mutations are introduced into 
viral genomes during replication, and (2) mutations are introduced by recombination between 
viral genomes. 
Mutations are introduced into the viral genome primarily due to the error prone nature 
of the viral replication enzyme, reverse transcriptase (Roberts et al., 1988). This enzyme 
introduces approximately one error for every 2000 nucleotides it incorporates (Preston et al., 
1988).  In addition, unlike the human polymerases, reverse transcriptase has no proof-reading 
activity and is therefore unable to correct these errors.  As a consequence, within an infected 
individual, no two viruses are identical. This assemblage of unique individual mutants is 
referred to as a quasispecies. 
In addition, mutations occur in HIV as a result of recombination. Recombination 
occurs during reverse transcription where the reverse transcriptase enzyme frequently 
switches between any HIV RNAs that are in close proximity (reviewed by Temin, 1993). The 
resulting proviral DNAs that are generated, and eventually integrated, will almost invariably 
be recombinant.  
The most visible result of recombination is the high number of recombinant and CRFs 
of HIV (reviewed by Peeters and Sharp, 2000). These CRFs are the results of co- and/or 
super-infections, particularly in areas where several HIV subtypes co-circulate (Hoelscher et 
al., 2002; Peeters and Sharp, 2000). Analyses of recombinant viruses had helped in 
determining the frequency of occurrence of recombination breakthrough points in different 
genes. Env has the highest frequency (34.6%), followed by gag (24.7%), pol (19.7%), 
accessory genes (11.1%), LTR (7.4%) and nef (2.5%; Robertson et al., 2000). Examples of 
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CRF structures are shown in Figure 1.4. This large number of recombinant viruses implies 
that co-infection involving divergent HIV strains is a more common phenomenon than 
previously thought (Apetrei et al., 2004; Spira et al., 2003). Several studies have reported that 
super-infections are often followed by recombination (Altfeld et al., 2002; Blackard et al., 
2002; Fang et al., 2004). However, this is usually observed in areas where several subtypes 
co-circulate, particularly in west central Africa (Gao et al., 1998; Janssens et al., 1997; Kanki 
et al., 1997; Renjifo et al., 1998). Cases of HIV-1/HIV-2 dual infection have also been 
reported, but there has been no reported case of recombination between these two viruses 
(Curlin et al., 2004; Kanki et al., 1997; Nkengasong et al., 2000). Recombination in HIV has 
also been shown to occur between isolates of different groups, or between the same subtypes 
(McVean et al., 2002). In line of this, co-infections and group M and O recombinant lineages 
have been identified, especially in Cameroon where the two groups of viruses co-circulate 
(Peeters et al., 1999; Takehisa et al., 1999; Vergne et al., 2003). The low number of full 
genomes sequenced in some areas suggests that the impact of recombination in the HIV 
epidemic is still underestimated. 
1.3.6 Origin of the HIV pandemic 
After SIV crossed species into humans, early viruses likely circulated in a very small 
population for several years before wider spread. This has been attributed to environmental, 
social and demographic factors like migrations, massive urbanisation, and mass medicine 
practices, such as non-sterile needles in vaccination campaigns (Hahn et al., 2000).  
Given that all HIV-1 viruses infecting humans fit into the same phylogenetic HIV-
1/SIVcpz/SIVgor radiation, it is likely that cross-species transmission took place in equatorial 
west Africa, and especially in south Cameroon, habitat of western gorillas and chimpanzees 
P. t. troglodytes. (Keele et al., 2006; Van Heuverswyn et al., 2007). After transmission to 
humans, HIV-1 group M began to diversify. The greatest genetic diversity of HIV-1 M in 
terms of number of subtypes and genetic diversity within subtypes has been observed in the 
western region of the Democratic Republic of Congo (DRC), suggesting that this was the 
epicentre of the epidemic (Vidal et al., 2005; Kalish et al., 2004).  
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Figure 1.4 Mosaic structures of the most dominant circulating recombinant forms in the HIV 
pandemic. Each colour represents a specific HIV-1 subtype and arrows indicate where the CRFs are 
most prevalent (taken from Hemelaar et al., 2011).  
 
 
Different variants of HIV-1 began to spread around the world from this region, and the 
heterogeneous spatial distribution of subtypes/CRFs is the result of different founder effects 
(a single introduction followed by a rapid spread), demographic factors and the displacement 
and migration of populations (Figure 1.5; Tebit and Arts, 2011).  
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Figure 1.5 Global spread of HIV groups and subtypes from the Congo basin epicenter region. 
(taken from Tebit and Arts, 2011) 
 
1.3.7 HIV-1 molecular epidemiology 
The geographical distribution of HIV-1 subtypes/CRFs is variable (Figure 1.6) 
(http://www.hiv.lanl.gov). Different HIV-1 subtypes predominate in different regions of the 
world. For example, subtype B is predominant in Europe, Australia and North America 
(Hemelaar et al., 2011). In east Africa, subtypes A, D and C predominate, while subtype C is 
the major clade in southern Africa. Recombinant subtype CRF02_AG predominates in west 
central Africa. In India, subtype C is the major circulating virus, while in southeast Asia the 
main subtypes include B and CRF01_AE. In Latin America, three main subtypes 
predominate, namely B, F and C. The greatest diversity had been observed in DRC, where 
almost all subtypes and CRFs are found (Figure 1.6; Hemelaar et al., 2011). Overall, the 
predominant viral forms in the world are subtype C (48%), A (12%), B (11%), followed by 
recombinant CRF02_AG (8%) and CRF01_AE (5%).   
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The geographical distribution of subtypes is a dynamic process; an increasing 
frequency of recombinant viruses may arise as different HIV subtypes spread across all 
continents and recombinant viruses continue to recombine (Hemelaar et al., 2011).     
 
 
Figure 1.6 Global distribution of HIV-1 subtypes and CRFs. Each pie represents the contribution 
of the particular subtype or CRF to the each world region (taken from Hemelaar et al., 2011) 
 
1.3.8 HIV diversity in Cameroon 
HIV infection in Cameroon is the main focus of this thesis. By the end of 2012, the 
prevalence of HIV infection in the adult population in Cameroon was estimated at 4.5% 
(4.1% to 4.9%), down from 5.2% in 2001 (UNAIDS, 2013). Although the prevalence is 
decreasing, it remains one of the highest in the region (UNAIDS, 2013). Cameroon is located 
in west central Africa, where the HIV-1 pandemic originated from cross-species transmission. 
Likely as a consequence of this, it has one of the most genetically diverse HIV epidemics in 
the world. This has led to Cameroon being termed the ‘Ground Zero’ of the epidemic (Carr et 
al., 2010). A number of studies have characterised HIV-1 genetic diversity in Cameroon both 
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in urban and rural areas (Zhong et al., 2002; Ndongmo et al., 2006; Njai et al., 2006; Konings 
et al., 2006; Ndembi et al., 2008; Torimiro et al., 2009). From these studies, it appears that 
HIV-1 distribution exhibits extensive diversity not only in urban settings, but also in rural 
regions and isolated remote areas. In the most extensive study to date, Carr et al. (2010) 
investigated HIV diversity in rural villages in Cameroon, demonstrated that while the 
majority (66 %) of isolates were CRF02_AG, the remainder were pure subtypes including A, 
A1, A2, F (F2 only), B, D, G, H and J and other recombinant forms such as CRF01_AE, 
CRF06_cpx, CRF11_cpx and CRF13_cpx. Another particularity of the HIV epidemic in 
Cameroon is the presence of about 10% of URFs or mosaic viruses, likely to be extant 
examples of early diverging lineages, possibly resembling the pre-epidemic viruses or 
evolutionary relics (Carr et al., 2010). The second most prevalent HIV-1 group is O, which 
accounts for 1-5% of all HIV infection in Cameroon. Furthermore, groups N and P are only 
found in Cameroon or in Cameroonian individuals (Roques et al., 2004; Simon et al., 1998; 
Bodelle et al., 2004). Inter-group recombinants have also been described in Cameroon, for 
example M/O recombinants (Peeters et al., 1999; Takehisa et al., 1999; Vergne et al., 2003). 
Although CRF02_AG is the predominant group M subtype in Cameroon, it is thought to have 
originated from DRC, where it migrated to Cameroon and the rest of the region (Faria et al., 
2011). This subtype is also characterised by its remarkable diversity, and it is believed that at 
least two lineages circulate in the country (Faria et al., 2011).  
1.3.9 Consequences of HIV-1 genetic diversity 
HIV genetic diversity has consequences for virulence, transmission, diagnosis, 
antiretroviral therapy and vaccine development.  
Several independent studies have shown that progression to AIDS may depend on 
genetic variant; For example, a large study in Uganda showed that individuals infected with 
subtype D progressed faster to AIDS than those infected with subtype A (Kaleebu et al., 
2002). Meanwhile, there was no difference in the rate of mother to child transmission between 
these two subtypes (Eshleman et al., 2001). In another study of a large Kenyan cohort, higher 
viral load and lower CD4 counts were observed in individuals infected with subtype C 
compared to subtypes A or D (Alaeus et al., 1999); however, the biological mechanism for 
this has not yet been determined (Wright et al., 2011). Contradictory results regarding the 
pathogenesis within the group M have been reported. Laurent et al. (2002) compared 
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individuals infected with CRF02_AG and non-AG subtypes, and found no difference in CD4 
decline and viral loads over time. A prospective study in Thailand showed no difference 
between the progression to disease in patients infected with CRF01_AE and those infected 
with subtype B (Amornkul et al., 1999). 
Diagnostic tests are essential for monitoring HIV infection, and need to be extremely 
sensitive. Although current tests detect all known genetic variants (type, subtype or group), 
this was not the case early in the pandemic. The first commercial tests were developed based 
on subtype B, and did not detect genetic variants from group O (Loussert-Ajaka et al., 1994). 
This suggests that monitoring of genetic variants is important, especially in west central 
African countries where there is a high genetic diversity and where new variants may easily 
emerge as a result of other zoonotic transmissions. The failure to detect the emergence of a 
new variant can have dramatic consequences, such as a breakthrough of a new epidemic.  
Another tool, quantification of viral load, is indispensable to monitor infection and the 
impact of ART. Genetic diversity may also affect this method, since it is based on molecular 
detection of viral genomes. Tests used to quantify viral load have been optimized and are now 
able to identify many genetic variants (Peeters et al., 2010; Rouet and Rouzioux, 2007). 
However, several studies have reported that commercial tests used for the detection of viral 
load are unable to properly detect or quantify viral RNA in patients infected with group O 
strains (Gueudin et al., 2003; Rouet and Rouzioux, 2007). Given the diversity of HIV-1, these 
tests require continuous updating to assess the effectiveness of primers and probes to detect 
the full spectrum of viruses.  
ART is now widely used in developing countries where non-B HIV-1 subtypes are 
predominant. HIV-1 group O and HIV-2 are naturally resistant to non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (Lal et al., 2005; Quiñones-Mateu et al., 1998). There is 
also a differing sensitivity within group M. For example, subtype F is less sensitive to certain 
NNRTIs such as the tetrahydroimidazo[4,5,1-jk] [1,4]-benzodiazepin-2-(1H)-one and -thione 
(TIBO) derivate R82913 (Apetrei et al., 1998), and some subtype G viruses are less sensitive 
to protease inhibitors such as ritonavir and saquinavir (Descamps et al., 1998). Under the 
action of ART, resistance mutations can occur, allowing virus to escape drug pressure. The 
speed at which these resistant strains emerge appears to vary amongst subtypes. For example, 
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it has been shown that subtype C viruses generated NNRTI-resistance faster than subtype B 
(Loemba et al., 2002).  
HIV genetic diversity and the ability of the virus to evade immune responses through 
genetic variation are among the major obstacles to the development of an effective HIV 
vaccine (Esparza and Osmanov, 2003; Stratov et al., 2004; Thomson et al., 2002). This 
obstacle was clearly illustrated in Altfeld et al. (2002), where it was shown that superinfection 
with a second subtype B virus was coincident with the loss of immune control. The sudden 
increase in viraemia was associated with a decline in half of the CD8+ T cell responses and 
that the declining of these responses were coupled with sequence changes relative to the 
initial virus that resulted in impaired recognition (Altfed et al., 2002). The issue of viral 
diversity leading to immune escape will be dealt with in more detail in the next section.  
 
1.4 ADAPTIVE IMMUNITY TO HIV 
1.4.1 T cell responses to HIV 
CD8+ T cells are the main effector cells during HIV infection. Their mechanisms of 
action include production of cytokines, and lysis of infected cells through perforin and 
granzyme secretion (Schmitz et al., 1999; Moore et al., 2002; Hersperger et al., 2010). Early 
studies demonstrated that HIV-infected people mount vigorous CD8+ T cell responses to the 
virus (reviewed by Mills et al., 1989; Walker and Plata, 1990), and these responses were 
considered as potential effectors for future HIV vaccines (reviewed by Berzofsky, 1991; 
Johnson and Walker, 1991). Understanding the dynamics of cellular immune responses in 
natural HIV infection in humans and SIV infection in animal models has been the topic of 
much study over the last 20 years (McMichael et al., 2000; McMichael and Rowland-Jones, 
2001; Mudd et al., 2012). These studies have provided strong evidence that CD8+ T cells are 
important in controlling virus replication during HIV infection. 
HIV-specific CD8+ T cells become detectable around 2 to 3 weeks after infection, and 
their frequency increases gradually and reaches a peak when viraemia levels decline 
(reviewed by McMichael et al., 2010). This initial CD8+ T cell response is narrow, and it is 
critical in the reduction of viral replication during primary infection (Lichterfeld et al., 2004).  
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In response to CD8+ T cell pressure, HIV mutates to escape recognition, and this has 
been observed to happen approximately 20 days post-infection, at the time of peak CD8+ T 
cell responses (Goonetilleke et al., 2009). Therefore, CD8+ T cells corresponding to the 
initial viral epitopes decrease rapidly; new CD8+ T cells recognising the mutated sequences 
may arise, leading to a new selection pressure and promoting new mutations (Soudeyns et al., 
1999). The race between the CD8+ T cell responses and the virus takes place throughout the 
asymptomatic phase of infection and leads to the exhaustion of the T cell response (Streeck et 
al., 2009). During chronic infection, HIV-specific CD8+ T cells persist at high frequencies 
and the number of epitopes targeted broadens (Addo et al., 2003), especially in people with 
progressive infection compared to those who control the infection (Pereyra et al., 2008). The 
functions of most of these cells are seriously impaired and this limits their efficacy in the 
control of HIV replication. Day et al. (2006) reported that PD-1, a negative immune-
regulatory molecule present at the surface of CD8+ T cells, is significantly upregulated. PD-1 
expression correlated with impaired HIV-specific CD8+ T cell function, as well as higher 
plasma viral load and an inverse correlation with CD4+ T cell count (Day et al., 2006). A 
small percentage (1–5%) of HIV-infected individuals experience a lack of decline of CD4+ T 
cell counts, and control of virus replication below 1000 HIV RNA copies/ml for an extended 
period of time (at least 7–10 years) in the absence of ART (reviewed by Walker and Korber, 
2001). These individuals are called long-term nonprogressors (LTNPs) (Pantaleo et al., 1995). 
Furthermore, an even smaller percentage (<1%) of individuals show control of virus 
replication below 50 HIV RNA copies/ml regardless of the length of the time of control and 
are called elite controllers (EC) (reviewed by Deeks and Walker, 2007). Study of these 
individuals has led to important insights into T cell correlates of viral control. 
1.4.2 The role of T cells in the control of HIV 
Several arguments underscore the essential role of the CD8+ T cell response in 
controlling viral replication during HIV infection. These include the parallel decrease of HIV 
viral load with the peak of CD8+ T cell response during the acute phase (Koup et al., 1994), 
the loss of control of SIV infection in macaques after removal of their CD8+ T cells (Jin et 
al., 1999; Schmitz et al., 1999) and the correlation between certain HLA class I alleles and 
better control of the infection (Pereyra et al., 2010; Fellay et al., 2007). Thus, the search for 
the characteristics of HIV-specific CD8+ T cell responses that are associated with viral 
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control, including the quantity, specificity and functional and phenotypic nature of the 
response, would certainly help with designing an effective HIV vaccine.  
The first studies on the quantity of HIV-specific T cell responses examined the 
magnitude and breadth, in an attempt to determine how these parameters were associated with 
clinical measures of disease. Addo et al. (2003), using an interferon-gamma enzyme-linked 
immunospot (IFN-γ ELISPOT) assay, screened PBMC from HIV-infected individuals from 
the US for virus-specific T cell responses using peptides spanning all HIV proteins. Despite 
broad and strong HIV-specific responses amongst these individuals, neither the breadth nor 
the magnitude of the total HIV-specific CD8+ T cell response was associated with plasma 
viral load (Addo et al., 2003). These findings were replicated in many other studies, including 
those infected with subtype C virus from southern Africa (Masemola et al., 2004). These 
studies were performed at a single time point with infected individuals at different stages of 
infection. Follow up studies using the same methodology on longitudinal samples, even those 
from early infection, also found no association with the rate of CD4 T cell decline or the 
course of disease in the first year of infection (Peretz et al., 2005; Gray et al., 2009). 
Collectively, the conclusion drown from these studies were that most HIV-infected 
individuals can mount robust CD8+ T cell IFN-γ responses and that the overall breadth and 
magnitude of these responses was not a correlate of viral control. These studies also suggested 
that other features, including the specificity (i.e. which regions of HIV were targeted) or the 
quality (eg other functions of immune cells) of the response may be important for viral 
control. 
Edwards et al. (2002) demonstrated that targeting of the HIV Gag protein was 
associated with reduced viral load. They measured T cell responses in PBMC from 
individuals in chronic HIV-1 infection after stimulation with overlapping HIV-1 peptides 
spanning the Gag, Pol, Env, and Nef proteins using the IFN-γ ELISPOT assay. The 
magnitude and breadth of T cell responses directed to Gag correlated inversely with viral load 
and directly with absolute CD4+ T cell counts (Edwards et al., 2002). No such associations 
were found with other HIV proteins. Consistent with this finding, Masemola et al. (2004) 
showed that the hierarchical targeting of the HIV Gag protein, rather than the overall 
magnitude of T cell responses to HIV proteins, was associated with viral control. In a more 
extensive study to define the relationship between the specificity of the cellular immune 
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response and viral control, Kiepiela et al. (2007) showed that a greater breadth of Gag-
specific CD8+ responses were associated with reduced viral load, while Env-specific 
responses were associated with higher viraemia. This association was independent of major 
histocompatibility complex class one (MHC-1) type and unrelated to epitope sequence 
conservation. These data serve as strong evidence that major MHC class I presentation of Gag 
peptides is an essential feature for any HIV vaccine designed to elicit optimal CD8+ T cell 
responses. Recently, these observations were extended to other HIV proteins. Budde et al. 
(2012) showed that macaques that controlled SIV replication shared durable T cell responses 
against similar regions of Nef. In addition, vaccinated groups of macaques controlled 
replication of the highly pathogenic SIV mac239 virus by means of high frequencies of CD8+ 
T cells against Vif and Nef epitopes (Mudd et al., 2012). These studies therefore suggest that 
other proteins besides Gag can also play a role in the control of viral replication, and that this 
should guide in the design of vaccine immunogens. 
All the studies mentioned above employed the IFN-γ ELISPOT assay as a general 
screening method for the quantification of the HIV-specific T cell responses. The utility of 
this assay was challenged due to the lack of efficacy of a recently conducted HIV vaccine trial 
(the STEP trial, discussed later), where despite induction of robust ELISPOT responses 
(Buchbinder et al., 2008), no efficacy was observed. This finding, plus advances in 
multiparameter flow cytometry, directed researchers to examine the immune response to HIV 
in more depth, by assessing the quality rather than the quantity of virus-specific T cell 
responses. Efforts at elucidating qualitative features of T cell responses that control viral 
replication have been done mainly by studying of individuals who control virus without ARV 
treatment. Betts et al. (2006) compared the capacity of CD8+ T cells from HIV progressors 
and nonprogressors to produce different cytokines by measuring five different functions of 
CD8+ T cells (secretion of IFN-γ, IL-2, TNF-α, MIP1β, and expression of CD107a as a 
surrogate for degranulation). Polyfunctionality, or the capacity to produce three or more 
cytokines simultaneously, was associated with control of viral replication, and nonprogressors 
consistently maintained highly functional CD8+ T cells (Betts et al., 2006). Beyond 
polyfunctionality, cytotoxicity appears to be vital to the control of HIV replication. 
Hersperger et al. (2010) measured perforin upregulation, cytokine production, and 
degranulation after stimulation with peptide pools to all HIV proteins in various HIV infected 
groups, including those who controlled and those who did not control viral replication. They 
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observed that CD8+ T cells from elite controllers produced significantly higher perforin and 
granzymes than progressors (Hersperger et al., 2010). Dissection and characterisation of 
different combination of functions in these HIV-specific T cells generated suggested that 
highly functional HIV-specific T cells were distinguished by perforin and IL-2 up regulation 
(Hersperger et al., 2010). Another qualitative feature of CD8+ T cells, namely their 
proliferative capacity, is inversely associated with viral load (Day et al., 2007). A recent study 
demonstrated that the proliferative capacity of HIV-specific CD8+ T cells correlated with 
delayed disease progression while the magnitude of IFN-γ responses did not (McKinnon et 
al., 2011). Very recently, in an effort to combine quantitative and qualitative measures of 
immunity, Riou et al. (2013) evaluated the impact of both the quantity and quality of CD8+ T 
cell responses at approximately 6 months post-infection on the viral set point at 12 months in 
a cohort of HIV-infected individuals in South Africa. A high frequency of highly functional 
Gag- and Nef-specific CD8+ T cell responses was the best predictors of a low viral set point 
(Riou et al., 2013). These findings further highlight the importance of eliciting such cells by 
vaccination to control HIV replication.  Functional avidity, the capacity of T cells to respond 
to low concentrations of peptide, and differentiation phenotype of HIV-specific T cells has 
also been examined. Mothe et al. (2012) analysed HIV Gag p24-specific T cell responses in 
controllers and non-controllers to determine the functional avidity of these responses. 
Although responses to p24 were of comparable breadth and magnitude, significantly higher 
avidity responses were observed in controllers compared to non-controllers (Mothe et al., 
2012). The phenotype of CD8+ T cells is likely to be a key parameter of viral control. Fully 
differentiated HIV-specific CD8+ effector cells were seen to be more frequently detectable in 
controlled than in progressive HIV infection (Addo et al., 2007; Northfield et al., 2007), 
whilst central memory CD8+ T cells were associated with lower viral set points in early 
infection in another study (Burgers et al., 2009). 
There are strong data to suggest that not all HLA alleles have a similar impact on HIV-
1 control. Certain HLAs have been associated with better diseases outcomes, including HLA 
B*57, B*27, B*58:01and B63 (reviewed by Kaslow et al., 2005). On the other hand, HLA 
B*35, B*58:02 and Cw*04 have been shown to negatively affect the outcome of disease 
(reviewed by Kaslow et al., 2005). Mutations in viral epitopes may result in abrogation of the 
peptide presentation by HLA. A major concern regarding this may be that escape mutants 
may accumulate at the population level, leading to a loss of recognized epitopes and vaccine-
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induced T cell responses with reduced effectiveness over time. Indeed, HIV has been shown 
to adapt at the population level in the face of immune pressure (Kawashima et al., 2009).  
Therefore, knowledge of the distribution of HLA alleles within local populations is essential 
for the development of peptide-based vaccines with large population coverage. 
1.4.3 The B cell response to HIV 
Seroconversion usually occurs 3-12 weeks after HIV infection, and the first antibodies 
to be produced are IgG targeting the gp41 region (reviewed by Liu et al., 2011). After peak 
viraemia, when viral load starts to decline, antibodies against other HIV proteins begin to 
appear, such as antibodies against gp120 in chronic infection. However, these binding 
antibodies have no detectable effect on viremia (Tomaras et al. 2008), and apparently do not 
exert any selective immune pressure on the envelope (Keele et al. 2008). It is specifically 
neutralizing antibody (NAbs) that can potentially protect against infection by blocking viral 
entry into host cells (Gallarda et al., 1992). 
NAb responses to HIV usually arise only several weeks after infection (Tomaras et al., 
2008), most are strain-specific (or autologous), and are not able to neutralise more divergent 
viruses (heterologous viruses) isolated from other individuals (Moore et al., 1994; Legrand et 
al. 1997; Moog et al., 1997; Gray et al., 2007). These autologous NAbs drive neutralisation 
escape, as evidenced by the fact that contemporaneous viruses are less sensitive to autologous 
neutralisation than earlier viruses, although later viruses remain sensitive to new NAb 
responses. Escape occurs mostly through single amino acid substitutions, insertions and 
deletions (Overbaugh and Rudensey 1992; Chackerian et al., 1997; Herrera et al., 2003; 
Bunnik et al., 2008). Some infected individuals, however, develop broadly neutralising 
antibodies (bNAb) in their serum that can neutralize primary virus isolates in a cross-clade 
manner (Gray et al., 2007; Shen et al., 2009; Scheid et al., 2009; Moore et al, 2012). Their 
development seems to correlate with greater time after infection, implying a need for antibody 
affinity maturation, as well as higher viral plasma load, suggesting a need for chronic antigen 
exposure (Sather et al., 2009; Stamatatos et al., 2009; Doria-Rose et al., 2009). Moore et al. 
(2012) analysed sequence and neutralisation data from 101 transmitted/founder subtype C 
viruses and they found that glycan at residue 332 of the Gp120 is underrepresented in 
transmitted subtype C viruses compared to chronic viruses. They subsequently identified two 
HIV-1–infected individuals who developed BCN antibodies targeting the glycan at Asn332 
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and that this glycan was absent in the initial infecting virus. Only 15 to 25% of HIV-infected 
individuals develop these bNAbs (Binley et al., 2008; Euler et al., 2010). A recent study 
demonstrated that the frequency of a subset of circulating follicular helper CD4+ T cells was 
greater in individuals that developed bNAbs (Locci et al., 2013).  
Antibodies can also mediate the clearing of the virus through their Fab fragment and in 
this case, they bind specifically to HIV antigens on the surface of HIV-infected cells and 
recruit innate immune cells such as natural killers (NK) cells by their Fc fragment (reviewed 
by Forthal et al., 2009; 2001). These cells can bind through their Fc receptor and kill the 
infected cell, and this is known as antibody dependent cell-mediated cytotoxicity (ADCC). If 
it is rather inhibition of viral replication that occurs, then this is referred to as antibody-
dependent cell-mediated virus inhibition (ADCVI). Such interactions are likely to play an 
important role in preventing or modulating HIV infections. 
1.4.4 The role of broadly neutralizing antibodies in the control of HIV 
For several years, the isolation of bNAbs has focused the attention of the scientific 
community. The first generation of these antibodies derived from individuals infected by 
HIV-1 subtype B and was limited in their breadth (Binley et al., 2004; Pantophlet et al., 2007; 
Conley et al., 1994). They targeted the CD4-binding site (CD4bs; Burton et al., 1991; 1994), 
the gp120-glycan complex (Kunert et al., 1998; Calarese et al., 2003) and the membrane-
proximal external region (MPER) of gp41 (Buchache et al., 1994; Binley et al., 2004). 
Following this, many second-generation human monoclonal antibodies, also targeting the 
glycan and MPER region but with a far greater ability to neutralise viruses from different 
subtypes have been isolated (Walker et al., 2009; Gorny et al. 2005; Wu et al., 2011; Moore 
et al., 2012). Some of these new bNAbs contain highly-mutated VH chains, underscoring the 
importance of the affinity maturation process that takes place in the development of these 
antibodies (Scheid et al., 2009; Wu et al., 2010). Naturally occuring bNAbs do not prevent or 
slow disease progression (Binley et al., 2008; Euler et al., 2010), most likely because they 
appear late during the course of infection and viral escape occurs rapidly. In addition, they 
have been difficult to induce by vaccination, largely as a result of our inability to design 
appropriate immunogens that induce a bNAb response (Wyatt et al., 1998). Current efforts to 
identify protective HIV vaccine immunogens are inspired by the results of recent passive 
immunisation studies with bNAbs, demonstrating a profound therapeutic effect in SHIV-
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infected rhesus monkeys as well as an impact on host immune responses (Barouch et al., 
2013; Shingai et al., 2013).  
1.4.5 Role of non-neutralizing antibodies in the control of HIV 
Several studies have underscored the role of ADCC/ADCVI in the prevention of SIV 
infections in the rhesus macaque model. Van Rompay et al. (1998) showed that new-born 
macaques were prevented from acquiring oral SIV after administration of non-neutralizing 
anti-SIV serum. In addition, rhesus macaques were partially protected against SIV after 
vaccination in the absence of a neutralizing antibody response (Patterson et al., 2004). More 
importantly, ADCC and ADCVI have been found to reduce viraemia both at the acute and 
chronic phases of the infection in rhesus macaques after vaccination (Gomez-Roman et al., 
2005; Hidajat et al., 2009; Xiao et al., 2010). In humans, ADCVI developed before the 
appearance of the neutralising antibody response (Tomaras et al., 2008; Forthal et al., 2001). 
Furthermore, ADCC activity was shown to be more potent in elite controllers compared to 
viraemic individuals (Lambotte et al., 2009). Finally, non-neutralizing together with vaccine-
elicited neutralizing antibodies were associated with protection against acquisition of 
infection in macaques immunised with an HIV Env mosaic vaccine (Barouch et al., 2013).  
 
1.5 HIV VACCINES 
1.5.1 HIV vaccine development 
 The development of an HIV vaccine is an enormous task. Immunisation has been 
successful in the eradication or elimination of infections of some viral diseases, such as 
smallpox, polio and measles. Many traditional vaccines have been developed using live 
attenuated forms of virus, inactivated (killed) virus or protein subunits (reviewed by Girard, 
2006). These approaches are not suitable for developing a vaccine against HIV. Attenuated 
HIV may mutate and regain its pathogenicity after inoculation (reviewed by Letvin, 2006). 
Inactive HIV on the other hand may still contain enough live viruses to pose a risk (reviewed 
by Burgers and Williamson, 2005). Finally, subunit vaccines to HIV envelope monomers 
were shown not to be protective in two large Phase III efficacy trials in humans, though 
protein boosts were used in the only "successful" trial to date (Gilbert et al., 2005; Flynn et 
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al., 2005). Thus, challenges to developing an HIV vaccine are complex and immense, and 
include the high genetic variability of the virus, the difficulty in generating broadly 
neutralising antibody responses, unknown correlates of protection, limitations of animal 
models, and the difficulty in performing large clinical trials.  
1.5.1.1 HIV latent reservoir 
To date, there have been no spontaneous cures of HIV infection and no documented 
cases of immune-mediated clearance of HIV from an infected individual. This is a result of a 
major property of the virus, that it rapidly establishes a persistent reservoir of latently infected 
memory T cells (reviewed by Haase et al., 2010). Latency occurs within days to week after 
infection and once established, cannot be eradicated (Finzi et al., 1997). This is clearly seen in 
patients on antiretroviral therapy, where the virus persists in a latent state and replication 
resumes upon treatment interruption. This viral reservoir poses a serious challenge to the 
development of an effective HIV vaccine, as such a vaccine would have to generate effective 
immune responses very quickly after infection, at relevant sites of exposure such as genital 
tissue. 
1.5.1.2 HIV genetic diversity 
Another major obstacle to the development of an effective HIV vaccine is the 
enormous genetic variability of the virus, with high numbers of subtypes and CRFs. In 
addition, co-infections and super-infections which can result in recombination between 
subtypes increase the genetic diversity. The overall variability of the virus is further 
complicated by a complex mixture of viral populations or quasispecies, closely related but not 
identical, which vary continuously under immune pressure. For example, Korber et al. (2001) 
have demonstrated that the variability of HIV within one host is comparable to the global 
variation of influenza A. The mutability of HIV readily allows it to escape the neutralising 
antibody and T cell responses of the host during the course of infection (Boutwell et al., 
2010). This phenomenon has been well documented in SIV-vaccinated macaques, where 
CD8+ T cell escape variants have led to the vaccine failure (Allen et al., 2000; Barouch et al., 
2002). More recently, to test the causal role of the vaccines tested in the RV144 trial in 
preventing certain HIV variants from infecting vaccinated individuals, Rolland et al. (2012) 
performed a sieve analysis, which compares breakthrough viruses between vaccinees and 
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individuals who received the placebo during the trial. The vaccine was 48% effective (higher 
than the overall efficacy of 31%) at preventing infection with viruses that matched the vaccine 
at amino acid position K169 (lysine) in V2. These results suggest that RV144 preferentially 
blocked viruses matching the vaccine immunogen at this residue and that responses to the Env 
V2 may not have blocked infections with viruses not matching the vaccine at K169 (Rolland 
et al., 2012). This can complicate the development of an effective vaccine in humans. 
1.5.1.3 Unknown correlates of protection 
In addition to all these obstacles, we do not know exactly what type of immune response 
should be induced to protect from HIV infection or control viral replication (Pantaleo et al., 
2004; Friedrich et al., 2008). In the absence of natural immune clearance of HIV, the search 
for immune correlates of viral control has largely been performed in the SIV macaque model 
and in individuals who control HIV replication (reviewed by Koup et al., 2011; Blankson et 
al., 2011). This does not imply that immune characteristics identified in these studies would 
provide protection if elicited by a vaccine. For example, polyfunctional cells were found to be 
associated with control of viral replication in HIV-infected individuals, but at the same time 
these polyfunctional cells are just a small fraction of the total CD8+ T cell compartment and 
are absent in many individuals who control HIV replication (reviewed by Makedonas and 
Betts, 2011).   
1.5.1.4 Animal models 
The use of SIV vaccines to protect macaque monkeys against experimental SIV 
infection provides the most reliable animal model for the testing of candidate vaccines against 
HIV available today. The pathophysiology of SIV infection in monkeys closely mimics that 
of HIV in humans (Brenchley et al., 2010; reviewed by Hartigan-O’Connor and Hirao, 2011). 
Plasma viral loads at the peak of primary SIV infection and at the set point during chronic 
SIV infection in macaques parallel those observed in HIV-infected humans (Parker et al., 
2001). However, there are features of the SIV macaque model that limit its utility. The 
challenge virus used is often homogenous, using a virus containing sequences very similar to 
the vaccine sequence, which may be more easily controlled than a heterologous challenge, 
which is more relevant to natural human HIV infection (reviewed by Wilson and Watkins, 
2009). A good illustration of the caution in the use of this model came from the the STEP 
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study (to be discussed later), where the vaccine failed in human trials, whilst it showed 
reduced viral loads in challenged macaques (McElrath et al., 2008; Buchbinder et al., 2008; 
Shiver et al., 2002). Therefore, improvement and standardisation should be made in terms of 
challenge virus, route and dose and endpoint measurement (Morgan et al., 2008) to provide 
meaningful information on whether a candidate vaccine should be advanced to human trials.  
 
 
Table 1.1 Summary of phase IIb/III HIV vaccine trials performed in humans for HIV (adapted 
from Girard et al., 2011) 
Type of vaccine Code name and place of trial Results 
Gp120 (B/B or B/E) + alum VAX003 (Americas) 
VAX004 (Thailand 
No protective efficacy observed 
Ad5-HIV-1 trivalent vaccine 
(Gag, Pol and Nef) 
STEP (Americas + Australia) 
Phambili (South Africa) 
No efficacy observed 
Enhanced rate of infection in 
uncircumcised Ad5-sero-
positive male volunteers 
Canarypox (ALVAC)-Gag, 
Pol and Env-E + gp120 B/E + 
alum 
RV144 (Thailand) 31% protective efficacy against 
HIV acquisition 
DNA-Gag, Pol and Env 
priming + Ad5-Gag, Pol and 
Env (A, B and C) boost 
HVTN505 (America) No protective efficacy observed 
 
1.5.1.5 Human efficacy trials 
  Under these conditions, HIV vaccine development and testing proceeds in an 
empirical manner. In addition, testing vaccines in humans remains the best way to evaluate 
protection against infection or control of viral replication. Since the start of HIV vaccine 
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development, more than 40 candidate vaccines have been tested in over 80 Phase I/II clinical 
trials, involving more than 10 000 healthy human volunteers (reviewed by Mascola and 
Montefiori, 2010; Ross et al., 2010). HIV vaccines that were tested in humans were first 
developed to elicit antibodies, then later to induce cellular immune responses (reviewed by 
Bansal et al., 2010). Five vaccine regimens have advanced to Phase III or IIb in humans to 
date (Table 1.1).  
The first two phase III clinical trials of an HIV vaccine were initiated in 1998. The two 
vaccines consisted of a recombinant form of the gp120 and were administrated in the attempt 
to generate neutralising antibodies. The first vaccine, AIDSVax B/B (VAX003) was trialled 
in North America and the Netherlands in men who sex with men and showed no efficacy 
(Flynn et al., 2005; Girard et al., 2005). The second vaccine, AIDSVax E/B (VAX004), 
(subtypes CRF01_AE and B) was trialled in injection drug users in Thailand. Similarly, it 
showed no protection (Pitisuttithum et al., 2006).  This was likely because gp120 monomers 
fail to elicit neutralising antibodies.  
The next large clinical trial, the STEP trial, was initiated in the late 2004 and was the 
first vaccine focusing on producing T cell immune responses. A sister trial, Phambili, was 
performed in South Africa. This will be discussed more in the next section. 
Following this, the RV144 trial was designed to test the efficacy of a prime-boost 
vaccine against HIV. This trial, which involved a canarypox vector (ALVAC) expressing HIV 
genes including env as a prime, accompanied by boosts with the same gp120 used in the 
VAX004 trial, was performed in Thailand in heterosexual men and women and resulted in a 
modest but significant 31% protection against infection in low-risk volunteers (Rerks-Ngarm 
et al., 2009). This protective effect was seen in the first year following vaccination (Rerks-
Ngarm et al., 2009). Although the vaccine provided modest protection against infection, it 
had no impact on disease progression (viral load or CD4 cell count) in vaccinated individuals 
who became infected (Haynes et al., 2012). Subsequent analyses revealed that non-
neutralising antibodies specific to the V1V2 region of Env were associated with a reduced 
risk of acquisition in vaccinated participants (Haynes et al., 2012).  
The last efficacy trial was a Phase III trial, HVTN 505. It was initiated in the USA in 
individuals at risk for HIV infection (Hammer et al., 2013). It consisted of a prime-boost 
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regimen involving three vaccinations with DNA encoding HIV subtype B gag, pol, and nef 
genes, and env gene from HIV subtypes A, B, and C, followed by an Ad5 vector-based 
vaccine candidate encoding subtype B gag and pol genes, and env from subtypes A, B, and C 
(Catanzaro et al., 2006; 2007). Vaccine and placebo were administered to 1253 and 1251 
participants respectively in a population of men or transgender women who have sex with 
men. At week 28 post administration, 27 participants in the vaccine group and 21 in the 
placebo group were diagnosed positive. This DNA/rAd5 vaccine regimen also failed to 
reduce either the rate of HIV acquisition or the viral load set point in the population studied 
(Hammer et al., 2013). 
These trials have shown that testing a vaccine candidate in humans is the best way of 
determining vaccine efficacy, as well as highlighted the difficulties in achieving such a task. 
1.5.2 T cell vaccines against HIV 
In view of the lack of success of the early development of vaccines that would elicit a 
protective neutralising antibody response, HIV vaccine development proceeded to attempt to 
induce T cell responses for protection Vaccines that elicit cellular immunity against HIV 
could be partially effective, resulting in lower virus levels, less destruction of CD4+ T cells, 
and a delay in disease progression (reviewed by Barouch, 2008; Wilson and Watkins, 2009). 
This could also lower the probability of virus transmission (Figure 1.7). The induction of 
CD8+ T cell responses could be achieved through the use of vectors, and based on this 
hypothesis, several types of HIV vaccine candidates capable of inducing T cell responses 
have been developed over the past decade. 
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Figure 1.7 Goal of an HIV vaccine. After infection with HIV, replication as determined by viral load 
continues to a point, then drops to set point and is partially maintained (dark blue). An ideal T cell 
vaccine (red) would reduce peak viral replication during the acute phase and results in lower or 
undetectable set point viral load during chronic infection (taken from Wilson and Watkins, 2009). 
 
1.5.2.1 T cell vaccine vectors 
DNA plasmid vaccines were the first to be developed (reviewed by Lu, 1998). They 
are referred to as genetic vaccines and are based on bacterial plasmids that, once injected into 
a host, express the desired antigen in situ, which leads to induction of an immune response 
(Wang et al., 1995; 1993). Because they allow the immune system to focus only on the 
immunogen, they are safe and have no risk of virulence (MacGregor et al., 1998). They 
generally elicit low magnitude of responses of short duration (reviewed by Lu et al., 1998; 
MacGregor et al., 1998; Graham et al., 2006). To address that problem, different approaches 
were explored to enhance the immunogenicity of DNA vaccines, including co-expression of 
adjuvants and different ways of administration (reviewed by Webster and Robinson, 1997; 
Hutnick et al., 2011). DNA vaccines have a great capacity to drive a CD8+ T cell responses 
when used in a prime-boost regimen, as they were found to prime cellular responses to viral 
candidate vectors well (reviewed by Paris et al., 2010; Harari et al., 2008; Goepfert et al., 
2011).  
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Live vector (viral or attenuated bacteria) recombinant vaccines were another type of T 
cell vaccine to be developed. Two viral vectors have been widely used for the development of 
HIV vaccines, namely poxviruses and adenoviruses. Live recombinant vaccine candidates for 
HIV were constructed using poxviruses as vectors, especially human non-replicating 
poxviruses such as canarypox (ALVAC; Belshe et al., 2001), the avian fowlpoxvirus (FPV; 
Kent et al., 1998), or attenuated strains of vaccinia virus, NYVAC (Tartaglia et al., 1992) and 
MVA (modified vaccinia Ankara; Amara et al., 2001; Im et al., 2004). These candidate 
vaccines were unfortunately not capable of inducing high magnitude and long lasting CD8+ T 
cell responses in humans (reviewed by Robinson, 2002). However, their immunogenicity was 
improved when used in a prime-boost strategy, when given after a DNA prime (reviewed by 
Robinson, 2002). Many other live recombinant vaccines have been developed in the past 
decade (reviewed by Excler, 2005; Sauter et al., 2005). Adenovirus (or Ad) vectors have been 
intensively explored as a vector for HIV vaccines, mostly with the goal of eliciting HIV-
specific cellular immune responses (reviewed by Lasaro and Ertl, 2009; Barouch and Nabel, 
2005). A candidate vaccine using a mixture of recombinant Ad5 vectors expressing the HIV 
gag, pol and nef genes from subtype B was tested in phase I clinical trials and found to be safe 
and immunogenic (Priddy et al., 2008). This was the vaccine used in the STEP and Phambili 
trials (see below), which unfortunately turned out to raise the risk of HIV infection Other 
alternative Ad vectors are now being developed based on less prevalent human adenovirus 
types, or on simian adenoviruses for which no pre-existing immunity exists in human 
populations (reviewed by Barouch, 2010; Dicks et al., 2012; Barouch et al., 2011; O‘Hara et 
al., 2012). Ad26 vector with an EnvA insert was found to be well tolerated in a phase 1 study 
(Baden et al., 2013), and elicited broad immune responses, including humoral and CD4+ and 
CD8+ T cell responses (Barouch et al., 2013). Similar results were obtained with Ad35 
(Ratto-Kim et al., 2012). Nonhuman Ad vectors were also shown to be well tolerated in 
chimpanzees as an alternative to Ad5 (Dicks et al., 2012).  Additional live recombinant 
vaccine candidates have also been developed using bacterial vectors, such as BCG 
(Lagranderie et al., 1997; Ami et al., 2005) and attenuated Salmonella strains (Devico et al., 
2002).  
A replication-competent viral vector that has attracted much attention recently is 
cytomegalovirus (CMV), as it can elicit potent and long lasting CD4+ and CD8+ T effector 
memory (Tem) responses (Remmerswaa et al., 2012). Tem reside in tissues and can rapidly 
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proliferate and control early virus replication (reviewed by Ahlers and Belyakov, 2010). 
Remarkable vaccine efficacy in rhesus macaques was obtained with a replicating simian 
CMV vector expressing the SIV gag, rev, tat, nef and env genes (Hansen et al., 2011). The 
vaccine efficiently induced effector memory CD4+ and CD8+ tissue-resident T cells, which 
did not protect the animals against infection following low-dose rectal challenge, but elicited 
early and profound control of virus replication, with half of the monkeys showing viral loads 
below detection level (Hansen et al., 2011). These findings were extended and clearance of 
infection was confirmed in additional vaccinated and challenged cohorts (Hansen et al., 
2013). These results have paved the way for development of a well-tolerated recombinant 
CMV candidate vaccine for humans.  
1.5.2.2 The Step and HVTN505 trials 
The Step trial was a Phase IIb study which involved 3 000 volunteers at risk of HIV 
infection, from Australia, Brazil, Canada, the Dominican Republic, Haiti, Jamaica, Peru, 
Puerto Rico and the United States (Buchbinder et al., 2008). In all these countries HIV 
subtype B is prevalent, matching the subtype of the vaccine-delivered antigens. The goal of 
the trial was to see if the vaccine could prevent HIV infection or reduce viral load in those 
who became infected. The vaccine regimen (MRKAd5 HIV-1) consisted of an Ad5 vector 
expressing the gag, pol and nef genes of HIV-1 subtype B. The Phambili trial of the same 
vaccine also entered phase IIb evaluation in South Africa, to explore whether it would also be 
effective at preventing infection from HIV subtype C, which is prevalent in southern Africa, 
and was halted prematurely after the immunisation in the Step study was stopped, due to lack 
of efficacy and a higher incidence of infections in the vaccine arm. The two trials showed that 
the vaccine failed to prevent HIV infection or lower viral load set point (Buchbinder et al., 
2008; Gray et al., 2011). However, 77% of vaccinees mounted CD8+ T cell responses to the 
vaccine, detected by ELISPOT. Intracellular cytokine staining revealed similar results, with 
73% of vaccinated individuals mounting CD8+ T cell responses. Lower magnitude CD4+ T 
cell responses were detected (Buchbinder et al., 2008). It is important to note that vaccinees 
only mounted responses to two to three epitopes and this response may not have been broad 
enough to recognise epitopes in the infecting virus (reviewed by Wilson and Watkins, 2009). 
Thus, despite the generation of T cell responses in these trials, no protection from infection or 
effect on viral load was demonstrated. However, it may be possible that greater breadth, 
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different targeting, higher magnitude, and eliciting T cells at the local site of exposure remain 
challenges to overcome for T cell-inducing vaccines.  
1.5.3 T cell vaccine design in the context of HIV diversity 
Selection of immunogens in vaccine development remains a crucial issue as we do not 
know the true extent of HIV diversity on immune responses. Various approaches have been 
taken, including the development of vaccine candidates with single natural sequences or 
sequences from multiple subtypes, centralised and mosaic sequences, and conserved epitopes.  
1.5.3.1 Single or multi-subtype vaccines 
Many vaccines have been developed with sequences that match circulating HIV 
subtypes with the hope that if effective, they can generate protection against heterologous 
subtypes (cross-clade protection). In fact, cross-clade responses or immune responses 
generated by infected individuals to heterologous HIV subtypes have been largely 
demonstrated (Zembe et al., 2011; Aidoo et al., 2008; Currier et al., 2003; Gillespie et al., 
2002; Keating et al., 2002). In an extensive study on cross-clade immune responses, Coplan et 
al. (2005) determined cellular immune responses to HIV subtypes A, B and C peptides as 
measures by IFN-γ ELISPOT assays. In a large cohort of HIV-infected individual from four 
continents, with subtype A, B and C epidemics. Cross-reactivity of cellular immune responses 
measured as the magnitude of responses to pools of peptides was observed in all HIV proteins 
tested, with Gag and Nef contributing most of the responses (Coplan et al., 2005). Further 
analyses from the same cohort extended to more HIV-infected individuals demonstrated 
similar extensive cross-reactivity among the three HIV-1 subtypes tested for Gag and Nef. In 
this larger cohort, cross-reactivity measured by the number of infected individuals who 
reacted to heterologous peptides was 99.1% between subtype C-infected individuals and 
subtype B Gag proteins, and 97.8% between subtype A infected individuals and subtype B 
Gag proteins (Gupta et al., 2006). In another study involving 39 subtype C-infected 
individuals, the magnitude and breadth of IFN-γ Gag-specific T cell responses were assessed 
for reactivity to five sets of overlapping peptides, two sets matching subtype C strains from 
South Africa and China, and three peptide sets corresponding to consensus subtypes A, B, and 
D sequences. A total of 84 peptides were recognized, of which 19 were exclusively from 
subtype C, 8 exclusively from subtype B, one peptide each from A and D and 17 were 
Chapter 1: Literature review  Page 41 
 
commonly recognized by subtypes A, B, C and D (Zembe et al., 2011). When taken together, 
these studies demonstrate that HIV-specific T cells from individuals infected with a particular 
HIV subtype can cross-recognise HIV proteins or peptides based on others HIV subtypes. 
Although these kinds of studies have their limitations, and since those immune responses 
generated in natural infection might differ from those generated by a vaccine, they may 
nevertheless reveal important insights into whether vaccine immunogens may be sufficiently 
cross-reactive in a given population with particular HIV subtypes circulating. 
The phase III/IIb STEP and Phambili trials used a vaccine based on genes from HIV-1 
subtype B (Buchbinder et al., 2008). These trials were performed in the Americas and 
Australia with a subtype B epidemic and in South Africa with a subtype C epidemic, to study 
cross-protection (Buchbinder et al., 2008; Gray et al., 2010; 2011). Unfortunately the vaccine 
was not effective, so no insights could be gained on cross-protection. Another example of a 
subtype-specific vaccine was the RV144 trial, which used in a prime-boost strategy utilising 
subtype B and CRF01_AE genes, the infecting subtypes in Thailand where the trial was 
conducted (Rerks-Ngarm et al., 2009). The latest vaccine formulation to enter a phase III/IIb 
trial contained gene sequences from subtypes A, B and C in the HVTN505 trial in the US 
(Hammer et al., 2013). The trial showed no efficacy against HIV.  
1.5.3.2 Centralised sequences 
Different strategies have been proposed to tackle the huge genetic variability of the 
HIV in vaccine immunogen design. One of these approaches is the design of centralised HIV 
sequences that are based on a subtype or on all group M viruses. This includes the most recent 
common ancestor (MCRA) sequence, which represents the ancestor from which a given 
group of sequences have descended (Doria-Rose et al., 2005; Kothe et al., 2006), the centre-
of-tree sequence (COT), which is a sequence whereby the average evolutionary distance to 
each tip of a phylogeny tree is minimised (Nickle et al., 2003; Nickle et al., 2007; Rolland et 
al., 2007), and a consensus sequence, which is a sequence that consists of the most common 
amino acid found at a given position in the group of sequences (Gaschen et al., 2002; Kothe 
et al., 2006).  
To date, there have been no vaccine trials in humans that have tested and compared the 
efficacy of these centralised immunogens in different regions of the world (IAVI, 2013). 
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However, these sequences have been tested as candidate vaccines in preclinical studies in 
animal models, and most of these data are generated with Env protein sequences. It was 
shown that BALB/c mice, when vaccinated with a DNA vaccine followed by recombinant 
vaccinia virus boost expressing consensus M gp120 and gp140, elicited T cell responses that 
targeted epitopes not only from group M Env proteins, but also from subtype B and C (Gao et 
al., 2005). In addition, Weaver et al. (2010) found a similar magnitude and breadth of 
immune responses when comparing group M consensus Env immunogens with a B/C 
recombinant virus isolate in mice. These studies and others (Kothe et al., 2006; Weaver et al., 
2006) have clearly demonstrated at least similar HIV-specific T cell responses are elicited 
compared to immunogens based on a single or multiple subtypes in mice.  
In humans, in the absence of clinical trials testing centralised sequences, numerous 
studies have characterised the immunological recognition of HIV centralised peptides in HIV-
infected individuals. In a study involving HIV subtypes B and C chronically-infected 
individuals from the US and South Africa respectively, Bansal et al. (2006) measured T cell 
immune responses to consensus Gag from subtype A, B, C and group M peptides and to 
ancestral subtype B and group M peptides using the IFN-γ ELISPOT assay. They 
demonstrated a similar broad cross-reactivity among the different peptides tested in both B 
and C epidemics. Additionally, Malhotra et al. (2007) also showed a comparable magnitude 
and breadth of immune responses among subtype-specific peptides and group M peptides, all 
based on centralised sequences. On the other hand, Frahm et al. (2008) found that group M 
peptides were less frequently targeted compared to subtype B peptides in a subtype B 
epidemic, whereas there was a similarity in the frequency of responses between group M 
reagents and subtypes C peptides in the same study involving subtype C-infected individuals. 
Similarly, a higher magnitude of HIV-specific T cell responses to consensus M Gag and Nef 
peptides was observed in Brazil in a multi-subtype epidemic (subtypes B, F1 than C; Côrtes et 
al., 2013). Overall, these studies suggest that centralised sequences, and especially group M 
peptides, were able to detect broad T cell responses. At the same time, these studies also 
emphasise the need to test centralised reagents in other epidemics, as the results generated 
from these studies may not be directly applicable to areas with different infecting subtypes or 
with a large degree of HIV diversity, such as west central Africa. One limitation of this 
approach is that centralised sequences are generated with available sequences and need 
permanent updating; many regions of the world have few sequences available.  
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1.5.3.3 Mosaic sequences 
HIV mosaic antigens are bioinformatically-optimised immunogens that maximise the 
coverage of natural variation of the virus, and also take into account the diverse major 
histocompatibility complex class haplotypes (Korber et al., 2009). They were developed by 
combining sequences from different HIV subtypes using artificial recombination methods 
designed to mimic the recombination process that occurs during natural HIV evolution 
(Fischer et al., 2007). This can be performed for a single subtype of for all the group M 
variants. Vaccines based on this approach utilise computerised algorithms to generate 
optimised sequences similar to naturally circulating HIV sequences (Fischer et al., 2007). 
They are intended to demonstrate a greater depth or coverage of HIV potential T cell epitopes 
(PTEs) for different HIV proteins (Fischer et al., 2008). Preliminary data on this approach 
suggested that mosaic approach provides enhanced coverage of 9mer peptides compared to 
the COT approach using the same data set (Fischer et al., 2008).   
Several vaccine candidates using the mosaic approach have been tested in mice and 
macaques. In mice, DNA vaccines expressing mosaic Env antigens were compared to natural 
Env and mutated Env (gp120 without V regions and gp41 deletion) strains. Mosaic candidates 
elicited responses to an average of eight peptide pools, compared to two pools for a set of 
natural Envs (Kong et al., 2009). Similar observations were made in rhesus macaques. 
Barouch et al. (2010) immunised macaques with a recombinant, replication-incompetent 
Ad26 expressing mosaic HIV Gag, Pol and Env antigens, M consensus, combined subtypes B 
and C, or natural subtype C. The total number of Gag-, Pol- and Env-specific cellular immune 
responses to PTE peptides elicited by the mosaic antigens was higher than the number of 
responses induced by the consensus or natural sequence antigens (Barouch et al., 2010). 
Santra et al. (2010) also demonstrated an increase in both the breadth and depth of mosaic 
HIV Gag and Nef antigens expressed by a DNA prime-recombinant vaccinia regimen, 
compared with consensus or natural sequence HIV antigens in macaques. Barouch et al. 
(2013) evaluated for the first time the protective efficacy of an HIV mosaic vaccine. They 
immunised macaques with Ad/poxvirus and Ad/Ad vector-based vaccines expressing HIV 
mosaic Env, Gag, and Pol and challenged the monkeys with the difficult-to-neutralise SHIV-
SF162P3. HIV mosaic antigens protected rhesus monkeys against acquisition of infection 
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following heterologous challenge, and this protection correlated with vaccine-elicited 
neutralising and non-neutralising antibodies (Barouch et al., 2013).  
No vaccine candidates expressing mosaic peptides have been tested in humans to date. 
However, one study tested the ability of mosaic HIV immunogens expressed by recombinant, 
replication-incompetent Ad26 vectors to process and present major HIV subtypes B and C 
CD8+ T cell epitopes in human cells in an in vitro immunisation (Ndhlovu et al., 2011). A 
bivalent mosaic vaccine expressing HIV Gag sequences was used to transduce PBMC from 
12 HIV-infected individuals from the US and 10 HIV-infected individuals from South Africa. 
Mosaic Gag expressed all eight subtype B epitopes tested in all US samples, and all five 
subtype C epitopes tested in all South Africans. In addition, the magnitude of responses 
induced by stimulation with mosaic immunogens was comparable to subtypes B and C 
immunogens tested, but the mosaic elicited greater cross-clade recognition (Ndhlovu et al., 
2011). Polyvalent mosaic antigens therefore represent a promising strategy to expand cellular 
immunologic vaccine coverage for genetically diverse pathogens such as HIV. 
1.6.3.4 Conserved epitopes 
Certain regions of HIV are less variable than others due to a need for functional or 
structural conservation, and changes in these regions result in a cost to the viral fitness, or the 
capacity of the virus to replicate (Fernandez et al., 2005; Martinez-Picado et al., 2006). 
Therefore, targeting conserved regions may be beneficial in the design of HIV vaccines, to 
generate both cross-reactive and highly effective immune responses. This strategy was 
applied by Letourneau et al. (2007) in designing a T cell immunogen, HIVCONSV. They made a 
chimeric protein with the 14 most conserved regions of the HIV proteome derived from a 
consensus sequence from subtypes A, B, C and D, and used three most studied vaccine 
vectors, namely DNA, Ad5 and MVA expressing HIVCONSV to deliver the protein in mice. 
HIVCONSV was found to be immunogenic in these animals, inducing HIV-specific T cell 
responses that produced cytokines and were capable of killing target cells (Letourneau et al., 
2007). In addition, using PBMC from healthy donors and from an HIV vaccine trial, they 
found that these conserved regions primed CD8+ and CD4+ T cell to highly conserved 
epitopes in human PBMC (Letourneau et al., 2007). In a more recent study, Borthwick et al. 
(2013) provided a proof of concept of this approach in human. They used a vaccine to target T 
cell conserved epitopes. A DNA, simian adenovirus and modified vaccinia virus Ankara 
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vaccine, delivered in a prime-boost strategy, was administered in a Phase I trial in the UK. 
The vaccine induced high levels of T cells that recognised virus-infected autologous CD4+ 
cells and with strong viral inhibition capacity. The virus inhibition was mediated by both 
Gag- and Pol- specific effector CD8+ T cells targeting epitopes that are typically subdominant 
in natural infection (Borthwick et al., 2013). One group (Rolland et al., 2007) also proposed 
the use of conserved regions for an HIV vaccine referred to as conserved elements (CE)-
vaccine, that is composed of 45 discrete viral segments of at least eight amino acids 
(resembling the minimum length of a CD8+ T cell epitope) that fulfil a certain conservation 
criteria. This analysis resulted in identification of first tier segments in which there was 98% 
conservation of a single amino acid at a single position across the group M sequences, and 
second tier segments in which there was 99% conservation of two variant amino acids at a 
single position across group M sequences (Rolland et al., 2007). These results provide 
evidence that vaccines targeting conserved elements in the HIV proteasome may be able to 
achieve control of HIV replication. Which approach is superior can only being determined in 
human trials. Since these trials are very difficult to implement, costly and lengthy, other 
strategies should be employed to understand the potentially relevant responses that T cell-
based vaccines to peptides based on these candidate immunogens should elicit.  
 
1.7 AIMS AND OBJECTIVES OF THE THESIS 
Consideration of global HIV diversity has been a central focus of world-wide efforts 
to develop HIV vaccines. The question of whether the global burden of viral diversity can be 
controlled by an effective HIV vaccine has quite appropriately become somewhat of a huge 
challenge amongst researchers hoping to develop HIV vaccines. To date, the question of 
whether region-specific vaccines are necessary, or a universal vaccine is feasible, still needs 
to be answered. Tremendous efforts have been made to generate immunogens that can cope 
with HIV diversity. These vaccine projects derive hope from the fact that despite the 
incredible rate at which HIV sequences can evolve, it is apparent that there are regions of the 
genome where sequences are quite significantly conserved. With the disappointing results 
from vaccine trials around the world (apart from the modest protection achieved in the RV144 
trial), the search for sequences or groups of sequences capable of eliciting immune responses 
that would be cross-reactive against all HIV-1 group M viruses is still an important focus. 
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Artificial sequences have been proposed to reduce the genetic distance amongst circulating 
subtypes, and thus addressing the issue of HIV diversity. It is therefore very important to 
understand the potentially relevant responses that T cell-based vaccines to these new 
immunogens should be elicited. This can be done using blood from HIV-1 infected 
individuals and identify highly targeted epitopes that can be used in vaccines formulation 
even though responses seen in infected individuals may not necessarily be the ones that 
should be induced by a vaccine.  
Objectives 
This study aimed to evaluate the influence of HIV diversity on the patterns of T cell 
recognition to peptides based on proposed HIV-1 immunogens (consensus and mosaic), 
mounted by HIV-infected individuals from Cameroon, a country with a highly diverse HIV 
epidemic. The specific objectives of the study were as follows: 
Aim 1: To characterise HIV-1 genetic diversity in Cameroon 
Aim 1a: To characterise HIV-1 gag and nef gene from Cameroon 
Aim 1b: To characterise new HIV near full length viruses from Cameroon  
Rationale 
  Cameroon is located in the Congo basin in west central Africa and is likely the country 
within which HIV-1 group M originated. Possibly as a consequence of this, it has one of the 
most genetically diverse HIV epidemics in the world. Alongside CRF02_AG, which accounts 
for more than half of infections in the country, circulating virus lineages include every known 
HIV-1 group M subtype, numerous CRFs, and a variety of URFs or apparently mosaic viruses 
which are not easily classifiable into any existing subtypes. The range of subtypes and the 
amount of intra-subtype diversity within any geographical region will very likely significantly 
impact HIV vaccine efficacy in that region. It is therefore imperative to constantly monitor 
and characterise HIV in different regions of the world, and more specifically in HIV diversity 
hot spots like Cameroon. 
Aim 2: To measure immune responses to HIV-1 group M consensus Gag and Nef peptides 
using the IFN-γ ELISPOT assay, in order to assess their recognition by HIV-infected 
Chapter 1: Literature review  Page 47 
 
individuals from Cameroon harbouring a large degree of HIV diversity, and compare this to a 




Numerous studies have described broadly cross-reactive T cell immune responses in 
several African populations, namely from Uganda, Kenya, Cote d’Ivoire and South Africa, 
using the IFN-γ ELISPOT assay. Predictably, these studies have shown that the majority of 
cross-reactive responses were directed towards regions of low intra-subtype diversity and 
high inter-subtype homology. In addition, the majority of these studies have focused on 
measuring responses to immunodominant regions of HIV-1 subtypes A, B or C, the three 
subtypes that dominate the epidemic globally, since testing responses to all isolates on the 
African continent is not feasible. The results generated from such studies may not be directly 
applicable to areas with a large degree of HIV diversity, such as west central Africa. One of 
the simplest ways to reduce the genetic distance between a vaccine strain and contemporary 
circulating viruses is to create artificial sequences such as the consensus Group M sequence. 
There is a need to evaluate cross-reactive responses to reagent sets based on these new 
sequences, particularly in HIV-infected populations in areas where multiple subtypes and 
recombinant forms circulate, such as West Central Africa. In fact, there is a paucity of 
immunological studies on HIV infection from this region, with only a single published study 
to date on T cell responses in HIV-infected individuals from Cameroon. 
Aim  3: To measure immune responses to HIV-1 group M potential T cell epitope (PTE) Gag 
and Nef peptides using the IFN-γ ELISPOT assay in HIV-infected individuals from 
Cameroon, and compare these to consensus peptide responses, in order to determine whether 
reagents based on immunogens designed to encompass greater HIV variability would lead to 
detection of broader immune responses than consensus reagents. 
Rationale  
New candidate HIV vaccine immunogens have recently been designed that attempt to 
take into account the large degree of genetic diversity of HIV, by including a vast array of 
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potential T cell epitopes from multiple subtypes. These are known as ‘mosaic’ constructs and 
preclinical studies in rhesus macaques have demonstrated that they augment both the breadth 
and depth of antigen-specific T cell responses compared to both natural and central (e.g. 
consensus) sequences. PTE peptides based on the mosaic constructs will be tested in order to 
identify T cell epitope reactivity in PBMC from HIV-infected Cameroonians, and determine 
whether this approach leads to broader detection of T cell responses than consensus M 
reagents.  
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2.1 INTRODUCTION 
 The Congo basin in west central Africa is thought to be the origin of HIV, where several 
cross-species transmission events from chimpanzees to humans occurred (Keele et al., 2006; 
Sharp and Hahn, 2011). Cameroon, located in this region, has one of the most genetically 
diverse HIV epidemics in the world (Brennan et al., 2008; Ragupathy et al., 2011; Machuca 
et al., 2007; Ndembi et al., 2008). Alongside CRF02_AG, which accounts for more than half 
of infections in the country, circulating virus lineages include every known HIV-1 group M 
subtype, numerous CRFs and a variety of apparently URFs (Carr et al., 2010). The prevalence 
of HIV-1 in Cameroon is 4.5%, which is one of the highest in west central Africa (UNAIDS, 
2013). This, together with the co-circulation of divergent variants of multiple subtypes, has 
created the conditions for frequent mixed infections and inter-subtype recombination. 
 Despite the high diversity of HIV in Cameroon and the west central African region as a 
whole, HIV-1 group M CRF02_AG dominates the epidemic throughout this part of Africa. 
CRF02_AG is largely confined to west central Africa, and in addition to Cameroon, makes a 
major contribution to the epidemics of Guinea-Bissau, Senegal, Gambia, Nigeria, Ghana, 
Cote d’Ivoire and Mali (Esbjornsson et al., 2011; Hamel et al.,  2007; Sankalé et al., 2007; 
Delgado et al., 2008; Toni et al., 2007; Imamichi et al., 2009). In the most recent overview of 
global subtype distribution, CRF02_AG made up 8% of all HIV-1 infections, representing the 
fourth most prevalent HIV-1 variant worldwide, after subtypes C, A and B (Hemelaar et al., 
2011). Interestingly, this was an increase of over 60% from the three year period prior to that. 
 Given the high degree of HIV diversity in Cameroon, several studies have questioned 
whether CRF02_AG has a replicative advantage over other variants circulating there. There is 
some evidence of CRF02_AG variants having both greater replicative fitness than subtype A 
and G variants in vitro (Njai et al., 2006; Konings et al.,  2006), and yielding viral loads 
which are five-fold higher than those found in infections with other HIV-1 group M subtypes 
and recombinants (Fischetti et al., 2004). 
 Constantly improving phylogenetics-based analytical techniques and rapidly expanding 
HIV sequence datasets allow for better characterisation of diverse sequences, and promise to 
yield important insights into the origin, evolution and spread of HIV-1. 
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Given the potential impact of HIV-1 diversity on both vaccine development and the 
sustainability of antiretroviral therapies, it is particularly important that molecular 
epidemiological surveillance is continued in HIV diversity hotspots such as Cameroon. 
The study described in this chapter characterised the diversity of gag and nef genes of 
Cameroonian HIV-1 isolates. These genes are particularly relevant because they encode 
highly immunogenic proteins that are frequently included in candidate vaccines (Masemola et 
al., 2004; McMichael and Haynes, 2012; Stephenson et al., 2012). To obtain a phylogenetic 
view of Cameroonian HIV diversity that explicitly accounted for the confounding effects of 
recombination, extensive recombination-aware phylogenetic analyses were performed with 
these new sequences along with publically available homologous HIV-1M gag and nef 
sequences from the Congo basin and a representative selection of the major known HIV 
lineages from the rest of the world. This study also characterised nine new HIV-1 near full 
length sequences from Cameroon.  
 
2.2 MATERIALS AND METHODS  
2.2.1 Study participants 
Anonymously-donated HIV-infected blood units (n=59) were collected between 
December 2006 and August 2007 from Yaoundé Central Hospital, Cameroon, in a study 
approved by the National Ethics Committee of the Cameroonian Ministry of Health and the 
University of Cape Town Research Ethics Committee. Although no data on risk factors for 
HIV was available for the blood donors, they are believed to represent the general adult 
population of Yaoundé. All donors were antiretroviral therapy naïve and only age and gender 
information were obtained. CD4 counts were performed by flow cytometric analysis (Becton 
Dickenson) and viral load was determined from plasma by a second-generation real-time 
reverse transcription RT polymerase chain reaction (PCR; Abbott). 
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2.2.2 PCR amplification 
2.2.2.1 Gag and Nef sequences  
RNA was extracted from plasma samples using a Magna-Pure compact Nucleic Acid 
extractor (Roche). HIV gag and nef complementary DNA (cDNA) were generated using the 
Invitrogen Thermoscript
TM
 RT-PCR system (Invitrogen). cDNA from the RT step was PCR 
amplified as described previously (Bredell et al., 2007) using non-specific HIV-1 primers for 
HIV-1 full length gag (Bredell et al., 2007) and nef (Artenstein et al., 1996) genes. The gag 
and nef genome fragments were amplified, producing 1.5 kb fragment spanning the whole 
gag region and 700 kb sequences spanning the entire nef region. PCR was performed using 
the Expand High Fidelity kit (Roche-Mannheim). The first and second round reactions were 
performed using 1ul dNTP (10mM), 5ml 10X buffer plus MgCl2 (15mM), 1ul of each primer 
(10mM), 0.75ul Expand High Fidelity Enzyme (5U/ul), water and template, in 50ul total 
reaction volume with no hot-start method. For gag, first round cycling conditions were: 94
0
C, 
2 min, and then 10 cycles of 94
0




C 1 min, followed by 20 cycles of 940C 
15s, 55
0
C 2 min, 72
0
C 1.5 min and then 72
0
C 7 min. The second round cycling conditions 
consisted of 94
0






C 1.5 min and 
then 72
0
C 7 min. The gag first round primers were: Gag D forward (HXB2: 626-644; 5’–
TCTCTAGCAGTGGCGCCCG) and Gag D reverse (HXB2: 2402-2382; 5’–
AATTCCTCCTATCATTTTTGG). The second round reaction was with Gag A forward 
(HXB2: 683-704; 5’-CTCTCGACGCAGGACTCGGCTT) and Gag C reverse (HXB2: 2356-
2334; 5’–TCTTCTAATACTGTATCATCTGC); in some cases, Gag D forward was replaced 
by Gag Polm1 reverse (HXB2: 2632-2610; 5’-TCTGTCAATGGCCATTGTTTAAC).  
 For nef, the cycling conditions were the same for both first and second round, 
consisting of 94
0






C 50s and then 
72
0
C 7 min. The nef first round primers were: Nef outer5-Ie (HXB2: 8513-8533; 5’–
GTGCCTCTTCAGCTACCACCG) and Nef outer3-3e (HXB2: 9808-9488; 5’–
AGCATCTGAGGGTTAGCCACT). The nef second round primers were Nef inner5-Ie 
(HXB2: 8698-8717; 5’-TGGACAGAYAGGGTTATAGAA) and Nef inner 3-7e (HXB2: 
9467-9448; 5’-CACCTCCCCTGGAAAGTCCCC). All sequences had at least two clear 
readings in each direction for completion. 
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2.2.2.2 Near full length sequences   
RNA from plasma samples selected based on phylogenetic analyses of the gag and nef 
sequences were manually extracted using the QIAamp Viral RNA Mini Kit (QIAGEN, 
Roche). Virtually full-length HIV cDNA was generated using the Thermoscript
TM 
RT-PCR 
system (Invitrogen) and was amplified. Limiting template dilution into the first round was 
performed to obtain single genome amplificons (SGA) (Salazar-Gonzalez et al., 2009) with 1 
ul, 1:3, 1:9, and 1:27 dilutions of cDNA for initial screening of the cDNA of the first round, 
and with each dilution consisting of eight replicate reactions. If only non-specific bands were 
visible after gel electrophoresis of second round products, further dilution (at 1:50, 1:100, 
1:200 etc) of cDNA was performed for subsequent reactions. Additionally, if there was no 
amplification following initial screening, 2ul to 5ul of undiluted cDNA was added to further 
reactions in order to obtain a full-length (~9kb) product. The desired number of positive full-
length products equated to: the number of positive full-length amplicons divided by the 
number of reactions and should be >20%. This percentage results in the likely production of 
SGAs, which will, when sequenced, have no “double-peaks” (Salazar-Gonzalez et al., 2009). 
The virtually full-length genomes were amplified using the first primers (Treurnicht et al., 
2010), 1.U5C (HXB2: 538-571; 5’-GGGTGAGTGCTCTAAGTAGTGTGTGCCCGTCTGT) 
1.U5Cb (HXB2: 538-571; 5’-GGGTGAGTGCTCTAAGTAGTGTGTGCCCATCTGT), 
1.3.3PIC (HXB2: 9625-9665; 5’-GGGACTTAGAGCACTCAAGGCAAGCTTTATTG), 
followed by amplification with the second round primers, 2.U5C (HXB2: 540-580; 5’-
GGCCGCGGATCCAGTAGTGTGTGCCCGTCTGTTGTGTGACT) and 2.3.3plC (HXB2: 
9650-9604; 5’-GGCCGCGCGGCCGCTAGAGCACTCAAGGCAAGCTATTGAGGCTTA). 
PCRs was performed as described (Treurnicht et al., 2010) using the Expand Long Template 
kit (Boehringer-Mannheim) and a hot-start method. The first and second round reactions were 
performed using 0.9ul dNTP (20mM), 5ml 10X buffer plus MgCl2 (15mM), 0.3ul of each 
primer (50pmoles/ul), 0.75ul Expand High Fidelity enzyme (5U/ul), water and template in a 
50ul total reaction volume. Cycling conditions were: 94
0





C for 30s and 68
0
C for 8 min. This was followed by 20 cycles where the annealing 
temperature was 68
0
C. The final extension step was 68
0
C for 20 min. In some cases, multiple 
second round PCR amplifications were combined to provide sufficient template for 
sequencing.  
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2.2.3 DNA sequencing  
Sequencing was performed at the University of Stellenbosch core facility 
(www.us.ac.za) using four primers for Gag, two for Nef and 32 for HIV full length. Fifty full 
length HIV-1 gag sequences and 55 nef genes from 59 HIV-infected blood donors in 
Cameroon were obtained. In addition, nine near full length HIV genomes were obtained.   
2.2.4 Analysis 
2.2.4.1 Gag and Nef sequences 
Sequenced fragments were assembled using ChromasPro. Full length gag and nef 
sequences were generated, together with a representative selection of 270 gag and 279 nef 
HIV sequences from the rest of the world and all other published gag (266) and nef (278) 
sequences from Cameroon and other west central African countries available in the Los 
Alamos National Library (LANL; http://hiv-web.lanl.gov/content/hiv-db) and Genbank 
databases (May 2012). These were aligned using MUSCLE (Edgar, 2004) with default 
settings and manual editing of alignments in MEGA5. The representative sequences chosen 
from the rest of the world were specifically selected to include the broadest diversity of 
sequences previously identified as belonging to known HIV-1 group M subtypes and CRFs. 
This was achieved by constructing  maximum likelihood trees from all available gag and nef 
sequences for each subtype and CRF, and selecting one sequence from each of the up to ten 
most basal lineages from the root of these subtypes and CRFs. Maximum likelihood 
phylogenetic trees were constructed from these sequences with 100 full maximum likelihood 
bootstrap replicates implemented in PHYML (Guindon et al., 2005), following either 
complete removal of recombinant sequence fragments or the division of recombinant 
sequences into their constituent fragments by a blinded fully exploratory screen for 
recombination using RDP4 (Martin et al., 2011). The gag tree was rooted using HIV-1 group 
N, O and P and SIVcpz isolates, while the nef tree was rooted with HIV-1 group N, O and P 
isolates. The recombination screen was fully exploratory in that every sequence was analysed 
for evidence of both intra- and inter-subtype recombination.  Either full nef and gag 
sequences or the sub-fragments of these sequences identified as having recombinant origins 
were classified as belonging to particular HIV subtypes if they clustered with reference 
sequences of these subtypes.  
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2.2.4.2 Near full length sequences  
Sequenced fragments were assembled using ChromasPro. Near full length sequences 
were generated and aligned using MUSCLE with manual editing in MEGA5, together with a 
representative selection of 395 near full length sequences from the rest of the world and all 
144 published full length sequences from Cameroon and other west central African countries 
that were available in the LANL (http://hiv-web.lanl.gov/content/hiv-db) and Genbank (Jjune 
2013) databases. Computations were performed using facilities provided by the University of 
Cape Town’s ICTS High Performance Computing Facility (http://hpc.uct.ac.za). As for gag 
and nef sequences, the same method was used to select a representative selection of the major 
known HIV lineages from the rest of the world. A maximum likelihood phylogenetic tree was 
constructed from these sequences with 100 full maximum likelihood boostrap replicates using 
Fastree. Only HIV-1 group M sequences were included in this analysis and the phylogenetic 
tree was midpoint rooted.    
Divergent sequences were defined as those residing on isolated branches outside of 
subtrees containing previously defined HIV-1 subtype or CRF lineages. Outlier sequences, on 
the other hand, were defined as those residing on basal branches of subtrees containing 
previously defined HIV-1 subtype or CRF lineages.  
 
2.3 RESULTS 
2.3.1 Characteristics of study individuals 
 Clinical and demographic data of the 59 HIV-infected Cameroonian study participants 
are summarised in Table 2.1. Individuals were between 19 and 54 years of age, with a median 
age of 31 years, and consisted of 46 males and 13 females. The median CD4 cell count was 
432 cells/mm
3
 (interquartile range or IQR 301-665). All individuals were antiretroviral 
therapy-naïve, and there was a wide range of viral levels, with a median HIV-1 RNA viral 
load of 4.93 Log RNA copies/ml (IQR 3.29-6.32). The HIV seroconversion dates for these 
individuals were not known. 
 






























Median and IQR 
 
 
2.3.2 HIV-1 distribution in Cameroon based on gag and nef sequences 
  Fifty full length HIV-1 gag and 55 nef genes were sequenced from 59 HIV-infected 
blood donors in Cameroon. All sequences were derived from HIV-1 group M viruses (Table 
2.2). The sequences clustered with different subtypes and CRFs and were distributed 
throughout the HIV-1 group M gag and nef phylogenetic trees (Figure 2.1), an observation 
that is consistent with the breadth of HIV-1 diversity previously described in Cameroon.       
 CRF02_AG-like viruses dominated the subtype distribution, infecting 50% of the 46 
participants for which both genes were sequenced (Figure 2.2 and Table 2.2). Participants 
infected with viruses having both nef and gag sequences that clustered within known HIV-
1group M subtypes included those belonging to subtypes G, D, A, and F. Subtype G 
sequences accounted for 11% of infections, subtype D for 4% and sub-subtypes A1 and F2 for 
2% each. In addition to CRF02_AG, other CRFs identified were CRF37_cpx (4%), and 
CRF01_AE and CRF36_cpx (2% each). In two samples for which only gag or nef sequences 
was typed, these were classified as belonging to CRF11_cpx. Notably, despite subtypes B and 
C collectively accounting for approximately 60% infections worldwide (Hemelaar et al., 
2011), none of these new sequences were classified as belonging to either of these subtypes. 
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Table 2.2 Subtype distribution of HIV-1 in Cameroon
 
 









 CRF02_AG URF 











BS06 CRF02_AG CRF02_AG CRF02_AG 
BS09 CRF02_AG A1 URF 
BS10 A1 A1 A1 
BS11 CRF02_AG F URF 
BS12 G G G 
BS13 CRF02_AG A1 URF 
BS14 CRF02_AG CRF02_AG CRF02_AG 












BS21 CRF02_AG CRF02_AG CRF02_AG 
BS22 CRF02_AG CRF02_AG CRF02_AG 
BS23 CRF02_AG CRF02_AG CRF02_AG 
BS24 CRF37_cpx  CRF37_cpx CRF37_cpx 
BS25 CRF02_AG F URF 
BS26 CRF01_AE
b
 CRF01_AE CRF01_AE 
BS27 CRF37_cpx
b
















BS38 CRF02_AG CRF02_AG CRF02_AG 
BS39 CRF02_AG CRF02_AG CRF02_AG 
BS40 CRF36_cpx CRF36_cpx CRF36_cpx 
BS42 URF  CRF01_AE
b
 URF 






BS45 CRF02_AG CRF02_AG CRF02_AG 
BS46 G G G 
BS47 CRF02_AG CRF02_AG CRF02_AG 
BS48 G G G 
BS49 F2 F F2 
BS50 CRF02_AG CRF02_AG CRF02_AG 
BS51 G G G 
BS53 CRF02_AG CRF02_AG CRF02_AG 
BS54 D D D 
BS55 CRF02_AG F URF 








BS64 CRF02_AG CRF02_AG CRF02_AG 
BS65 CRF22_01A1 CRF01_AE URF 
BS66 CRF02_AG CRF02_AG CRF02_AG 





 CRF01/F  URF 








BS75 CRF02_AG CRF02_AG CRF02_AG 























Genotype was uncertain in samples for which only a single gene was determined ; 
b
Outlier;
   c
ND: Not done 
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Figure 2.1 (previous page) Maximum likelihood trees indicating the phylogenetic relationships 
between (A) 727 gag and (B) 628 nef sequences of HIV-1. The trees were constructed from these 
sequences with 100 boostrap replicates following removal of recombinant sequence fragments by a 
blinded fully exploratory screen for recombination using RDP3. Black squares at the end of the 
branches represent the gag and nef sequences sampled from Cameroon in this study, while red squares 
represent intragene recombinant fragments in our the samples. The gag tree was rooted using HIV-1 
group N, O, P and SIVcpz isolates, while the nef tree was rooted with HIV-1 group N, O and P 
isolates. Solid and open circles indicate branches with greater than 70% and 50% bootstrap support, 
respectively. The arrow in the nef tree indicates an outlier of both subtypes G and CRF02_AG.
 
 
 In 10/46 samples for which both nef and gag sequences were analysed, the genes were 
classified as belonging to different subtypes from one another. One of the two gene sequences 












Figure 2.2 Pie chart summarising the distribution of HIV-1 group M subtypes and recombinant 
forms full length gag and nef gene sequencing (n=46). Intergene recombinants are detailed in the 
right panel.  The 13 samples that were typed in only one of the genes were excluded from this 
analysis. 
 CRF37_cpx  
CRF02_AG  












         CRF01_AE  
   Gag                      Nef 
CRF02_AG       A1 
CRF02_AG       A1 
CRF02_AG        F 
CRF02_AG        F 
CRF02_AG        F 
CRF02_AG        U 
CRF02_AG CRF01_AE 
      A-like  CRF02_AG 
CRF22_01A1 CRF01_AE 
CRF36_cpx/F2 CRF01_AE/F  
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2.3.3 Identification of intra- and inter-subtype gag and nef recombinants 
 Numerous recombination breakpoints were also detected within the genome regions 
analysed. Among the newly sequenced gag genes, three (6%) were identified as containing 
recombination breakpoints between gene segments that phylogenetically clustered within two 
distinct groups of the same subtype, indicating that they were likely intra-subtype 
recombinants. Whereas two of these (BS05 and BS55) were CRF02_AG/02_AG 
recombinants, one (BS57) was a CRF11_cpx/11_cpx recombinant (Table 2.3 and Figure 2.3). 
Four of the newly sequenced nef genes (7%) also showed evidence of intra-subtype 
recombination, including three (BS12, BS48 and BS51) which were intra-subtype G 
recombinants and one (BS39) which was an intra-CRF02_AG recombinant (Table 2.3 and 
Figure 2.3).  
 Whereas one of the newly sequenced gag genes (BS72) was apparently derived through 
inter-subtype recombination between F2 and CRF36_cpx parental viruses, one of the nef 
genes was apparently derived through recombination between F and CRF22_01A1 parental 
viruses (Table 2.3).  
 
Table 2.3 Inter- and intra-subtype recombinants  
 









BS09 CRF02_AG A1 
BS11 CRF02_AG F 
BS13 CRF02_AG A1 







BS39 CRF02_AG CRF02_AG/CRF02_AG 















BS12 G G/G 
BS48 G G/G 
BS51 G G/G 
aOutlier; bND: Not done 



















Figure 2.3 Maximum likehood subtrees indicating examples of the intragene recombinants in 
gag and nef. The trees were constructed following removal of recombinant sequence fragments by a 
blinded fully exploratory screen for recombination using RDP4. Each colour represents fragments of 
the same sequence. 
 
2.3.4 Viruses with highly divergent gag and nef sequences 
The phylogenetic analysis of gag sequences derived from the Cameroonian samples 
further revealed five other Cameroonian gag sequences determined here that branched very 
near the base of the subtypes that they grouped with. These were: BS02 from the base of 
CRF09_cpx/CRF45_cpx, BS27 from the base of CRF37_cpx, BS26 from the base of 
CRF01_AE, BS57 from the base of the CRF11_cpx and BS72 from the base of the F2 and 
CRF36_cpx clades (Figure 2.4). Similarly, in nef, three such sequences also branched from 
near the base of the subtypes that they were most closely clustered with: BS74 near the base 
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of the A subtype, BS42 near the base of the CRF01_AE subtype and BS29 near the base of 










Figure 2.4 Maximum likehood subtrees indicating examples of the divergent outlier sequences in 
gag and nef.  The phylogenetic analysis of gag and nef sequences derived from the Cameroonian 
samples revealed sequences (represented here with a red square) that were situated at the base of the 
subtypes that they grouped with. 
 
Finally, the blind recombination screen also revealed that some divergent 
Cameroonian viruses previously identified as being complex recombinants, such as 
CRF11_cpx, is a highly divergent but not obviously recombinant lineage forming an isolated 
branch in both phylogenetic trees (at least in gag and nef; red portion in Figure 2.5) 




















Figure 2.5 Maximum likehood subtrees showing the portions of subtype CRF11_cpx both in gag 
and nef.  CRF11_cpx may represent at least in gag and nef a highly divergent not obviously 
recombinant lineage forming and isolated branch in both phylogenetic trees (red portion in both trees). 
 
2.3.5 Near full length HIV-1 sequences from Cameroon 
  Nine viruses were selected for further full genome sequencing based on the results of 
the gag and nef phylogenetic analyses. These samples were chosen either because they were 
divergent sequences residing on isolated branches of subtrees containing previously defined 
HIV-1 subtype or CRF lineages, or because they were outlier sequences residing on basal 
branches of subtrees containing previously defined HIV-1 subtype or CRF lineages. 
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 Based on the maximum likelihood phylogenetic trees generated using these and other 
representative sequences both from the global HIV-1group M epidemic and from central 
west-Africa (Figures 2.6 and 2.7), several observations were made for the nine full genome 
sequences determined here.  
 BS29 had a divergent nef sequence that was an outlier of the subtypes G and 
CRF02_AG groups, but had a full genome sequence that clustered within the subtype 
CRF02_AG subtree. For BS57 although the gag sequence was an outlier of all know 
CRF11_cpx lineages, the full BS57 sequence clustered within the CRF11_cpx subtree. For 
BS46 and BS48, both had divergent gag sequences branching near the base of the subtype G 
subtree, but have full genome sequences that clustered within the subtype G subtree (albeit 
with a divergent subtype G subtype). For BS40, as was the case for its gag sequence, was an 
outlier of the only two CRF36_cpx lineages that are available in the LANL. For BS13, it was 
a divergent sequence residing on isolated branch of CRF02_AG subtree in gag; the full 
genome sequence was an outlier of all the CRF02_AG sequences sampled to date. This newly 
acquired sequence may help trace the temporal and spatial origins of this important CRF as 
well as resolve the controversy surrounding the potentially recombinant origins of subtype G 
(Zhang et al., 2010; Carr et al., 1998; Abecasis et al., 2007). 
 Two full length sequences, BS11 and BS55, were both too divergent to be placed within 
any existing subtype or CRF grouping and therefore remained unclassified. They may in fact 
belong to a novel CRF or subtype, since they clustered with three other previously 
characterised Cameroonian sequences.  The full length viral genome of BS72 was also too 
divergent to be placed within any existing subtype or CRF grouping. 
 Finally, the phylogenetic tree revealed that some of the Cameroonian sequences 
previously identified as URFs are divergent outliers of some of the major HIV-1M subtypes. 
Sequences 02CM.1807LE is an outlier of a group of subtypes including B, D, F, C and K; 
sequence 02CM.1710LE is an outlier of subtype CRF11_cpx; sequence 02CM.1895LE is an 
outlier of subtype CRF01_AE; sequence 97CA-MP645M/O is outlier of another group of 
major HIV-1M lineages including CRFs 09_cpx, 36_cpx, 01_AE, 22_01A1 and 02_AG (red 
arrows in Figures 2.6 and 2.7). These results therefore provide further evidence that 
Cameroon is a major hotspot of HIV diversity.  
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Figure 2.6 (previous page) Maximum likehood tree indicating the phylogenetic relationships 
between 539 full length sequences of HIV-1, indicating the nine new full length sequences 
generated from Cameroon. The tree was constructed from these sequences with 100 boostrap 
replicates. Red arrows in the tree indicate previously identified URF sequences from Cameroon that 
are divergent outliers. The tree was rooted using an HIV-1 sequence from Cyprus 
(U.CY.2008.CY223.JF683772). Solid and open circles indicate branches with greater than 0.95 and 




















































Figure 2.7 Maximum likehood subtree showing the unclassified (Un) viruses sequenced in this 
study (BS72, BS11 and BS55) and the outlier sequence (BS13) of all the 02_AG viruses sequences 
to date.  Red arrows in the tree indicate previously identified URFs sequences from Cameroon that are 
divergent outliers. Solid and open circles indicate branches with greater than 0.95 and 0.8 midpoint 
support, respectively.  
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2.4 DISCUSSION 
Several studies have characterised HIV-1M sequences from Cameroon (Brennan et al., 
2008; Ragupathy et al., 2011; Machuca et al., 2007; Ndembi et al., 2008; Carr et al., 2010). 
Analysis done here of all available full-length gag and nef gene sequences from west central 
Africa clearly reinforces the findings of these previous studies regarding the high degree of 
HIV-1group M genetic diversity in the country. Also, unsurprising in the light of previous 
Cameroonian diversity studies, was the finding that most of the newly sampled sequences 
were CRF02_AG (accounting for 50% of HIV-1M infections), with the other “pure” subtypes 
(G, D, A, and F) and CRFs (CRF11_cpx, 36_cpx, 37_cpx, and CRF01_AE) accounting for 
the remainder of infections.  
The blind recombination screen also revealed that some divergent Cameroonian 
viruses previously identified as being CRF_cpx like CRF11_cpx may either be, or at least 
contain nef and gag sequences derived from, relatively “pure” but under-sampled subtype-
level lineages.  
Phylogenetic and recombination analyses yielded results partially consistent with 
previous interpretations of the origins of various CRFs. For example, the gag gene of 
CRF01_AE isolates grouped with subtype A, whereas the nef sequences of these viruses 
represented a divergent lineage. Similarly, whereas the nef gene of CRF37_cpx grouped 
within the subtype G, CRF37_cpx gag sequences formed a branch distinct from all other HIV 
lineages. Other examples include (1) the gag sequences of CRF36_cpx viruses grouping with 
subtype A while the nef sequences of these viruses groups with CRF01_AE; (2) the gag 
sequence of CRF13_cpx grouping with subtype G while the nef sequences formed an isolated 
branch; (3) the nef gene of CRF02_AG and subtype G grouping together whereas they 
respectively form isolated clusters of sequences in Gag.  
Both the gag and the nef sequences of several additional apparent CRFs such as 
CRF06_cpx, CRF09_cpx, CRF11_cpx and CRF45_cpx formed isolated branches in the 
phylogenetic analysis, suggesting that, even if these sequences are indeed recombinant, they 
contain genome fragments derived from highly divergent HIV-1group M parental viruses. 
 CRF02_AG and subtype G viruses are broadly distributed across west central Africa 
and have apparently been circulating stably there for many years (Brennan et al., 2008; Hamel 
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et al., 2007; Faria et al., 2012). This notion is consistent with the presence of fragments of 
these viruses having been identified in a large number of CRFs and URFs that have been 
sampled from this region. Analysis performed in this chapter, demonstrated that these two 
subtypes are highly diverse, and in most instances where gag and nef sequences from an 
individual patient had discordant subtype/CRF classifications, the sequence of one of the 
genes clustered within the CRF02_AG subtype. This further reinforces the notion that this 
viral subtype is a major contributor of genetic material to new recombinants (Zhang et al., 
2010). An alternative explanation, however, could be that the gag and nef genes were 
amplified from different viruses co-infecting the same patients. Ongoing molecular and 
clinical surveillance will reveal whether new recombinants will begin to circulate stably, will 
harbor biological properties that favor their transmission, or will impact clinical outcomes.  
Carr et al. (2010) recently identified sequences that were outliers of various HIV-
1group M subtypes, and presented analyses that many of these viruses were likely URFs, 
which might explain the phylogenetic placement of these sequences on the outskirts of known 
subtypes (Carr et al., 2010). Although the majority of the outlier viruses found in this study 
were also URFs, they remained outliers after the removal of recombinant segments. It thus 
appears that these sequences represent viruses that are genuinely highly divergent and contain 
sequence fragments that have been acquired from previously unknown early divergent HIV-
1group M lineages. Such sequences could help tremendously with efforts to piece together the 
early evolutionary history of HIV-1 group M. 
The characterisation of nine new full genome sequences for some of the most 
divergent viruses identified during the gag and nef sequence analyses confirmed the great 
extent of the HIV diversity in Cameroon. Some of the newly sequenced viruses, such as 
BS11, BS55, BS72 and other Cameroonians viruses appeared to form separate, highly 
divergent clusters within the analysed phylogenetic trees. This suggests that some divergent 
Cameroonians viruses previously identified as being difficult to classify URFs might, rather 
than simply being phylogenetically misplaced inter-subtype recombinants, be the extant 
descendants of early diverging HIV-1M lineages. Regardless of whether or not these so-called 
complex URFs are recombinant, there is unquestionably a far more diverse pool of HIV 
sequences circulating amongst humans than presently accounted for in the current HIV-1 
group M classification. Some of the divergent lineages, such as that represented here by 
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BS13, which is an outlier of the important CRF02_AG cluster, might help resolve 
controversies surrounding the early origins of subtypes G and CRF02_AG (Zhang et al., 
2010; Carr et al., 1998; Abecasis et al., 2007), and provide invaluable data for the 
computational inference (and even perhaps the chemical synthesis and biological 
characterisation) of early HIV-1M ancestral sequences. 
In summary, this work demonstrates the predominance in an urban Cameroonian 
setting of HIV-1 CRF02_AG viruses alongside viruses belonging to a multiple known and 
unknown HIV-1 group M subtypes lineages. Further characterisation of the divergent 
sequences identified here may certainly provide new insights into the evolution and 
emergence of HIV-1group M over a century ago in west central Africa. 
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3.1 INTRODUCTION 
The design of immunogens capable of eliciting effective T cell immune responses 
against HIV is challenged by the extreme diversity of the virus, as well as the genetic 
heterogeneity of human populations. The protective efficacy of a vaccine is likely to vary in 
different populations infected with different HIV clades, unless effective approaches to target 
the variability of diverse viral strains are developed.  
Artificial sequences such as consensus group M constitute an immunogen designed to 
cope with the high degree of HIV-1 diversity (review by Gao, 2004). They consist of a 
sequence where the most common amino acid found at each position is selected from a set of 
available sequences (Korber et al., 2001; Novitsky et al., 2002). They can reduce the genetic 
distance between a vaccine strain and circulating viruses, and may be particularly useful in 
regions where multiple HIV-1 clades and recombinant forms co-circulate. Other centralised 
sequences included (i) centre-of-tree or COT (the point in a phylogenetic tree that minimises 
the evolutionary distances to all sampled viruses); or (ii) most recent common ancestor or 
MRCA (the derived progenitor to a set of sequences (reviewed by Ellenberg et al., 2002, 
Mullins et al., 2004; Nickle et al., 2002). Preclinical studies testing consensus M-based 
immunogens both in murine (Gao et al., 2005; Weaver et al., 2006, 2010) and non-human 
primate models (Santra et al., 2008) have demonstrated stronger HIV-specific T cell 
responses compared to immunogens based on a single clade. To date, there have been no 
vaccine trials in humans that have tested and compared the immunogenicity of consensus M 
immunogens in different regions. Therefore, their potential for eliciting broad immune 
responses and for providing protection against multiple subtypes from group M is unknown.  
Numerous studies have however characterised the immunological recognition of HIV-
1 consensus M peptides in HIV-infected individuals, and the results suggest a broad 
recognition amongst individuals infected with different subtypes (Rutebemberwa et al., 2005; 
Bansal et al., 2006; Malhotra et al., 2007; Frahm et al., 2008; Serwanga et al., 2012;  Côrtes 
et al., 2013).  One such a study evaluated HIV-1 specific T cell responses to seven different 
Gag peptide reagents, including peptides based on subtype B consensus, subtype B isolate 
HXB2, ancestral group M, ancestral subtype B and consensus A, C and group M in 43 
subtype B-infected individuals from the US (Bansal et al., 2006). Out of the 42 reactive 
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peptides, 29 (69%) demonstrated cross-reactivity among all the seven Gag peptide reagents 
tested in at least one of the study individuals investigated. Cross-reactivity was highest for 
p24 Gag (71%), following by 15 (67%) and lastly p17 (63%). This study also evaluated 
responses to these peptide reagents in a limited number of subtype C-infected participants 
from Zambia (n=13) of which reactive peptides were only confirmed in six individuals. 
Overall, when subtype B and C infected populations were assessed, the subtype consensus 
peptides that matched the infecting virus subtype detected responses of similar magnitude and 
breadth to consensus M and ancestral M reagents, and these were higher than responses to 
subtype consensus that were not matched to the infecting virus (Bansal et al., 2006). This 
study and others illustrate the value of investigating different types of centralised reagents to 
assess the effect of genetic diversity on HIV-specific T cell responses in infected individuals. 
However, many of these studies have used peptide pools to test the reactivity to consensus M 
reagents, and few data are available regarding differential targeting at the epitope level, and 
therefore questions remain regarding the specificity and frequency of consensus M peptides 
that are targeted within a population or between populations. It may be particularly important 
to generate data from different epidemics in order to understand to what extent the diversity 
of HIV impacts the immunological recognition of consensus M reagent sets, especially where 
rare clades may be under-represented in the sequence databases. 
  One country at the extreme end of the spectrum of viral diversity is Cameroon in west 
central Africa, where several groups have characterised the HIV-1 epidemic (Machuca et al., 
2007; Brennan et al., 2008; Ndembi et al., 2008; Ragupathy et al., 2011; Tongo et al., 2013). 
Along with almost every known subtypes, there is a predominance of recombinant forms of 
HIV-1 in Cameroon, particularly CRF02_AG, which is also the main source of the epidemic 
also in other parts of the region (Mamadou et al., 2002; Pandrea et al., 2002; Djoko et al., 
2010; Tebit and Arts, 2010; Ajoge et al., 2011). In addition to the viral heterogeneity, the 
Cameroonian population is a mosaic of more than 250 ethnic groups with extensive HLA 
diversity (Ellis et al., 2000; Torimiro et al., 2006). Despite the viral epidemic being so well 
characterised, there is a paucity of immunological studies on HIV infection from Cameroon, 
with only a single published study to date on T cell responses in HIV-infected individuals 
from Cameroon (Gupta et al., 2006). This contrasts with the urgent need to test candidate 
vaccines in a region such as this, where multiple HIV-1 clades and recombinant forms 
circulate. 
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The study described in this chapter investigated the T cell reactivity and 
immunodominance patterns towards HIV-1 consensus group M Gag and Nef in HIV-infected 
Cameroonians. These two HIV proteins were focused on as they are frequently targeted by 
HIV (Masemola et al., 2004; Mendiratta et al., 2008), and included in most candidate 
vaccines (McMichael et al., 2012; Stephenson et al., 2012).  Consensus M peptide reagents 
were used to detect T cell responses, since they were hypothesised to provide greater coverage 
of more conserved regions of the HIV genome. These analyses were performed in a highly 
diverse epidemic, namely Cameroon, where individuals infected with the predominant 
CRF02_AG subtype were compared with those infected with diverse non-CRF02_AG 
subtypes. Furthermore, the results from this multiclade epidemic from Cameroon were 
compared to T cell responses measured in individuals from South Africa, a monoclade C 
epidemic, using an identical protocol and reagents (data provided by Lycias Zembe), as part 
of a multi-country initiative to map immune reactivity to HIV in different regions of Africa. 
 
3.2 MATERIALS AND METHODS  
3.2.1 Study individuals and infecting viruses 
Fifty-seven HIV-infected study participants from Cameroon were involved in this part 
of the study. They were described in Chapter 2. The infecting HIV-1 subtype was determined 
and also described in the previous chapter, in 53 of the study participants. This chapter also 
includes data from 44 HIV-infected participants from South Africa. These data were provided 
by Lycias Zembe (PhD dissertation, University of Cape Town, graduation June 2012). Donors 




were recruited from a clinic in Cape Town, in a 
study approved by the Research Ethics Committee of the University of Cape Town. Each 
participant provided written informed consent. CD4 count was determined using FlowCARE 
PLG (Beckman Coulter, CA, USA) and plasma viral load determined using NucliSENS 
EasyQ
®
 HIV-1 (Version 2.0, BioMerieux SA). The median viral load of these participants 
was 3.9 Log RNA copies/ml (IQR 2.7-4.7) and the median CD4 was 441 cells/mm
3
 (334-
580). All study participants from both sites were ART-naïve. 
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3.2.2 Processing of peripheral blood mononuclear cells 
Blood collected from each participant was processed within 8 hours of collection. 
Peripheral blood mononuclear cells (PBMC) were obtained using standard Ficoll-Hypaque 
(Sigma, St. Louis) density gradient separation and cryopreserved in liquid nitrogen. For 
ELISPOT assays, frozen samples were thawed, and the cells were rested in RPMI-HEPES 
1640 containing 20% foetal calf serum, 50 U/ml penicillin and 50 µg/ml streptomycin (all 
Invitrogen) at 37°C and 5% CO2 overnight.  
3.2.3 Synthetic HIV-1 peptides 
A set of 182 peptides based on the HIV-1 group M consensus sequence from 2001 (14 
to 16 mers overlapping by 11 amino acids) spanning full-length Gag and Nef were obtained 
from the NIH AIDS Research and Reference Reagent Program. They were used at a final 
concentration of 1.5 µg/ml in ELISPOT assays. For screening, peptides were arranged in a 
pool-matrix (Table A1 in Appendix A) format as previously described (Masemola et al., 
2004) to predict single reactive peptides.  Pools and single peptides were tested in duplicate. 
3.2.4 IFN- ELISPOT assays 
For analysis of T cell responses, PBMC were tested using the IFN- ELISPOT assay 
(ELISPOT screening plate is shown in Table A2, Appendix A), as described previously 
(Zembe et al., 2011).  Briefly, microtiter polyvinyledene plates (Millipore were coated with 
anti-IFN-γ monoclonal antibody 1-D1K (Mabtech), and 100 000 cells were incubated in each 
well with peptide pools. Control wells included media only, cells and media and 
Phytohaemagglutinin (PHA, BD Biosciences).  Following overnight incubation, plates were 
washed and incubated biotinylated anti-IFN-γ 7-B6-1 (Mabtech), washed again and incubated 
with streptavidin-HRP conjugate (BD Pharmingen, Canada), and then with NovaRed 
substrate (Vector Laboratories). Spots were counted using an automated ELISPOT plate 
reader (CTL Analyzer, CTL Technologies, Cleveland, OH) and expressed as spot forming 
units per million (SFU/10
6
) PBMC. ELISPOT test acceptance criteria were as follows: (1) 
>300 spots in the positive wells; (2) <100 spots in the negative control wells; and (3) <5 spots 
in the wells containing media only. Overall, an HIV-specific response was regarded as 
positive when it was ≥100 SFU/10
6
 PBMC after background subtraction, and at least three 
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times the mean of the background response (media and cells only). Individual reactive 
peptides predicted from the pools were confirmed in a second assay using single peptides. 
 The total response magnitude of response was determined by summing responses to all 
the protein-specific pools for each sample. To enumerate the breadth of the responses, 
recognition of the stronger of two adjacent peptides were considered as a response to one 
peptide/epitope to avoid overestimation.  In the case of three adjacent peptides, the weakest of 
all three peptides was excluded, and the responses were counted as recognition of two 
peptides. In the case of four adjacent peptides, they were counted as two.  
3.2.5 Statistical analysis 
Statistical analyses were performed using Prism 5 (GraphPad Software, San Diego, 
CA). All data were analysed using non-parametric statistics, and expressed as medians with 




3.3.1 Characteristics of the study population and infecting viruses from 
Cameroon 
Clinical and demographic data of 53 HIV-1 infected Cameroonian blood donors in 
whom the infecting viral subtype was characterised are shown in Table 3.1. The median age 
of the cohort was 31 years (IQR 21-54), and the majority of the individuals were male (79%). 
The median CD4 count was 457 cells/mm
3
 (IQR 301-665), and plasma HIV-1 RNA viral load 
was 4.94 log10 copies/ml (IQR 4.4-5.3). All individuals were ART-naïve, and HIV infection 
dates were not known. The genetic diversity of HIV-1 for these 53 study participants was 
reported in the previous chapter. Briefly, 49% (26/53) of individuals were infected with 
CRF02_AG, 38% (20/53) with a variety of circulating recombinant forms or pure subtypes, 
found at frequencies of between 2-11% each, and the remaining 15% (7/53) with viruses that 
showed discordant clade distributions in gag and nef (Table 3.1). There were no significant 
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differences in clinical or demographic characteristics of CRF02_AG and non-CRF02_AG-
infected individuals, although there was a trend towards lower CD4 counts in the latter group. 
Table 3.1 Clinical characteristics and infecting subtype of study participants from Cameroon 
(n=53)
  
CRF02_AG                                                                       Non-CRF02_AG 
 






















BS01 23 M 976 5.46  BS02d NDb  M 838 4.29 A-like 
BS02a NDb M 838 4.29 BS03 NDb  M  NDb 5.54 G 
BS05c,* 42 M 552 4.89 BS04 NDb  M 480 4.82 G 
BS06 32 M 765 4.94  BS09e 38 F 574 4.70 A1 
BS09c 38 F 574 4.70 BS10 34 M 1083 4.83 A1 
BS11c 23 M 666 5.53  BS11e 23 M 666 5.53 F 
BS13c 31 M 489 5.12 BS12 36 M 334 4.84 G 
BS14 49 M 620 4.85  BS13e 31 M 489 5.12 A1 
BS16 32 M 574 4.35 BS24 44 M 504 5.20 CRF37_cpx 
BS18a,* 41 M 521 4.39  BS25e 37 M 42 4.64 F 
BS19 34 M 630 5.54 BS26 30 M 430 5.13 CRF01_AE 
BS20a,* 24 M 782 4.27 BS27 29 M 278 5.45 CRF37_cpx 
BS21 31 M 862 4.62  BS29e 22 M 388 5.19 U 
BS22 27 F 1972 4.41 BS30 28 M 242 5.37 D 
BS23 32 M 390 4.86 BS35 54 M 434 4.22 CRF11_cpx 
BS25c 37 M 42 4.64 BS40 26 M 567 5.08 CRF36_cpx 
BS29c 22 M 388 5.19 BS46 46 F 230 4.90 G 
BS31a,* 31 F 131 3.51 BS48 29 M 878 5.12 G 
BS32 27 M 663 6.18 BS49 42 M 400 5.22 F2 
BS38 44 F 681 5.22 BS51 31 M 278 5.41 G 
BS39 27 M 373 5.09 BS54 22 F 254 4.88 D 
BS43 38 M 774 4.49  BS55e 29 M 337 5.70 F 
BS45 29 M 312 4.93 BS57 31 M 359 4.48 CRF11_cpx 
BS50 35 M 599 4.25 BS78 52 M 278 5.21 CRF01_AE 
BS53 31 M 515 5.32 BS65 49 M 282 4.82 URF 
BS55c 29 M 337 5.70 BS72 21 M 276 5.53 URF 
BS56 28 M 242 5.37 BS74 26 F 427 3.91 A-like 
BS64 28 M 732 5.27        
BS73 27 F 141 6.32       
BS75 29 F 152 5.43       
BS77 31 F 321 5.00       
BS79a,* 30 F 289 4.05       
























CRF02_AG in nef only; 
c





Non-CRF02_AG in gag only; 
e
Non-CRF02_AG in nef only (genotype differed between gag and 
nef); 
f
Number Male to Female;  *Only genotyped in one gene; U= Unknown, URF= Unique Recombinant Form. 
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3.3.2 Relationship between viral sequences and peptide reagents for 
CRF02_AG and non_AG subtypes 
In order to determine the relationship between infecting viruses and group M 
consensus peptides that were to be used as immunological reagents in the ELISPOT assay, 
amino acid distances were calculated. The median amino acid distance between viral 
sequences and consensus M peptide reagents was significantly lower for Gag (median 11%, 
range 9–13%) than for Nef (median 15%, range 10–22%). The CRF02_AG and non-
CRF02_AG sequences did not differ in distance to the consensus M sequence in Gag (Figure 
3.1A). For Nef, however, non-CRF02_AG clades exhibited a wider range of distances from 
consensus M (10 to 22% compared to 11 to 19% for CRF02_AG viruses), and the median 
amino acid distance to consensus M for non-CRF02_AG subtypes was significantly higher 
than CRF02_AG sequences (17% compared to 14%, p=0.0008; Figure 3.1A).   
To complement the genetic distance results, the putative epitope coverage of 
consensus M for Gag and Nef proteins were calculated using Epicover (www.hiv.lanl.gov), 
by determining the proportion of exactly-matched 9 mers, or 9 mer coverage with one or two 
amino acid mismatches. There were no significant differences in epitope coverage between 
CRF02_AG and non-CRF02_AG viruses for either Gag or Nef (Figures 3.1B and C). Overall, 
the consensus peptides had the same pattern of coverage even when epitopes with 1 or 2 
amino acid mismatches were taken into consideration in CRF02_AG and non-CRF02_AG 



























Figure 3.1 The relationship between infecting viral sequences and peptide amino acid sequences.  
(A) Amino acid distances between infecting viral sequences and consensus M peptide sequences for 
Gag and Nef, shown for CRF02_AG (dark grey) and non-CRF02_AG viruses (light grey). Differences 
were tested for significance by the Mann-Whitney U test. (B) Predicted 9 mer epitope coverage of 
consensus M Gag, and (C) Nef peptide sequences and CRF02_AG and non-CRF02_AG sequences. 
Coverage of 9 mers exactly matched to the viral sequences, 9 mers with one mismatch and 9 mers 
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3.3.3 T cell responses in CRF02_AG and non-CRF02_AG-infected 
individuals from Cameroon 
Specific T cell responses to Gag and Nef were investigated using the IFN-γ ELISPOT 
assay, using peptides spanning HIV-1 Group M consensus Gag and Nef. Ninety-five percent 
(54/57) of individuals recognised at least one of the peptide pools tested. Of these 54 
responders, nine participants showed no detectable Gag and seven no detectable Nef-specific 
responses. Strikingly, peptides from 16 of the 17 tested pools covering Gag and Nef were 
targeted (Figure 3.2), suggesting a broad cross-reactivity to the group M reagents. Among the 
Gag responding individuals, Pool 7 (P7; Gag p24) was the most targeted pool recognised by 
23/57 (42%) study participants. It was followed by P1 (Gag p17; 39%), P5 (Gag p24; 26% 
participants), P4 (Gag p24; 25%), P8 (Gag p24; 21%), P6 (Gag p24; 19%), P10 (Gag p24; 
9%), P11, P12 (Gag p15) and P2 (Gag p17), targeted by 7% of participants each, and P9 (Gag 
p24; 4%). In Nef, P15 (Nef central) was the most targeted pool and was recognised by 35% 
participants, followed by P14 (Nef central; 29%) and finally P13, P17 and P16 (all from Nef 









Figure 3.2 T cell responses to Gag and Nef pools. HIV-specific T cells were detected in 16 out of 17 
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The frequency of responders in the CRF02_AG and non-CRF02_AG-infected groups 
was compared, to determine whether the more diverse group of viruses demonstrated a 
different immunogenicity profile. Forty-five samples were typed in the gag gene, 27 of which 
were classified as CRF02_AG and 18 as non-CRF02_AG.  For nef, 26 of 51 samples typed 
were CRF02_AG, and 25 genotyped as non-CRF02_AG. There was no difference in the 
frequency of responders in each group, with 85% and 78% for Gag for the CRF02_AG and 
non-CRF02_AG-infected groups, respectively, and 88% for both groups for Nef reactivity 
(Figure 3.3A). 
The total magnitude of responses differed substantially among responders (Figure 
3.3B), a likely reflection of a range of factors, including immunocompetence, different levels 
of viral replication and time since infection. The total magnitude of responses against the 
entire Gag and Nef protein ranged from 107 to 7865 SFU/10
6 
PBMC (median, 1038).  At the 
protein level, the median response to Gag was 1045 SFU/10
6 
PBMC (range, 107-4508); whilst 
the median response to Nef was 884 SFU/10
6 
PBMC (range, 115-7865).  In the Gag region, 
there was a trend towards a higher total magnitude of responses (p=0.0624) in the CRF02_AG 
infected individuals compared to the non-CRF02_AG infected population (Figure 3.3B). In 
the Nef region, despite a difference in the genetic distance to consensus M peptides between 
the CRF02_AG and the non-CRF02_AG viruses, the magnitude of ELISPOT responses was 
similar between the two groups (Figure 3.3B). In terms of the breadth of the response, the 
median number of Gag peptides targeted in the CRF02_AG-infected individuals was double 
that of the non-CRF02_AG-infected population, although this difference was not significant 
(Figure 3.3C). The breadth of responses per person was equivalent for Nef, with a median of 
two targeted peptides for responders (Figure 3.3C).  
Taken together, these data suggest that despite the high diversity of the HIV-1 
epidemic in Cameroon, the magnitude and breadth of the immunological recognition of group 
M consensus peptides does not differ between CRF02_AG and non-CRF02_AG-infected 
individuals. 




















Figure 3.3 T cell responses to Gag and Nef consensus M reagents. HIV-specific T cells were 
detected in 23 CRF02_AG (dark grey) and 22 non-CRF02_AG-infected individuals (light grey) using 
the IFN-γ ELISPOT assay. (A) The frequency  of responders, (B) the total magnitude of responses, 
and (C) the breadth of responses to Consensus M Gag and Nef peptides in CRF02_AG- and non-
CRF02_AG-infected individuals. The number of responding peptides represents the minimum 
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3.3.4 Immunological targeting and immunodominance in CRF02_AG and 
non-CRF02_AG-infected individuals from Cameroon 
Having demonstrated that T cell responses were similar in frequency, magnitude and 
breadth between CRF02_AG and non-CRF02_AG-infected individuals from Cameroon, it 
was next determined whether there were differences in the specificity of peptide recognition 
across Gag and Nef. For Gag, CRF02_AG and non-CRF02_AG-infected individuals targeted 
a similar total number of peptides (27 and 22, respectively, Figure 3.4A). The majority of the 
peptides were recognised by only one individual (Figure 3.4B), and approximately one third 
of peptides (11/38) were commonly recognised by both groups (Figure 3.4C). Only two 
peptides were recognised by five or more (>25%) of individuals in the CRF02_AG group, and 
only one peptide (Gag5) was commonly recognised by at least 15% of the study participants 
(three individuals in the CRF02_AG-group and four in the non-CRF02_AG group), indicating 
a profound lack of immunodominance (peptides that are commonly targeted within a given 
population) of targeted peptides (Figure 3.4A). For Nef, peptides targeted by only one 
participant each also represented the majority of those recognised (Figures 3.4D and E).  
In contrast to Gag, however, a greater proportion of peptides were targeted by two or 
more individuals (Figure 3.4D and E), and four peptides were commonly targeted by at least 
three individuals.  The pattern of shared recognition also differed in Nef compared to Gag, 
with three times more peptides exclusively targeted in the diverse non-CRF02_AG  group 
compared to the CRF02_AG group  (10 vs 3), and more than half of all targeted Nef peptides 
(14/27) were recognised by both groups (Figure 3.4F). 
It is interesting to note that some peptides were preferentially targeted in one group 
compared to another; for example, in Gag, Gag77290-304 was targeted by 7 (35%) participants 
in the CRF02_AG  while only 1 participant (9%) targeted the same peptide in the  non-
CRF02_AG group; Gag78294-308 was targeted by 3 (15%) participants infected with 
CRF02_AG and no participants infected with non-CRF02_AG viruses; Gag93349-363 was 
targeted by 0 and 3 (27%) participants, respectively, in the  CRF02_AG  and non-CRF02_AG 
group. In Nef, Nef2179-92, Nef2490-104 and Nef28104-118 were targeted by 3 (15%) and 0, 1 (5%) 
and 4 (21%), and 6 (30%) and 1 (5%) participants, respectively, in the CRF02_AG and non-
CRF02_AG groups (Figure 3.4A and D).  


















Figure 3.4 Pattern of recognition of gag and Nef consensus M peptides in CRF02_AG and non-
CRF02_AG infected Cameroonians. The number of individuals specifically recognizing consensus 
M peptides in (A) Gag (38 peptides), in (D) Nef (27 peptides), shown for CRF02_AG (dark bars) and 
non-CRF02 virus infection (light bars). Pie charts represent the proportion of individuals recognizing 
1, 2, 3-4 and or more than 5 peptides in Gag (B) and Nef (E) in donors infected with CRF02_AG and 
non-CRF02_AG HIV-1 clades. The Venn diagrams show the total numbers of commonly and 
exclusively recognised peptides in Gag (C) and Nef (F) in CRF02_AG and non-CRF02_AG-infected 
participants. ELISPOT confirmation at the peptide level was performed for Gag in 20 and 11 
individuals, respectively, in the CRF02_AG and non-CRF02_AG group; and in Nef, on 20 and 19, 
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3.3.5 Similarities between a multiclade (Cameroon) and a monoclade 
epidemic (South Africa)  
Having observed differences and similarities between a homogeneous CRF02_AG and 
a diverse non-CRF02_AG group in Gag and Nef, the diverse epidemic in Cameroon as a 
whole was next compared to a more homogenous monoclade epidemic in South Africa. Table 
3.2 shows the characteristics of the Cameroonian cohort together with 44 HIV-infected 
individuals from South Africa, who were tested in an identical manner for ELISPOT 
responses to HIV-1 group M consensus Gag and Nef peptides (data provided by Lycias 
Zembe). CD4 counts were similar between the two groups, however viral loads were one log 
higher in the Cameroonian group (p<0.0001). Full-length gag and nef sequences were 
generated from 23 and 19 South African samples, respectively, and 100% were pure HIV-1 
clade C viruses (data provided by Lycias Zembe, PhD thesis from the University of Cape 
Town, June 2012), consistent with previous studies demonstrating the predominant 
monoclade C of the epidemic in South Africa (Zembe et al., 2011; Iweriebor et al., 2011).  
Amino acids distances between infecting viral sequences and consensus group M 
peptides were similar between the South African monoclade and Cameroonian multiclade 
epidemic in both Gag (11%) and Nef (16% and 15%, respectively; Table 3.2 and Figure A3 in 
Appendix A3). As for the within Cameroon CRF02_AG and non-CRF02_AG comparison, 
there was a trend towards a higher magnitude of responses in the monoclade compared to the 
multiclade epidemic in Gag (p=0.073; Table 3.2 and Figure A4 B in Appendix A4), and the 
median number of peptides targeted was similar. In Nef, the magnitude of ELISPOT 
responses was similar between the two cohorts, and the median number of targeted peptides 
was double in Cameroon (Table 3.2 and Figure A4 C in Appendix A4).  
When targeting of HIV-1 group M consensus Gag and Nef T cell responses in the 
mono- versus multiclade epidemic was examined, the pattern appeared very similar to the 
within-Cameroon homogenous versus diverse group comparison. Although a large number of 
peptides across Gag were targeted (74/129), the majority of peptides were targeted by only 
one individual in both groups (Figures 3.5A and B). There were few immunodominant 
responses in either group, and only two shared immunodominant responses that were 
recognised by four or more individuals from both groups (Figure 3.5A). 
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Table 3.2 Clinical Characteristics and Immunological Responses of Study Participants from 



























































Median and interquartile range; 
b
Median and range; 
c
Twenty-three samples in Gag and 19 in Nef 
were sequenced for the South Africa cohort.    
 
A similar number of Gag peptides were recognised in the two groups, namely 50 
peptides for Cameroon and 53 for South Africa; one third of these were commonly recognised 
by both groups (Figure 3.5C). In Nef, although peptides targeted by only one individual still 
made up the majority of those recognised, a greater sharing of targeted peptides was apparent 
(Figures 3.5D and E), as was observed for the within-Cameroon comparison of diverse and 
homogenous groups. More peptides were targeted in the highly diverse viral epidemic from 
Cameroon compared to South Africa (27 vs 16), and approximately half of all Nef peptides 
were recognised by both groups (Figure 3.5F). As for the within-Cameroon analysis, Nef 
exhibited a greater immunodominance compared to Gag, with five peptides being commonly 
recognised across the two populations, despite the fact that an equal frequency of peptides 
was recognised in each protein (31/53 [58%] Nef peptides and 57% in Gag). Taken together, 
these results demonstrate very similar findings for homogeneous CRF02_AG-infected 
individuals compared to diverse non-AG-infected individuals within Cameroon, and a 
 
 




 p-value   
    





a 441 (334-580) 494 (301-665) 
 
       0.5215 
  
 
Viral load (Log RNA copies/ml)
a
 3.9 (2.7-4.7) 4.9 (4.4-5.3) 
 
       0.003 
  
 
Amino acid distance to Con M
a
      Gag
c
 11 (11-12) 11 (10-12) 
 
       0.1790 
  
 (%)                                                    Nef
c
 16 (14-16) 15 (13-17)        0.1730   
 
Frequency of responders                Gag 75 79 
   




                  Gag 1455 (566-3448) 1064 (330-1769) 
 








                       Gag 2.5 (1-10)                 2 (1-9)                                           
 
      0.8721
  
(number of peptides)                       Nef  1 (1-6)                 2 (1-13)         0.2260   
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homogeneous monoclade epidemic in South Africa compared to a diverse multiclade 


















Figure 3.5 Pattern of recognition of Gag and Nef consensus M peptides in HIV-infected 
individuals from Cameroon and South Africa. The number of individuals specifically recognizing 
consensus M peptides in (A) Gag (74 peptides), in (D) Nef (31 peptides), shown for Cameroon (white 
bars) and South Africa (black bars). Pie charts represent the proportion of individuals recognizing 1, 2, 
3-4 and or more than 5 peptides in Gag (B) and Nef (E) in HIV- infected individuals from Cameroon 
and South Africa. The Venn diagrams show the total numbers of commonly and exclusively 
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the peptide level was performed on 26 and 41 participants for Gag, and 17 and 41 participants for Nef, 
for South Africa and Cameroon, respectively. 
The identification of regions of HIV commonly targeted in different populations has 
importance for the development of a universal HIV vaccine. The peptides that were 
commonly recognised between Cameroon and South Africa were further investigated. A total 
of 40 commonly targeted peptides were identified, 28 in Gag and 12 in Nef protein (Table 
3.2). Of these, 24/40 (60%) have previously been associated with a beneficial effect on viral 
load (Mothe et al., 2011), with 20 in Gag and four in Nef. Further characterisation of these 
peptides demonstrated that 21/28 (75%) in Gag and 9/12 (75%) in Nef were located in the 
conserved regions of these proteins, namely p24 for Gag and the central region of Nef, and all 
contained previously identified epitopes, confirming that consensus M reagents identify 
responses targeting conserved regions of HIV 
In addition to the low frequency of immunodominant commonly recognised peptides 
between the two geographically-distinct epidemics, there was a clear signal of preferential 
targeting in the different populations, as had been observed in the within Cameroon 
comparison. For example, peptide Gag517-31 was targeted by 10 (24%) participants in 
Cameroon and not targeted at all in South Africa; Gag47176-190 was targeted by 2 (5%) 
participants in Cameroon and by 5 (19%) participants in South Africa; Gag77290-304 was 
targeted by 8 (20%) participants in Cameroon and only 2 (8%) participants in South Africa; 
Gag81305-318 by 7 (17%) participants in Cameroon and only 1 (4%) participant in South 
Africa. In the Nef protein, Nef33124-138 was targeted by 1 (2%) participant in Cameroon and 
by 3 (18%) participants in South Africa; Nef35131-145 was targeted by 14 (34%) participants in 
Cameroon, and only a single participant (6%) in South Africa (Table 3.3).  
These differences in recognition are likely driven by viral and host genetic factors 
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Table 3.3 Commonly recognised peptides between monoclade (South Africa) and multiclade 
(Cameroon) epidemics  
Peptide No Peptide sequence Location Frequency of responders (%) Beneficial
a
 





p17 4 2 No 
8 YRLKHLVWASRELER p17 4 2 No 
11 LERFALNPGLLETS p17 4 12 Yes 
21 LYNTVATLYCVHQRI p17 12 2 Yes 
38 GQMVHQAISPRTLNA  
 
p24 12 2 No 





p24 12 5 Yes 
43 EEKAFSPEVIPMFSA  
 
p24 12 10 Yes 
47 SEGATPQDLNTMLNT  
 
p24 19 5 Yes 
48 TPQDLNTMLNTVGGH  
 
p24 27 12 Yes 
49 LNTMLNTGVGHQAAM P24 4 2 Yes 
51 GGHQAAMQMLKDTIN  
 
p24 8 2 Yes 
52 AAMQMLKDTINEEAA  
 
p24 4 2 Yes 
53 MLKDTINEEAAEWDR  
 
p24 8 12 Yes 
54 TINEEAAEWDRLHPV  
 
p24 4 2 No 
63 GTTSTLQEQIAWMTS P24 12 2 Yes 
67 NPPIPVGEIYKRWII  
 
p24 4 2 No 
68 PVGEIYKRWIILGLN  
 
p24 4 10 No 
71 GLNKIVRMYSPVSIL  
 
p24 4 5 Yes 
73 YSPVSILDIRQGPK  
 
p24 4 2 Yes 
77 KEPFRDYVDRFFKTL  
 
p24 8 20 Yes 
78 RDYVDRFFKTLRAEQ  
 
p24 15 10 Yes 
79 DRFFKTLRAEQATQ  
 
p24 8 2 Yes 
80 FKTLRAEQATQDVKN  
 
p24 4 2 Yes 
81 RAEQATQDVKNWMT  
 
p24 4 17 Yes 
88 CKTILKALGPGATL P24 4 7 No 
115 RQANFLGKIWPSNKG  
 
p2p7p1p6 12 2 Yes 
116 FLGKIWPSNKGRPGN  
 
p2p7p1p6 4 2 Yes 
      






outer region 6 7 No 
18 GFPVRPQVPLRPMTY  
 
outer region 29 24 No 
19 RPQVPLRPMTYKAAL  
 
outer region 24 32 No 
24 FLKEKGGLEGLIYSK  
 
central region 6 12 No 
27 LIYSKKRQEILDLWV  
 
central region 12 2 No 
28 KKRQEILDLWVYHTQ  
 
central region 29 20 No 
29 EILDLWVYHTQGYFP  
 
central region 6 5 No 
30 LWVYHTQGYFPDWQN  
 
central region 12 7 No 
31 HTQGYFPDWQNYTPG  
 
central region 24 12 No 
33 WQNYTPGPGIRYPLT  
 
central region 18 2 No 
34 TPGPGIRYPLTFGW  
 
central region 24 15 No 
35 PGIRYPLTFGWCFKL  
 
central region 6 34 No 
a“Yes” indicates that peptides have been classified as beneficial for lower viral load by Mothe 
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3.4 DISCUSSION  
The substantial genetic diversity of HIV is a major challenge for vaccine development.  
Whilst there is baseline knowledge of HIV diversity in most countries, there is limited 
information on the relationship between genetic diversity and cross-clade immune reactivity. 
Immunological responses to HIV-1 consensus M-based peptides were characterised in two 
distinct African HIV-1 epidemics, namely Cameroon in west central Africa, the origin of the 
HIV-1 pandemic (Tongo et al., 2013; Carr et al., 2010), a country with virtually every known 
clade of HIV-1 circulating (Machuca et al., 2007; Brennan et al., 2008; Ndembi et al., 2008; 
Ragupathy et al., 2011; Tongo et al., 2013), which has an evolving epidemic in which HIV-1 
recombinants predominate (Carr et al., 2010), within an ethnically diverse population; and 
South Africa, located at the southern-most tip of Africa, with one of the highest adult 
prevalences globally at 18% (UNAIDS, 2012), but with a homogeneous clade C epidemic 
(Zembe et al., 2011; Iweriebor et al., 2011). The primary analysis in Cameroon sought to 
describe the differences in immunological responses to the predominant CRF02_AG subtype 
with other rarer circulating subtypes and recombinants, and determine whether the use of 
consensus clade M reagents could broadly detect T cell responses, in light of the high levels 
of viral diversity. This has implications for the broader context of performing vaccine trials in 
the region (Ellenberger et al., 2002; Stephenson and Barouch, 2013). There was no difference 
in the frequency, cumulative magnitude or breadth of IFN-γ responses to Gag or Nef between 
the two groups. This was despite significantly higher genetic distances between the non-
CRF02_AG viruses and consensus M sequences for Nef. Differences between the two groups 
emerged at the peptide level, particularly in the Nef protein, where there were a higher 
number of targeted peptides in the non-AG subtypes compared to CRF02_AG, although a 
lack of immunodominance was evident, with most peptides targeted by only a single 
participant. The same observation was seen when the diverse epidemic of the Cameroon 
group as a whole was compared with a monoclade C epidemic in South Africa. These data 
suggest that higher HIV-1 diversity leads to the detection of broader HIV-1 specific responses 
at the cohort level, but not at the individual level.  Thus, the use of consensus M reagents did 
indeed result in broad recognition in HIV-infected individuals, consistent with studies in other 
populations (Rutebemberwa et al., 2005; Bansal et al., 2006; Malhotra et al., 2007; Frahm et 
al., 2008; Serwanga et al., 2012; Côrtes et al., 2013).  
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This work formed part of a multi-country study examining the immune reactivity of 
Group M consensus Gag and Nef using identical methodology. The findings generated here 
are similar to those of Serwanga and colleagues who examined immune responses in Uganda, 
a predominant clade A and D epidemic (Serwanga et al., 2012). Interestingly, of the seven 
most targeted peptides that they identified, five were also commonly targeted peptides in our 
study. One limitation of our study was that we did not performed HLA typing in our cohort; 
this would have allowed us to better see the impact of HLA on targeting of peptide. Despite 
this, our finding plus Serwanga et al. clearly demonstrates that consensus M reagents, despite 
being central to all the group M viruses, identify a narrow immunodominance spectrum in 
different HIV clade epidemics and populations. This could be because consensus M 
sequences do not take into account the true extent of HIV-1 diversity (Walker and Korber, 
2001), as well as the HLA composition in different populations having an effect on 
immunodominance (reviewed in Goulder and Watkins, 2008). In addition, the observation 
that there were immunodominance differences between cohorts favours the use of full-protein 
(not epitope-based) immunogens in the design of an HIV vaccine; this is mainly because 
different viruses and human drive immune response to specific epitopes.  Therefore, assessing 
reactivity to newer vaccine immunogens that incorporate both human and HIV diversity, such 
as the conserved elements or mosaic immunogens (Korber et al., 2009), may increase 
recognition and give a truer picture of reactivity.  
A major question that still remains in vaccine development is the importance of 
breadth of the T cell response compared to specificity of the response. Mothe et al. (2011) 
performed a large study to identify peptides that were beneficial for slower disease 
progression. These were frequently located in HIV Gag and Pol, but rarely in the more 
variable proteins such as Env and Nef. Despite the low frequency of immunodominant 
commonly-recognised peptides between the two geographically distinct epidemics in this 
study, 50% of the commonly recognised peptides could be considered beneficial according to 
Mothe et al., all of these located in Gag. Although very few peptides were identified as 
beneficial by Mothe et al., in Nef in that study, it exhibited a greater immunodominance in the 
presentis study compared to Gag, with three peptides being commonly recognised by at least 
20% of the study participants in both epidemics. These peptides might still induce strong and 
effective immune responses, as Mudd et al. (2012), have shown that few some epitopes in Nef 
were associated with viral control in macaques that expressed Mamu-B*08 in a vaccine study. 
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(Mudd et al., 2012). Thus, the current view on what may constitute a protective cellular 
immune response to HIV is likely biased towards immunodominant responses and those 
restricted by frequent HLA class I alleles and HLA alleles associated with superior disease 
outcome.  
In conclusion, these data show that the central nature of HIV-1 consensus M 
sequences resulted in their broad recognition by T cells, both in a highly diverse HIV 
epidemic from Cameroon, and a homogeneous epidemic from South Africa. As expected, 
different patterns of immunodominance prevailed at each site, likely governed by both viral 
and host HLA differences. Here, the most striking finding was that the consensus M reagents 
failed to identify highly immunodominant peptides that were common within or between 
homogeneous and diverse HIV epidemics. The implications for the development of a global 
HIV vaccine are that immunogens should take into consideration not only the overall 
diversity of the virus but also should address the diversity at the population level. Further 
refinement of immunogens based on consensus sequences, taking into account human 
diversity, is required for the development of a globally relevant vaccine.
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4.1 INTRODUCTION 
The development of a safe, globally effective and affordable vaccine offers the best 
hope for the future control of the HIV pandemic. One of the major challenges in developing 
such a vaccine is the high degree of genetic diversity the virus exhibits. This enormous 
variation in HIV-1 poses a barrier to both the design of a protective vaccine and the 
evaluation of such a vaccine, since a globally effective vaccine will most likely need to elicit 
cross-protective immunity against all circulating strains that an individual may encounter 
(McMichael and Hanke, 2003; Mullins and Jensen, 2006; reviewed by Nabel, 2001). To date, 
all vaccine candidates tested in human clinical efficacy trials have used single or multiple 
representatives of HIV from different subtypes, for example the RV144 trial tested subtypes B 
and CRF01_AE (Pitisuttithum et al., 2006), the STEP and Phambili trials used subtype B 
(Buchbinder et al., 2008; Gray et al., 2011) and the HVTN505 trial tested subtype B for gag, 
pol and nef genes and the env gene from HIV subtypes A, B and C (Catanzaro et al., 2006; 
2007). In the absence of any efficacy from all but one of these trials, and no T cell correlates 
of efficacy in a vaccine trial, we still do not know what kind of viral sequence or group of 
sequences is required to induce T cells that can cross-react and cross-protect against a broad 
spectrum of circulating viruses.  
Traditionally, the main approaches at attempting to improve immunogenic coverage 
have focused on the use of consensus sequences, MRCA and COT (Ellenberger et al., 2002; 
Gaschen et al., 2002; Korber et al., 2001; Mullins et al., 2004; Roland et al., 2007). These 
approaches for generating an artificial sequence minimise the genetic distance from 
circulating strains of the virus. A more recent and novel approach, mosaic sequences, involves 
the use of algorithms to improve 9mer epitope coverage that can accurately reflect immune 
responses to virus encountered by the host (Nickle et al., 2007; Fischer et al., 2007). For 
example, across a specific HIV protein sequence alignment, multiple 9mer epitopes at a given 
position which can vary in one or more amino could exist, reflecting the diversity within that 
set of sequences. Thus, when these multiple epitopes variants are included in an immunogen, 
they could be presented to CD8+ T lymphocytes and could then induce an immune response 
against multiple different variants of the virus. These 9mer epitopes embedded in multiple 
overlapping mosaic sequences are known as Potential T cell Epitopes or PTEs (Li et al., 
2006). In a mosaic approach, software algorithms combine sequences which allow the 
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processing and expression of a maximum of variants of the same epitope. Therefore, 
sequences based on the mosaic approach which are similar to naturally circulating HIV-1, 
would demonstrate a greater depth or coverage of potential T-cell epitopes for different HIV 
proteins (Fischer et al., 2007; Thurmond et al., 2008; Corey and McElrath, 2010). The 
optimisation process can be performed for a single HIV subtype or for all the group M 
subtypes. This is a great advantage over consensus sequences, which are also artificially 
derived but consist of a unique sequence that at each site contains the amino acid that was 
most common amongst the aligned sequences that it was generated to represent.  
Preclinical vaccine trials comparing these new mosaic immunogens containing 
multiple PTE variants, to consensus and natural sequences in rhesus macaques, showed an 
improvement in the T cell immune response generated. In one study (Barouch et al., 2010), 
bivalent mosaic Gag, Pol and Env antigens expressed by replication incompetent Ad26 were 
administrated to rhesus macaques, and compared to group M consensus, bivalent subtypes B 
and C and optimal natural subtype C immunogens also expressed by the same vector. Breadth 
and magnitude of vaccine-elicited HIV-specific T cell responses were assessed by IFN-γ 
ELISPOT assays using PTE peptides based on the mosaic sequences. The total number of 
Gag-, Pol- and Env-specific cellular responses to PTE peptides elicited by the mosaic antigens 
was 3.8-fold higher than the number of responses induced by the consensus or natural 
sequence antigens. More importantly, the mosaic vaccine induced T cell responses that 
recognised more variants within an epitope (depth) than consensus or natural sequence 
antigens. A second similar preclinical study compared responses in animals receiving either 
mosaic or consensus group M Gag and Nef immunogens delivered by a DNA prime–
recombinant vaccinia virus boost regimen (Santra et al., 2010). T cell immune responses were 
also assessed by IFN-γ ELISPOT assays using sets of peptides from subtypes A, B, C and G. 
Here, a greater magnitude, breadth and depth of responses to Gag mosaic immunogens were 
observed compared to consensus, but no difference was seen for Nef. These experimental 
results indicated that in addition to the vector involved, reagents used to map T cell responses 
influenced the outcome of experiments, with differences between the mosaic and consensus 
and natural sequences being less apparent when evaluated with subtype-specific peptides 
compared to PTE peptides (Barouch et al., 2010; Santra et al., 2010).  
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In the absence of clinical trials evaluating these new vaccine immunogens in humans, 
it is important to understand the potentially relevant responses that T cell-based vaccines to 
these mosaic sequences could elicit or detect. One of the ways to achieve this is to use the 
peptides based on the mosaic immunogens (PTE peptide sets) to stimulate PBMC from HIV-
infected individuals and evaluate their recognition. This may provide some information on 
whether mosaic vaccines, if tested in a particular population, would generate responses that 
were cross-reactive to the circulating HIV strains present in that population.  To date, only a 
single study has investigated the ability of a subtype B PTE peptide set based on Nef to detect 
T cells from HIV subtype B-infected individuals (Malhotra et al., 2007). T cells responses 
were evaluated with subtype B consensus and PTE Nef peptides in 23 individuals using the 
IFN-γ ELISPOT assay. Although the specificity of responses was comparable when the two 
sets of peptides were used, both the breadth and the magnitude of responses detected were 
significantly higher when PBMC were stimulated with PTE peptides compared to consensus 
peptides (Malhotra et al., 2007).  
This chapter describes the ability of T cells from HIV-infected blood donors from 
Cameroon, with a highly diverse HIV epidemic, to recognise multiple group M peptide 
variants using PTE peptide sets for Gag and Nef. These results were compared with responses 
detected using consensus M peptides, generated in the previous chapter. The hypothesis was 
that the use of PTE peptides would improve the immunological detection of responses 
compared to the use of consensus peptides. 

4.2 MATERIALS AND METHODS 
4.2.1 Study individuals 
 Thirty-two individuals from the cohort of HIV-infected blood donors from Cameroon 
that had previously been screened for consensus M responses by ELISPOT (reported in 
Chapter 3) were selected for this study. Selection was based on individuals mounting an HIV-
specific response to consensus group M peptides greater or equal to 100 SFU/10
6
 PBMC, and 
sufficient PBMC sample being available for further study. 
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4.2.2 Synthetic HIV-1 peptides 
A set of 320 Gag and 127 Nef peptides based on HIV-1 group M PTE sequences 
spanning the entire Gag and Nef proteins (Los Alamos National HIV sequence database, 
February 2005) were obtained from the NIH AIDS Research and Reference Reagent Program. 
The peptides are 15 amino acids in length and contain naturally occurring 9mer epitopes from 
HIV. For screening, peptides were arranged in pools using the Deconvolution program (Mario 
Roederer, Vaccine Research Center, NIH; Tables B1 and 2 in Appendix B) to allow for single 
peptide mapping using IFN- ELISPOT. There were 63 pools in total, 40 in Gag and 23 in 
Nef. In Gag, each pool consisted of 32 peptides, and in Nef, there were 7-20 peptides in each 
pool. The pattern of responses to the pools indicated specific candidate reactive peptides for 
confirmation. Group M PTE peptides contain 9mer epitopes with a frequency equal to or 
greater than 15% in any one of the subtypes A, B, C and non-A,B,C. Single peptides from all 
the variants were available as 1mg lyophilised preparations. These were reconstituted to 30µl 
aliquots of 10mg/ml as stocks and then further diluted to 40µg/ml as peptide pools or 
individual peptides and stored at -80
0
C. They were used at a final concentration of 1.5µg/ml 
in IFN-γ ELISpot assays.  
4.2.3 IFN- ELISPOT assay 
HIV-specific T cell responses were assessed by the IFN-γ ELISpot assay (ELISPOT 
screening plate layout is shown in Table B3, Appendix B), as previously described in Chapter 
3 of this thesis. The same protocol was used as previously described, with the same criteria 
for positivity. Experiments comparing the two sets of reagents (Consensus and PTE peptides) 
were not carried out simultaneously. Therefore, to ensure that a valid comparison could be 
made between the same PBMC tested several years apart, various analyses were performed. 
There was a correlation between the consensus and PTE ELISPOT responses (Figure B1, 
Appendix B ) when PBMC were stimulated with the CEF control peptide pool (p<0.0001), as 
well as when exactly matched peptides, or peptides shifted by one amino acid, between the 
two sets were compared PBMC (p<0.0001). These results indicate that the quality of PBMC 
sample and the reagents used in the ELISPOT gave equivalent responses and results from the 
two studies on the same samples could be compared. 
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4.2.4 Analysis of peptide responses  
The breadth of responses or number of epitopic regions only take into account the 
number of distinct peptides with no inclusion of variants.  As it was in chapter 3, recognition 
of the stronger of two adjacent peptides was considered as a response to one peptide/epitopic 
region to avoid overestimation.  In the case of three adjacent peptides, the weakest of all three 
peptides was excluded, and the responses were counted as recognition of two peptides. The 
total magnitude of response was determined by summing responses to all peptides or epitopic 
regions with the highest response among variants for each sample. To delineate the number of 
variants, PTE peptides with aa overlap of <10 were counted as one peptide. The depth of the 
T cell response was determined by taking all the reactive peptides plus their reactive variants.  
4.2.5 Statistical analysis 
Statistical analyses were performed by using GraphPad Prism version 5.0 (GraphPad 
Software).  Total magnitude and breadth of responses to PTE and consensus peptide sets for 
matching donors were compared using Wilcoxon nonparametric two-tailed paired tests. 
Mann-Whitney nonparametric analysis for unpaired measures was used to test for significant 
differences between Gag and Nef PTE peptide responses. Differences were considered 
statistically significant when p was <0.05. 
 
4.3 RESULTS 
4.3.1 Participants and viruses  
Clinical and demographic data of the 32 HIV-infected Cameroonian participants 
included in this chapter are summarised in Table 4.1. These individuals were selected from 
the full cohort described in the previous chapters based on their total magnitude of response to 
group M consensus Gag or Nef peptides reactivity (of at least 100 SFU/10
6
 PBMC), and with 
sufficient PBMC vials available for further testing. Twenty-two individuals were screened in 
Gag and they were 27 in Nef. Individuals had a median age of 31 years (IQR 21-54) and the 
majority were male, with a ratio of 23:9. The median CD4 count was 494 cells/mm
3
 (IQR 
312-663) and a median viral load of 4.9 Log RNA copies/ml (IQR 4.4-5.3).  
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Table 4.1 Characteristics of study individuals (n=32)  
Sample ID Age  Sex CD4 count  
Log Viral 
load   
Infecting virus 
          Gag Nef 
BS 09 38 F 574 4.7 CRF02_AG A1 
BS 11 23 M 666 5.5 CRF02_AG F 
BS 14 49 M 620 4.8 CRF02_AG CRF02_AG 
BS 16 32 M 574 4.3 CRF02_AG CRF02_AG 
BS 18 41 M 521 4.4 ND
a
 CRF02_AG 
BS 20 24 M 782 4.3 ND CRF02_AG 
BS 22 27 F 1972 4.4 CRF02_AG CRF02_AG 
BS 23 32 M 390 4.9 CRF02_AG CRF02_AG 
BS 25 37 M 42 4.6 CRF02_AG F 
BS 27 29 M 278 5.5 CRF37_cpx CRF37_cpx 
BS 29 22 M 388 5.2 CRF02_AG U 
BS 30 28 M 242 5.4 D D 
BS 35 54 M 434 4.2 ND CRF11_cpx 
BS 38 44 F 681 5.2 CRF02_AG CRF02_AG 
BS 39 27 M 373 5.1 CRF02_AG CRF02_AG 
BS 40 26 M 567 5.1 CRF36_cpx CRF36_cpx 
BS 46 46 F 230 4.9 G G 
BS 48 29 M 878 5.1 G G 
BS 49 42 M 400 5.2 F2 F 
BS 50 35 M 599 4.3 CRF02_AG CRF02_AG 
BS 51 31 M 278 5.4 G G 
BS 53 31 M 515 5.3 CRF02_AG CRF02_AG 
BS 54 22 F 254 4.9 D D 
BS 55 29 M 337 5.7 CRF02_AG F 
BS 64 28 M 732 5.3 CRF02_AG CRF02_AG 
BS 65 49 M 282 4.8 CRF22_01A1 CRF01_AE 
BS 72 21 M 276 5.5 CRF36_cpx/F2 CRF01_AE/F 
BS 73 27 F 141 6.3 CRF02_AG CRF02_AG 
BS 74 26 F 427 3.9 ND A 
BS 77 31 F 321 5.0 CRF02_AG CRF02_AG 
BS 78 52 M 278 5.2 ND CRF01_AE 
BS 79 30 F 289 4.0 ND CRF02_AG 
     
  
Median 
(IQR) 31 (21-54) 23:09
b




Number Male to Female 
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In this subset of selected individuals, based on the HIV gag and nef sequences 
generated in Chapter 2, CRF02_AG predominated, accounting for 44% (14/32) of the studied 
infections, followed by subtype G (9%, 3/32), subtype D (6%, 2/32), CRF37_cpx, CRF11-
_cpx, CRF36_cpx, F2, CRF01_AE (3% each with 1/32). In addition, 22% (7/32) of the 
studied viruses had nef and gag genes from viruses belonging to different subtypes. In Gag, 
16 out of 22 individuals (73%) were CRF02_AG. Nef was more diverse than Gag, with 11/27 
(41%) infected with CRF02_AG and 16/27 (59%) other subtypes.  
 
Both clinical characteristics and immune responses to consensus M (magnitude and 
breadth) were similar between this subset of the cohort and the full cohort described in 
Chapter 3.  
4.3.2 Frequency, magnitude and breadth of responses to HIV-1 Group M 
PTE peptides 
HIV-specific responses to PTE Gag and Nef proteins were investigated using the IFN-
γ ELISPOT assay in HIV-infected individuals from Cameroon. Twenty two individuals were 
screened in Gag and 27 in Nef. Ninety-one percent (20/22) in Gag and 85% (23/27) in Nef of 
all individuals recognised at least one of the PTE peptides. Two donors in Gag and four in 
Nef showed no detectable response to the PTE peptides even though they targeted group M 
consensus peptides.  
 
The level of immune reactivity to the PTE peptides within each individual tested was 
examined next. Confirmation of reactive peptides was performed in 17 individuals that had 
responded to both Gag and Nef PTE peptides. The range of HIV-specific T cell responses 
differed substantially among different individuals, with the total magnitude of responses 
against the entire Gag and Nef protein ranging from 230 to 5790 SFU/10
6 
PBMC. At the 
protein level, the median response to Gag was 1510 SFU/10
6 
PBMC (range 370-5790), whilst 
the median response to Nef was 1320 SFU/10
6 
PBMC (range 230-4190). There was no 
significant difference between the overall magnitude of the response to Gag versus Nef 
(p=0.3262; Figure 4.1 A). 
Subsequently, analyses of the HIV-specific T cell responses from study individuals at 
the single peptide level were performed. A total number of 83 out of 320 (26%) peptides 
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(including variants) were recognised in Gag. In Nef, substantially more peptides were 
targeted, namely 81 out of 127 (64%) of peptides. To determine the breadth of response, a 
strategy outlined in the Methods section was used. As observed with the magnitude of 
responses, the breadth of responses also varied substantially among study participants. The 
median number of peptides recognised per individual was 2, both in Gag (range, 1 to 6) and 























Figure 4.1 Total HIV-specific IFN-γ producing T cells against group M PTE Gag and Nef 
peptides. (A), total magnitude of responses to Gag and Nef individual peptides recognised in 17 study 
subjects. (B) Total number of peptides recognised in Gag and Nef proteins. The number of responding 
peptides represents the minimum response, after taking into consideration overlapping peptides and 
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4.3.3 Comparison of the reactivity of PTE peptides and consensus M 
peptides 
4.3.3.1 Magnitude and breadth of responses 
The magnitude and breadth of Gag and Nef reactivity for PTE and consensus group M 
peptides were next compared in the 17 responding study individuals. In Gag, the magnitude of 
responses per individual was significantly higher when PTE peptides were used compared to 
when consensus peptides were used (Figure 4.2A; left panel). The median response 
magnitude was 1510 and 1013 SFU/10
6
 PBMC (p=0.0045) for PTE versus consensus 
peptides (range, 370-5790 and 128-4850, respectively; Figure 4.2A; left panel). In Nef, in 
contrast to what was observed for Gag, the magnitude of IFN-γ responses was similar 
between the two sets of peptides (Figure 4.2A; right panel). The median magnitude of 
response was 1320 and 1342 SFU/10
6
 PBMC (p=0.2977) for PTE versus consensus peptides 
(range, 230-4190 and 260-3266, respectively; Figure 4.2A; right panel). The magnitude of 
responses followed a similar pattern for both proteins when only corresponding or matched 
peptides in the two panels were compared (Figure 4.3). Although the total magnitude of 
response was similar for Nef when the two sets of peptides were used, eight individuals 
representing 47% of the cohort had an increased magnitude of responses when PTE peptides 
set were used, compared to only five (29%) individuals who showed an increased magnitude 
of responses with consensus peptides (Figure 4.4A).  
 
Surprisingly, the overall breadth of IFN-γ ELISPOT responses to PTE peptides was 
similar to what was observed with consensus M peptides. A median of 2 Gag peptides were 
targeted when PTE and consensus peptides panel were used (range 1-6 with both set of 
reagents; Figure 4.2B; left panel). In Nef, a median of 2 peptides were also targeted when 
PTE peptides were used compared to consensus (range 1-7 for PTE and 1-5 for consensus; 
Figure 4.2B; right panel). There was also a similarity in the total number of epitopic regions 
targeted within the two proteins when the two sets of reagents were used. In Gag, study 
participants responded to a total of 46 peptides from consensus M, whilst they targeted 44 
PTE epitopic regions. In Nef, there was a total number of 38 and 46 peptides targeted to 
consensus M and PTE peptides, respectively. It appears from these data that PTE peptides 
were not able to dramatically increase the breadth of responses detected.  
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Figure 4.2 T cell responses to Gag and Nef consensus and PTE M reagents. HIV-specific T cells 
were detected in 17 infected individuals using PTE peptides (blue) and consensus peptides (red) and 
ELISPOT assay. (A) The total magnitude of responses (Gag, left panel; Nef, right panel), and (B) the 
breadth of responses (Gag, left panel; Nef, right panel). The number of responding peptides or epitopic 
regions represents the minimum response, after taking into consideration overlapping peptides and 
variants, as described in the Methods. Tcell responses between consensus and PTE peptide sets were 
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Figure 4.3 The total magnitude of responses from matched individuals for PTE and consensus 
group M peptides in Gag and Nef. Each dot represents a study participant and T cell responses 
between consensus and PTE peptide sets were compared by the use of Wilcoxon paired test. 
 
 
 However, when the data were looked at in more detail, some interesting observations 
emerged. Six individuals, representing 35% of the cohort, had a higher number of peptides or 
epitopic regions detected when PTE peptides set were used compared to three (18%) of 
individuals with consensus peptides in Nef (Figure 4.4B). When more PTE peptides were 
recognised, four out the six (67%) of individuals were infected with CRF02_AG, and when 
there were a higher number of consensus peptides recognised, all three individuals were 
infected with non-CRF_02AG subtypes. In Gag, an equal number of individuals (five 
representing 29% of the cohort) had a higher number of peptides detected when PTE peptides 
or consensus reagent were used (Figure 4.4C).  
 
There was also a clear signal that the same peptide was targeted (overlap by > 10 
amino acid) when both sets of reagents were used. For example in Gag, the majority of 
targeted consensus peptides (30/46, 65%) were also recognised when PTE peptides were used 
(Table 4.2). The majority of targeted consensus peptides was also targeted when using the 
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Figure 4.4 Comparison of PTE and consensus peptide set reactivity. (A) Magnitude of responses 
in Nef, (B) breadth of responses in Nef, and (C) breadth of responses in Gag.  
 
Thus, the magnitude of T cell responses in the Gag protein was significantly higher 
when PTE peptides were used in this highly diverse HIV-infected population compared to 
consensus peptides, although this was not the case for Nef.  In addition, whilst the overall 
median breadth of the response in the cohort did not change, a proportion of individuals in 
Nef had an increased number of responses. 
  
To determine whether the diversity within the cohort affected the immune recognition 
when the two sets of peptide were used, the cohort was divided into CRF02_AG-infected 
individuals and non-CRF02_AG. This could be performed only with Nef responses, with nine 
and eight individuals in each group, respectively. The comparison could not be performed 
with Gag responses, since the majority of individuals were infected with CRF02_AG. In the 
CRF02_AG-infected group, the magnitude of Nef responses was similar when the two sets of 
peptide were used. The median magnitude of response was 1770 and 1420 SFU/10
6
 PBMC, 
respectively, with PTE and consensus peptides (Figure 4.5A; left panel). The breadth of 
responses was also similar, with a median of two peptides recognised in the two sets of 
peptides (Figure 4.5B; left panel). In the non-CRF02_AG infected individuals, the same was 
observed. The magnitude of responses was similar when consensus peptides were used 
compared to PTE peptides. The median magnitude of response was 1171 and 635 SFU/10
6
 
PBMC (p=0.9), respectively with consensus and PTE peptides (Figure 4.5A; right panel). The 
median breadth of responses was also similar when the two sets of reagents were used, with 2 
  24% 29% 47% 
PTE Cons 
  41% 29% 29% 
PTE Cons 
  47% 18% 35% 
PTE Cons 
A B C 
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vs 1.5 targeted peptides (p=0.2) with consensus and PTE respectively (Figure 4.5B; right 
panel). In addition, a total number of 49 peptides (including variants) were targeted in the 


























Figure 4.5 Comparison of Nef responses in CRF02_AG and non-AG-infected individuals. HIV-
specific T cells were detected in nine CRF02_AG (right panel) and eight non-CRF02_AG-infected 
individuals (left panel) using the PTE (blue) and consensus (red) peptides. (A) the total magnitude of 
responses, and (B) the breadth of responses to Nef peptides detected in CRF02_AG and non-
CRF02_AG-infected individuals.  
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4.3.3.2 Distribution of reactive PTE and Consensus peptides in Gag and Nef  
It was next determined how targeted peptides from the two sets of peptides were 
distributed across the Gag and Nef proteins. Figure 4.6 shows the position of all the targeted 
consensus and PTE peptides across Gag and Nef. In Gag, the highest density of targeted 
peptides was observed for Gag p24 (amino acids 150-336). In both sets of reagents, reactive 
domains detected with both the consensus and PTE peptide sets were similar, spanning the 
entire protein; meanwhile, a minor acluster between amino acids 71-83 was exclusively 
detected using PTE peptides, and by only one study participant. Peptides that were targeted by 
at least three study participants with the two sets of reagents spanned amino acids 162-186 
and 296-311 (Figure 4.6).  
 
In Nef, the pattern of T cell responses between the two set of reagents was similar, 
with the central region, spanning amino acids 74-150 being the most frequently targeted 
(Figure 4.6). Reactivity was thus distributed along the most conserved regions of Gag and Nef 
for both PTE and consensus peptides.  
4.3.3.3 Depth of responses 
Next, the depth of the response, which is the cross-reactivity to different peptide 
variants, was determined for the PTE peptide set. For several of these peptides, recognition of 
multiple variants was detected with the PTE peptide set, with up to five variants being 
recognised for particular peptides (Table 4.2 and 4.3). An example of this can be seen with 
the most frequently targeted peptide when the two sets of reagents were used. Consensus 
Gag81 was targeted by five (29%) study participants while its corresponding PTE peptide was 
targeted by six (35%) participants; among these six participants, all except one also 
recognised at least one variant of this peptide, with some individuals reacting to three variants  
(Table 4.2). In Nef, consensus Nef35 was targeted by 8 (47%) study participants and its 
corresponding PTE peptide was recognised by seven (41%) participants, all of whom also 
recognised at least one variant of this peptide, with some individuals reacting to three variants 
(Table 4.3). In addition, out of a total of 83 peptides plus variants recognised in Gag, only 12 
(14%) had sequence that matched the autologous viral sequence. The same trend was 
observed in Nef, where only 8/81 (10%) of targeted PTE peptides matched the corresponding 
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viral sequence. Despite this, multiple peptide variants were recognised by individuals even 
when sequences did not match the autologous virus sequences (Tables 4.2 and 4.3).  
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Figure 4.6 Reactive peptide distribution across Gag and Nef. Total number of targeted PTE (blue) 
and consensus (red) peptides are displayed and shown is the mid-point amino acid position for the 
peptide. 
 
Figure 4.7 shows the proportion of recognised peptides with targeted variants in Gag 
and Nef. Individuals targeted a total of 44 peptides or epitopic regions in Gag. Out of these 
peptides, 25 (57%) had also at least one variant targeted, while 19 had no targeted variant. 
The opposite was observed in Nef, where a total of 46 epitopic regions were targeted. Out of 
these, only 18 (39%) had at least one variant that was also targeted (Figure 4.7A). Thus, the 
majority of targeted peptides in Gag had at least one variant targeted, but this was not the case 
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with Nef. Within Nef, although the majority of targeted peptides had no variant targeted in 
both the CRF02_AG and non-CRF02_AG infected individuals, there was a greater number of 








Figure 4.7 Proportion of recognised peptides with targeted variants. The number of peptides that 
were targeted along with variants (black bar) or with no targeted variants (grey bar) in (A) Gag and 
Nef and (B) in CRF02_AG and non-CRF02_AG-infected individuals for Nef.   
 
When the magnitude of responses was compared amongst variants of the same 
targeted peptide, there was an overall trend of similarity. There were 25 cases in Gag where a 
particular peptide and at least one variant were targeted. In 19 (76%) of these cases, there was 
no substantial variation in the magnitude of responses (a difference was considered substantial 
when the magnitude was three times greater). For example, BS39 in Gag recognised four 
different peptides, of which three had one variant and one had three variants. In all these 
peptides and their variants, there was no substantial variation in the magnitude of responses 
and all the variants had a sequence that contained mismatches with respect to the autologous 
virus (Table 4.2). In Nef, there were 19 cases when a particular peptide was targeted with at 
least one variant. In 17 (89%) of cases, the magnitude of responses to the variant(s) was not 
substantially different. One example is BS27, who targeted two peptides, of which one with 
two variants had similar magnitudes of responses. The peptide sequences also mismatched the 
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magnitude of responses between a peptide and its variant(s) was drastically different. For 
example, BS29 in Gag targeted four peptides, including two with two variants each. In one of 
these peptides, the magnitude of responses was drastically reduced in one variant (from 1700 
to 220 SFU/10
6
 PBMC; Table 4.2). This was also observed in Nef, where for example BS64 
recognised three peptides, of which two had two variants each, and there was a reduction of 
the magnitude in one variant of one of the peptides recognised (from 890 to 160 SFU/10
6
 
PBMC; Table 4.3). 
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Table 4.2 Summary of reactive PTE and Consensus peptides in the Gag protein in responders from Cameroon  
PID 
 PTE  Consensus dVirus Sequence 













BS29  PTEGag260 23-37 PGGNKKYKLKHIVWA 1720  ConsGag7 25-39 GKKKYRLKHLVWASR 485       PGG-KKQYKLKHLVW 
  PTEGag175 25-39 GKKHYMLKHLVWASR 1700                 GKKQYKLKHLVWASR 
  PTEGag79 26-40 KKKYRLKHLVWASRE 220             KKQYKLKHLVWASRE 
            
  PTEGag75 154-168 NAVKVVEEKAFSPEV 140  ConsGag42 156-170 VKVIEEKAFSPEVIP 175 NAWVKVIEEKAFSPEV 
  PTEGag181 154-168 AWVKAIEEKAFSPEV 170      NAWVKVIEEKAFSPEV 
            
  PTEGag14 160-174 EEKAFSPEVIPMFSA 230  ConsGag43 160-174 EEKAFSPEVIPMFSA 155 EEKAFSPEVIPMFTA 
            
  PTEGag129 332-346 TILRALGPGATLEEM 190      TILRALGPAATLEEM 
            
BS53  PTEGag28 292-326 PFRDYVDRFFKTLRA 3630  ConsGag77 290-304 KEPFRDYVDRFFKTL 4085 PFRDYVDRFFKTLRA 
  PTEGag48 292-326 PFRDYVDRFYKTLRA 2040      PFRDYVDRFFKTLRA 
            
  PTEGag268 65-74 LPALKTGSEELRSLY 100      LQSTLRTGSEELKSLF 
            
BS30  PTEGag67 304-318 LRAEQATQEVKNWMT 1230  ConsGag81 305-318 RAEQATQDVKNWMT 128 LRAEQATQEVKNWMT 
  PTEGag98 304-318 LRAEQASQEVKNWMT 398      LRAEQATQEVKNWMT 
            
  PTEGag232 25-39 GRKKYRLKHIVWASR 280      GKKRYKLKHIVWASR 
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BS77  PTEGag8 174-188 ALSEGATPQDLNTML 380  ConsGag47 176-190 SEGATPQDLNTMLNT 193 ALSEGATPQDLNMML 
            
       ConsGag49 184-198 LNTMLNVGGHQAAM 123  
            
  PTEGag11 427-441 TERQANFLGKIWPSH 120  ConsGag116 433-447 FLGKIWPSNKGRPGN 603 TERQANFLGKIWPSS 
  PTEGag201 428-442 ESKANFLGKIWPSNK 400      ERQANFLGKIWPSSK 
  PTEGag309 429-443 RQANFLGKIWPSYKG 120      RQANFLGKIWPSSKG 
  PTEGag179 431-445 ANFLGKIWPSSKGRP 280      ANFLGKIWPSSKGRP 
  PTEGag83 433-447 FLGKIWPSHKGRQEN 460      FLGKIWPSSKGRPGN 
            
BS22  PTEGag31 253-267 NPPIPVGEIYKRWII 2080  ConsGag68 257-271 PVGEIYKRWIILGLN 1508 NPPIPVGEIYKRWII 
  PTEGag53 255-269 PIPVGDIYKRWIILG 1200      PIPVGEIYKRWIILG 
  PTEGag223 255-269 PVPVGEIYKRWIVLG 880      PIPVGEIYKRWIILG 
            
  PTEGag67 304-318 LRAEQATQEVKNWMT 1420  ConsGag81 305-318 RAEQATQDVKNWMT 858 LRAEQATQEVKNWMT 
  PTEGag82 304-318 LRAEQATQDVKNWMT 800      LRAEQATQEVKNWMT 
  PTEGag98 304-318 LRAEQASQEVKNWMT 690      LRAEQATQEVKNWMT 
            
BS64  PTEGag47 198-212 MEMLKDTINEEAAEW 1020  ConsGag53 200-214 MLKDTINEEAAEWDR 885 MQMLKDTINEEAAEW 
  PTEGag80 198-212 MHMLKETINEEAAEW 1240      MQMLKDTINEEAAEW 
            
  PTEGag16 204-218 TINEEAAEWDRLHPV 910  ConsGag54 204-218 TINEEAAEWDRLHPV 305 TINEEAAEWDRTHPV 
            
  PTEGag67 304-318 LRAEQATQEVKNWMT 1410  ConsGag81 305-318 RAEQATQDVKNWMT 1315 LRAEQATQEVKNWMT 
  PTEGag82 304-318 LRAEQATQDVKNWMT 960      LRAEQATQEVKNWMT 
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  PTEGag77 179-193 ATPQDLNMMLNIVGG 300      ATPQDLNMMLNIVGG 
            
BS39       ConsGag11 41-54 LERFALNPGLLETS 378 LERFALNPGLLDTA 
            
       ConsGag51 192-206 GGHQAAMQMLKDTIN 248 GGHQAAMQMLKDTIN 
            
       ConsGag76 286-300 RQGPKEPFRDYVDRF 198 RQGPKEPFREYVDRF 
            
            
  PTEGag28 292-306 PFRDYVDRFFKTLRA 2940  ConsGag78 294-308 RDYVDRFFKTLRAEQ 3118 PFREYVDRFFKTLRA 
  PTEGag48 292-306 PFRDYVDRFYKTLRA 1730      PFREYVDRFFKTLRA 
            
  PTEGag139 331-345 KTILKALGPGATLED 620  ConsGag88 330-343 CKTILKALGPGATL 908 KAILRALGPGATLEE 
  PTEGag173 331-345 KSILRALGPGASLEE 640      KAILRALGPGATLEE 
  PTEGag129 332-346 TILRALGPGATLEEM 910      AILRALGPGATLEEM 
  PTEGag318 332-346 SILKALGTGATLEEM 800      AILRALGPGATLEEM 
            
  PTEGag120 71-85 GSEELRSLYNTVATL 950      GSEELKSLFNTVATL 
  PTEGag123 71-85 GSEELKSLYNTVATL 770      GSEELKSLFNTVATL 
            
  PTEGag289 76-91 KSLFNTVATLYCVHA 990      KSLFNTVATLCCVHQ 
  PTEGag54 77-92 SLYNTVATLYCVHQR 670      SLFNTVATLCCVHQR 
            
BS14  PTEGag21 235-249 DIAGTTSTLQEQIGW 1760  ConsGag63 238-252 GTTSTLQEQIAWMTS 1235 DIAGTTSNLQEQIGW 
  PTEGag89 239-253 TTSTLQEQIAWMTSN 1460      TTSNLQEQIGWMTSN 
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  PTEGag78 241-255 STLQEQIGWMTSNPP 150      SNLQEQIGWMTSNPP 
            
  PTEGag28 292-306 PFRDYVDRFFKTLRA 100  ConsGag77 290-304 KEPFRDYVDRFFKTL 485 PFRDYVDRFFKTLRA 
            
  PTEGag91 361-375 RVLAEAMSQVTNSAT 150  ConsGag96 361-375 RVLAEAMSQVTNAAI 115 RVLAEAMSQVQ---QAN 
            
       ConsGag71 269-283 GLNKIVRMYSPVSIL 105 GLNKIVRMYSPVSIL 
  PTEGag43 150-164 RTLNAWVKVVEEKAF 270      RTLNAWVKVIEEKAF 
            
  PTEGag46 326-340 ANPDCKTILKALGPA 160      ANPDCKSILKALGTG 
            
BS09  PTEGag163 40-54 ELERFALNPSLLETT 390  ConsGag10 37-51 ASRELERFALNPGLL 135 ELERFALNPSLLETA 
            
  PTEGag42 140-154 GQMVHQAISPRTLNA 290  ConsGag39 144-158 HQAISPRTLNAWVKV 765 GQMVHQAISPRTLNA 
  PTEGag127 142-156 MVHQALSPRTLNAWV 100      GQMVHQAISPRTLNA 
            
  PTEGag28 292-306 PFRDYVDRFFKTLRA 130  ConsGag77 290-304 KEPFRDYVDRFFKTL 605 PFRDYVDRFFKALRA 
            
            
       ConsGag81 305-318 RAEQATQDVKNWMT 105 RAEQATQEVKGWMT 
  PTEGag268 65-79 LPALKTGSEELRSLY 260      LQPALKTGSEELKSLF 
  PTEGag209 66-80 STLKTGSEELKSLYN 180      PALKTGSEELKSLFN 
  PTEGag182 67-81 ALKTGTEELRSLYNT 150      ALKTGSEELKSLFNA 
            
BS72       ConsGag11 41-54 LERFALNPGLLETS 120 LERFALNPNLLETT 
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  PTEGag8 174-188 ALSEGATPQDLNTML 210  ConsGag48 180-194 TPQDLNTMLNTVGGH 180 ALSEGATPQDLNMML 
            
       ConsGag68 257-271 PVGEIYKRWIILGLN 110 PVGEIYKRWIILGLN 
            
       ConsGag71 269-283 GLNKIVRMYSPVSIL 130 GLNKIVRMYSPVSIL 
            
  PTEGag67 304-318 LRAEQATQEVKNWMT 1120  ConsGag81 305-318 RAEQATQDVKNWMT 330 LRAEQATQEVKNWMT 
  PTEGag82 304-318 LRAEQATQDVKNWMT 260      LRAEQATQEVKNWMT 
  PTEGag98 304-318 LRAEQASQEVKNWMT 790      LRAEQATQEVKNWMT 
       ConsGag96 361-374 RVLAEAMSQVTNAA 170 RVLAEAMSQVQ--- 
            
BS73       ConsGag69 261-275 IYKRWIILGLNKIVR 293 IYKRWIILGLNKIVR 
            
       ConsGag111 414-427 WKCGKEGHQMKDCT 143 WKCGKEGHQMKDCT 
            
  PTEGag80 198-212 MHMLKETINEEAAEW 120      MQMLKDTINEEAAEW 
            
  PTEGag67 304-318 LRAEQATQEVKNWMT 830      LRAEQATQEVKNWMT 
  PTEGag98 304-318 LRAEQASQEVKNWMT 170      LRAEQATQEVKNWMT 
  PTEGag302 305-319 RAEQGTQEVKNWMTE 160      LRAEQATQEVKNWMT 
            
BS38  PTEGag14 160-174 EEKAFSPEVIPMFSA 210  ConsGag42 156-170 VKVIEEKAFSPEVIP 145 EEKAFSPEVIPMFSA 
            
  PTEGag201 428-442 ESKANFLGKIWPSNK 150  ConsGag115 429-443 RQANFLGKIWPSNKG 150 ERQANFLGKIWPSSK 
  PTEGag309 429-443 RQANFLGKIWPSYKG 140      RQANFLGKIWPSSKG 
  PTEGag179 431-445 ANFLGKIWPSSKGRP 180      ANFLGKIWPSSKGRP 
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  PTEGag83 433-447 FLGKIWPSHKGRQEN 340      FLGKIWPSSKGRPGN 
            
BS16       ConsGag5 17-31 EKIRLRPGGKKKYRL 315 EKIRLRPGGRKQYKL 
            
  PTEGag65 249-263 WMTSNPPIPVGDIYK 320  ConsGag66 249-263 WMTSNPPIPVGEIYK 165 WMTSNPPIPVGEIYK 
  PTEGag140 249-263 WMTSNPPVPVGEIYK 370      WMTSNPPIPVGEIYK 
  PTEGag185 251-265 TSNPPVPVGDIYKRW 300      TSNPPIPVGEIYKRW 
  PTEGag31 253-266 NPPIPVGEIYKRWII 120      NPPIPVGEIYKRWII 
            
BS11       ConsGag11 41-54 LERFALNPGLLETS 210 LERFALNPGLLES 
            
  PTEGag75 154-263 NAVKVVEEKAFSPEV 180  ConsGag42 156-170 VKVIEEKAFSPEVIP 430 NAWVKVIEEKAFSPEV 
  PTEGag181 154-263 AWVKAIEEKAFSPEV 110      NAWVKVIEEKAFSPEV 
            
  PTEGag14 160-174 EEKAFSPEVIPMFSA 840  ConsGag43 160-174 EEKAFSPEVIPMFSA 1020 EEKAFSPEVIPMFTA 
            
  PTEGag162 306-320 AEQATQEVKGWMTDT 840      AEQATQDVKNWMTDT 
  PTEGag67 304-318 LRAEQATQEVKNWMT 120      LRAEQATQDVKNWMT 
            
BS55  PTEGag8 174-188 ALSEGATPQDLNTML 2600  ConsGag48 180-194 TPQDLNTMLNTVGGH 1013 ALSEGATPQDLNMML 
  PTEGag77 179-193 ATPQDLNMMLNIVGG 2490      ATPQDLNMMLNIVGG 
            
BS25  PTEGag8 174-188 ALSEGATPQDLNTML 930  ConsGag48 180-194 TPQDLNTMLNTVGGH 340 ALSDGATPQDLNMML 
  PTEGag77 179-193 ATPQDLNMMLNIVGG 840      ATPQDLNMMLNIVGG 
            
       ConsGag52 196-210 AAMQMLKDTINEEAA 100 AAMQMLKDTINEEAA 
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BS48  PTEGag26 16-30 WEKIRLRPGGKKKYR 1230  ConsGag5 17-31 EKIRLRPGGKKKYRL 510 WEKIRLRPGGKKKYK 
  PTEGag156 19-33 IRLRPGGKKHYMLKH 450      IRLRPGGKKKYKMKH 
            
       ConsGag3 9-23 SGGKLDAWEKIRLRP 120 SGGKLDAWEKIRLRP 
            
            
            
a Different peptides and their variants are separated from each other by a line; b PTE amino acid differences from the consensus sequence are highlighted in red; c Peptides in red are consensus 
peptides with no corresponding targeted PTE peptide; d Autologous virus amino acid differences from the PTE sequence are highlighted in blue; e Differences between consensus and viral 
sequences are highlighted in green 
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Table 4.3 Summary of reactive PTE and Consensus peptides in the Nef protein in responders from Cameroon Cameroon 
  PTE  Consensus dVirus Sequence 













BS29       ConsNef1 1-15 MGGKWSKSSIVGWPA 565 MGGKWSKSSIVGWPQ 
  PTENef6 60-74 AQEEEEVGFPVRPQV 250      AQEDDEVGFPVRPQV 
            
  PTENef50 78-92 PMTYKGAFDLSHFLK 110      PMTYKGAFDLGFFLK 
            
  PTENef11 87-101 LSFFLKEKGGLDGLI 320      LGFFLKEKGGLDGLI 
            
  PTENef8 113-127 WVYHTQGYFPDWQNY 170  ConsNef30 112-126 LWVYHTQGYFPDWQN 125 WVYHTQGYFPDWQNY 
            
  PTENef30 123-137 WQNYTPGPGTRFPLT 580      WQNYTPGPGIRYPLT 
            
  PTENef10 129-143 GPGVRYPLTFGWCFK 1850  ConsNef35 131-145 PGIRYPLTFGWCFKL 1935 GPGIRYPLTFGWCYK 
  PTENef27 129-143 GPGIRYPLTFGWCYK 1880      GPGIRYPLTFGWCYK 
  PTENef31 129-143 GPGTRFPLTFGWCFK 2090      GPGIRYPLTFGWCYK 
            
  PTENef70 158-172 GENNSLLHPMSLHGM 350      GENNSLLHPICQHGM 
            
BS27  PTENef29 81-95 YKGAFDLSFFLKEKG 120      FKAAFDLSFFLKEKG 
            
  PTENef10 129-143 GPGVRYPLTFGWCFK 1260  ConsNef35 131-145 PGIRYPLTFGWCFKL 1648 GPGTRYPLTFGWCFK 
  PTENef27 129-143 GPGIRYPLTFGWCYK 1380      GPGTRYPLTFGWCFK 
  PTENef31 129-143 GPGTRFPLTFGWCFK 1260      GPGTRYPLTFGWCFK 
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BS30       ConsNef3 9-23 SIVGWPAVRERIRRT 218 ---GWPAVRERIRRT 
            
  PTENef51 68-82 FPVKPQVPLRPMTFK 280  ConsNef18 67-81 GFPVRPQVPLRPMTY 508 FPVRPQVPLRPMTFK 
  PTENef4 72-86 PQVPLRPMTYKGAFD 110      PQVPLRPMTFKAALD 
            
  PTENef11 87-101 LSFFLKEKGGLDGLI 400      LSHFLKEKGGLEGLV 
            
       ConsNef34 128-141 TPGPGIRYPLTFGW 105 TPGPGTRYPLCFGW 
            
  PTENef24 111-125 DLWVYNTQGYFPDWQ 400     108 DLWVYHTQGFFPDWH 
  PTENef8 113-127 WVYHTQGYFPDWQNY 130      WVYHTQGFFPDWHNY 
            
  PTENef10 129-143 GPGVRYPLTFGWCFK 490   ConsNef35 131-145 PGIRYPLTFGWCFKL 508 GPGTRYPLCFGWCFE 
  PTENef27 129-143 GPGIRYPLTFGWCYK 460      GPGTRYPLCFGWCFE 
  PTENef31 129-143 GPGTRFPLTFGWCFK 560      GPGTRYPLCFGWCFE 
            
BS22  PTENef66 6-20 SKSSIVGWPEVRERM 920  ConsNef3 9-23 SIVGWPAVRERIRRT 108 SKSSIVGWPQVRERM 
            
  PTENef120 10-24 GVGWPTVRERMRRAE 750      IVGWPQVRERMRQ-- 
  PTENef108 11-25 VGWPAVRERMRRTEP 600      VGWPQVRERMRQ--T-P 
  PTENef122 12-26 GWPEVRERMRRAPAA 750      GWPQVRERMRQ--T-P-- 
            
       ConsNef12 43-57 ITSSNTAANNPDCAW 168 ITSSNTAHTNADCAW 
  PTENef62 56-70 WPAVRERMRRAEPAA 770      WPQVRERMRQ--TPSAA 
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  PTENef37 80-94 TYKAAVDLSHFLKEK 110      TYKGAVDLSHFLKEK 
            
  PTENef18 99-113 GLIYSKKRQEILDLW 400  ConsNef27 100-114 LIYSKKRQEILDLWV 108 GLIYSKKRQEILDLW 
            
  PTENef47 102-116 YSQKRQDILDLWVYH 660  ConsNef28 104-118 KKRQEILDLWVYHTQ 928 YSKKRQEILDLWVYN 
  PTENef64 103-117 SRRRQEILDLWVYNT 840      SKKRQEILDLWVYNT 
  PTENef7 105-119 KRQEILDLWVYHTQG 910      KRQEILDLWVYNTQG 
  PTENef17 105-119 KRQDILDLWVYNTQG 580      KRQEILDLWVYNTQG 
            
  PTENef2 118-132 GYFPDWQNYTPGPGV 120  ConsNef32 120-134 YFPDWQNYTPGPGIR 108 GFFPDWQNYTPGPGT 
            
BS64  PTENef33 111-125 DLWVYHTQGFFPDWH 260  ConsNef30 112-126 LWVYHTQGYFPDWQN 255 DLWVYHTQGFFPDWQ 
  PTENef8 113-127 WVYHTQGYFPDWQNY 550      WVYHTQGFFPDWQNY 
  PTENef13 115-129 YHTQGFFPDWQNYTP 320      YHTQGFFPDWQNYTP 
            
            
  PTENef2 118-132 GYFPDWQNYTPGPGV 190  ConsNef31 116-130 HTQGYFPDWQNYTPG 545 GFFPDWQNYTPGPGT 
            
  PTENef10 129-143 GPGVRYPLTFGWCFK 1030  ConsNef35 131-145 PGIRYPLTFGWCFKL 915 GPGTRYPLTFGWCYK 
  PTENef27 129-143 GPGIRYPLTFGWCYK 890      GPGTRYPLTFGWCYK 
  PTENef31 129-143 GPGTRFPLTFGWCFK 140      GPGTRYPLTFGWCYK 
            
            
BS39  PTENef6 60-74 AQEEEE-VGFPVRPQ 1070  ConsNef16 60-73 AQEEEEVGFPVRPQ 348 AQEEGEVGFPVRPQV 
            
  PTENef4 72-86 PQVPLRPMTYKGAFD 1330      PQVPLRPMTYKGALD 
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BS72       ConsNef18 67-81 GFPVRPQVPLRPMTY 110 GFPVRPQVPLRPMTY 
            
  PTENef5 86-100 DLSHFLKEKGGLEGL 230  ConsNef24 90-104 FLKEKGGLEGLIYSK 150 DLGFFLKEKGGLDGL 
            
BS79  PTENef10 129-143 GPGVRYPLTFGWCFK 1320  ConsNef35 131-145 PGIRYPLTFGWCFKL 1923 GPGVRYPLCFGWCFK 
  PTENef27 129-143 GPGIRYPLTFGWCYK 1300      GPGVRYPLCFGWCFK 
  PTENef31 129-143 GPGTRFPLTFGWCFK 890      GPGVRYPLCFGWCFK 
            
BS73  PTENef33 111-125 DLWVYHTQGFFPDWH 1110  ConsNef30 112-126 LWVYHTQGYFPDWQN 2803 DLWIYHTQGYFPDWQ 
  PTENef8 113-127 WVYHTQGYFPDWQNY 2280      WIYHTQGYFPDWQCY 
  PTENef13 115-129 YHTQGFFPDWQNYTP 1500      YHTQGYFPDWQCYTP 
            
  PTENef36 135-149 PLTFGWCYKLVPVDP 450  ConsNef35 131-145 PGIRYPLTFGWCFKL 463 PLTFGWCYKLVPMDP 
            
BS20  PTENef1 66-80 VGFPVRPQVPLRPMT 410  ConsNef18 67-81 GFPVRPQVPLRPMTY 1860 VGFPVRPQVPLRPMT 
  PTENef51 68-82 FPVKPQVPLRPMTFK 1510      FPVRPQVPLRPMTFK 
            
  PTENef27 129-143 GPGIRYPLTFGWCYK 120  ConsNef35 131-145 PGIRYPLTFGWCFKL 520 GPGTRFPLTFGWCFK 
  PTENef31 129-143 GPGTRFPLTFGWCFK 490      GPGTRFPLTFGWCFK 
            
  PTENef37 80-94 TYKAAVDLSHFLKEK 100      TFKAAIDLSHFLKEK 
            
  PTENef117 191-205 RHLARELHPEYYKNC 2090      RHIAQEMHPEFYKDC 
            
       ConsNef17 64-77 EEVGFPVRPQVPLR 330 EEVGFPVRPQVPLR 
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       ConsNef34 128-141 TPGPGIRYPLTFGW 410 TPGPGTRFPLTFGW 
            
BS35       ConsNef19 71-85 RPQVPLRPMTYKAAL 240 RPQVPLRPMTYKAAF 
            
  PTENef47 102-116 YSQKRQDILDLWVYH 200  ConsNef28 104-118 KKRQEILDLWVYHTQ 690 YSRKRQDILNLWVYH 
  PTENef 87 103-117 SQRRQDILDLWIYHT 120      SRKRQDILNLWVYHT 
  PTENef7 105-119 KRQEILDLWVYHTQG 450      KRQDILNLWVYHTQG 
            
  PTENef35 108-122 DILDLWVYHTQGYFP 250  ConsNef29 108-122 EILDLWVYHTQGYFP 715 DILNLWVYHTQGFFP 
            
BS38  PTENef47 102-116 YSQKRQDILDLWVYH 160  ConsNef28 104-118 KKRQEILDLWVYHTQ 280 YSRKRQEILDLWIYH 
  PTENef64 103-117 SRRRQEILDLWVYNT 360      SRKRQEILDLWIYHT 
  PTENef7 105-119 KRQEILDLWVYHTQG 180      KRQEILDLWIYHTQG 
  PTENef17 105-119 KRQDILDLWVYNTQG 160      KRQEILDLWIYHTQG 
            
BS16  PTENef45 41-55 GAITSSNTAATNADC 180      GAVTISNTAATNANC 
            
  PTENef51 68-82 FPVKPQVPLRPMTFK 170  ConsNef18 67-81 GFPVRPQVPLRPMTY 315 FPVRPQVPLRPMTYK 
            
       ConsNef21 79-92 MTYKAALDLSHFLK 105 MTYKGALDLSHFLK 
  PTENef11 87-101 LSFFLKEKGGLDGLI 100      LSHFLKEKGGLDGLI 
            
  PTENef28 93-107 EKGGLDGLIYSKKRQ 100      EKGGLDGLIYSKKRQ 
            
  PTENef10 129-143 GPGVRYPLTFGWCFK 320  ConsNef35 131-145 PGIRYPLTFGWCFKL 235 GPGIRYPLTFGWCYK 
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  PTENef27 129-143 GPGIRYPLTFGWCYK 380      GPGIRYPLTFGWCYK 
  PTENef31 129-143 GPGTRFPLTFGWCFK 250      GPGIRYPLTFGWCYK 
            
BS18  PTENef24 111-125 DLWVYNTQGYFPDWQ 150      DLWVYNTQGFFPDWQ 
  PTENef8 113-127 WVYHTQGYFPDWQNY 200      WVYNTQGFFPDWQNY 
  PTENef13 115-129 YHTQGFFPDWQNYTP 470      YNTQGFFPDWQNYTP 
            
  PTENef2 118-132 GYFPDWQNYTPGPGV 570  ConsNef32 120-134 YFPDWQNYTPGPGIR 770 GFFPDWQNYTPGPGI 
            
BS78  PTENef35 108-122 DILDLWVYHTQGYFP 250  ConsNef29 108-122 EILDLWVYHTQGYFP 294 EILDLWVYHTQGFLP 
            
BS55  PTENef5 86-100 DLSHFLKEKGGLEGL 470  ConsNef23 90-104 FLKEKGGLEGLIYSK 273 DLSHFLKEKGGLEGL 
  PTENef11 87-101 LSFFLKEKGGLDGLI 570      LSHFLKEKGGLEGLI 
            
            
BS40  PTENef4 72-86 PQVPLRPMTYKGAFD 110  ConsNef19 71-85 RPQVPLRPMTYKAAL 700 PQVPLRPMTYKAAVD 
  PTENef21 74-88 VPLRPMTYKAAVDLS 250      VPLRPMTYKAAVDLS 
       ConsNef52 190-204 ALRHIARELHPEYYK 300 ARRHIARELHPEYYK 
            
 
a Different peptides and their variants are separated from each other by a line; b PTE amino acid differences from the consensus sequence are highlighted in red; c Peptides in red are consensus 
peptides with no corresponding targeted PTE peptide; d Autologous virus amino acid differences from the PTE sequence are highlighted in blue; e Differences between consensus and viral 
sequences are highlighted in green 
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4.4 DISCUSSION 
HIV-1 diversity represents a huge obstacle not only to the design of an effective 
vaccine but also to the evaluation of HIV vaccines. One of the proposed strategies to cope 
with this diversity is the use of mosaic constructs for vaccination. Mosaic proteins are 
assembled to resemble natural proteins but they maximise the coverage of potential T cell 
epitopes (PTEs, or epitopes of nine amino acids) for a viral population. This study aimed to 
evaluate the reactivity to PTE group M peptides in HIV-infected individuals from Cameroon, 
a country with considerable HIV-1 genetic diversity, and compare this reactivity to results 
obtained with consensus group M peptides generated in the previous chapter.  
This study revealed that T cells from HIV-infected Cameroonians are capable of 
recognising multiple variants of epitopes in Gag and Nef. Although the magnitude of 
responses was substantially lower in Nef to responses observed by Malhotra et al. (2007), 
with a median response magnitude of 1310 SFU/10
6
 here (compared to 2169 SFU/10
6 
in their 
study), the breadth of responses was however similar in the two studies, with a median 
breadth of 2 epitopic regions here and in their study. The magnitude difference could be 
explained by the fact that Malhotra and colleagues used a PTE peptide set from subtype B to 
detect responses in subtype B-infected individuals, and the closer match between peptides and 
viral sequences likely resulted in an increased magnitude of responses. This study used group 
M PTE and a population infected with diverse viruses. An additional consideration is that the 
individuals in that study were at an early stage of HIV infection, with viral loads more than 
three times greater than the present study. Whilst the infection date of individuals in the 
present study is unknown, it is likely, from CD4 count and viral load data, that the majority 
were in the chronic phase of infection.   
 Whilst we detected a significantly greater magnitude of T cell responses with the PTE 
peptide set than with the consensus M set in Gag, the magnitude of responses was similar 
between the two sets of peptides in Nef. The breadth of responses was also similar between 
the two set of peptides. This was surprising, as we hypothesised that the use of PTE peptides 
would increase immune coverage, as previously reported (Malhotra et al., 2007). It may be 
possible that HIV sequences from Cameroon are under-represented in the database, and 
because some of these individuals are infected with highly diverse viruses with rare epitopes, 
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that the PTE peptides do not increase the rate of epitope detection.  Overall, these data suggest 
that the PTE peptides do not sufficiently take into account the diversity represented by other 
subtypes and CRFs that circulate in Cameroon. 
 Another striking point was that the magnitude of responses to different variants of the 
same peptide broadly followed the same pattern of response. When the response to a 
particular peptide was high, the response to the variant was also high. This can be explained 
by the fact that the PTE set, as for the consensus peptides, include the most conserved 
epitopes across global lineages. This was found when the peptide distribution was mapped 
across the Gag and Nef proteins and most of the targeted peptides in both PTE and consensus 
sets were located in the conserved regions. It does appear that recognition to these conserved 
epitopes can tolerate some amino acid mismatch. Furthermore, most PTE variants were 
recognised even when there were mismatches from autologous virus sequence. This could be 
explained by the fact that either variations were tolerated in the epitopes, mismatches were 
outside the epitope, or minor viral variants were present that were not reflected in the bulk 
autologous sequence generated. the observation that the majority of the peptides targeted with 
PTE peptides set were also targeted with the consensus set and that recognition of multiple 
variants was detected with the PTE set constitute an improvement of the use of PTEs over 
consensus peptides.  
This study had several limitations.  Since HLA typing was not performed, it was not 
possible to precisely predict the epitope within the 15mer peptides tested, to understand the 
effect of sequence mismatches on epitope reactivity. Another limitation was the autologous 
viral sequence, since bulk sequencing was performed to assess the infecting subtype. This 
represented a bias since the method detects the most common variant in the viral population 
and it not excludes minor viral populations might match PTEs. Finally, only responders to 
consensus M peptides were chosen for this study, and some differences could have emerged if 
non-responders were also included in this study.  
In conclusion, Gag and Nef-specific T cells capable of recognising multiple variant 
epitopes were commonly detected in this study using PTE peptides. The immunological 
responses detected in HIV-infected individuals from Cameroon did not differ substantially 
between these peptides and consensus peptides. However, the observation that the majority of 
the peptides targeted with PTE peptides set were also targeted with the consensus set, that 
Chapter 4: Characterisation of HIV-specific T cell Responses to Potential T cell Epitopes (PTE) in a Highly 
Diverse Epidemic from Cameroon Page 125 
 
recognition of multiple variants was detected with the PTE set and a marginally improved 
magnitude of response with PTE set, constitute an improvement of the use of PTEs over 
consensus peptides. 
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CHAPTER 5: DISCUSSION 
This thesis focused on studying HIV diversity in Cameroon and characterising T cell 
immune responses in HIV-infected blood donors from Cameroon. Cameroon forms part of the 
Congo basin, where HIV originated from, and for this reason, the region has one of the oldest 
epidemics in the world. Very few immunological studies on HIV are available from the whole 
region, with only a single published study to date on T cell responses in HIV-infected 
individuals from Cameroon (Gupta et al., 2006). 
A vaccine that can induce immune responses capable of preventing or containing HIV 
offers the greatest hope of halting the pandemic. Some major challenges need to be overcome 
to develop such a vaccine, including the enormous diversity the virus exhibits. Several studies 
have characterised HIV diversity in Cameroon, and have found the presence of every known 
subtype, including many recombinant forms. Given the impact that viral diversity can pose to 
the development of an effective HIV vaccine, it is important to continue to monitor the 
diversity at the epicentre of the pandemic. Data presented in the first chapter of this thesis 
corroborates previous findings of extensive HIV diversity in Cameroon. CRF02_AG remains 
the major circulating subtype, accounting for more than half of the viruses sequenced, both in 
gag and nef. The remainder were primarily a range of CRFs and pure subtypes, with 22% 
being URF viruses. This study, using a new phylogenetic analysis tool, quantified the rate of 
intra-gene recombination for the first time. A blind, fully exploratory screen for 
recombination was performed, testing all sequences (whether a previously defined non-
recombinant pure subtype or not, for evidence of recombination. This analysis allowed 
information such as (1), the identification of recombinants as parental sequences of other 
recombinants, and (2), the detection of intra-subtype recombination. The range of intra-gene 
recombination (recombination breakpoints between gene segments that phylogenetically 
clustered within two distinct groups of the same subtype, indicating that they were likely 
intra-subtype recombinants) in Gag and Nef genes was estimated at 6% and 7%" respectively. 
This therefore suggests that even a pure subtype may in fact be a recombinant of different 
lineages from the same subtype. These findings therefore have implications for the 
development of a vaccine for the region, as the range of subtypes and the amount of intra-
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subtype diversity within any geographical region will significantly impact HIV vaccine 
efficacy.  
A further observation was that some previously identified CRFs, such as CRF11_cpx, 
are independent lineages and not obviously recombinant subtypes, at least in gag and nef. The 
identification and characterisation of certain CRFs and URFs have raised some questions, for 
example, the presence in the genome of sequences that are of indeterminate origin (Carr et al., 
2010). Some of these CRF_cpx sequences may therefore represent examples of under-
sampled subtype-level lineages. More importantly, despite the fact that the broadest HIV 
diversity, representative of all subtypes, was used to perform the analyses, some newly 
sequenced Cameroonian viruses were still too divergent to be placed within any existing 
subtype or CRF grouping, and they have remained unclassified. This was observed both with 
partial and full genome analysis. To date, the most extensive analysis of HIV in Cameroon 
was performed by Carr et al. (2010). They also found highly divergent viruses that were 
outliers of some existing lineages, and suggested that these divergent sequences were URFs. 
An advantage of the analysis tool used in Chapter 2 was that it breaks up the different 
recombinant fragments of a given sequence. Thus, after removal of recombinant fragments, 
some highly divergent viruses sequenced in this study remained outliers in gag and nef. This 
implies that there is potentially a less prominent, but far more diverse, pool of viruses 
circulating amongst humans than the currently classified subtypes and CRFs might suggest. 
This further complicates the design of an effective vaccine for the region.   
It is now well accepted that an effective vaccine against HIV would need to elicit both 
potent broadly neutralising antibodies as well as effective CD8+ T cell responses against the 
vast majority of HIV subtypes and recombinants, either to augment protection at the site of 
exposure, or potentially to reduce viral load if breakthrough infection occurs. Therefore, there 
has been a continued focus on HIV vaccine immunogen design to elicit T cell responses that 
can control viral replication and be cross-reactive (and cross-protective) against the full 
spectrum of HIV diversity globally. One such proposed artificial immunogen is based on a 
consensus sequence of group M viruses. Chapter 3 of this thesis assessed HIV-specific T cell 
responses to peptides based on consensus M in HIV-infected individuals from mono- and 
multi-clade epidemics. First, when comparing the reactivity to these reagents between 
CRF02_AG and non-AG infected individuals from Cameroon, no differences in the 
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magnitude, breadth or epitope coverage between CRF02_AG and non-CRF02_AG viruses 
was observed for either Gag or Nef. In addition there was poor immunodominance in both 
Gag and Nef in both groups, and similar results were obtained when South Africa, a mono-
clade C epidemic, and Cameroon, a multi-clade epidemic, were compared. Importantly, the 
same observations were made by Serwanga et al. (2011) in Uganda, which also represents a 
multi-clade epidemic, with few immunodominant epitopes being described. The targeting of 
peptides was directed towards conserved regions in Gag and Nef, and the use of consensus 
group M reagents likely resulted in the decreased detection of subtype-specific responses. The 
poor immunodominance that these central HIV consensus M sequences detected suggests that 
they may not be an ideal reagent for inclusion as a vaccine immunogen. They also suggest 
that consensus reagents are limited in their use as a standard panel to broadly assess HIV-
specific T cell responses in vaccine trials in multiple sites where different epidemics prevail.  
Despite the low immunodominance described in Chapter 3, there was a clear 
indication of preferentially targeted peptides when both CRF20_AG and non-AG-infected 
individuals and mono-clade and multi-clade epidemics were compared, an observation also 
made in the Ugandan study of consensus M peptide reactivity (Serwanga et al., 2011). Some 
peptides were preferentially targeted in the Ugandan population compared to Cameroon and 
South Africa. This suggests that on one hand, the infecting virus influences T cell immune 
recognition, as certain epitopes would be specific to certain viruses, and on the other hand, 
recognition is also driven by host genetic factors, as individuals from different ethnicities 
would express specific HLA molecules. The implication for an HIV vaccine design is that 
vaccine formulation needs to take into consideration both the circulating virus and the HLA of 
individuals targeted by this vaccine. This finding highlights the challenges of developing a 
global vaccine against HIV. It is unlikely that reasonably effective consensus M HIV vaccines 
will provide full protection against all subtypes. This favours the design of a vaccine made 
from a cocktail of conserved elements representing all subtypes from different epidemics, also 
taking into account global HLA diversity. Alternatively, a regional vaccine development 
approach for specific epidemics could also be considered.  
Chapter 4 of this thesis investigated whether the use of PTE peptides from group M 
could result in enhanced T cell detection compared to consensus M in the context of HIV 
diversity. Mosaic vaccines represent a novel approach that extends the coverage to multiple 
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9mer epitopes or PTEs, which can be targeted by the host immune response (Fischer et al., 
2007; Nickle et al., 2007). Therefore, potentially relevant T cell recognition to these PTE 
peptides could guide in the design of a mosaic vaccine. In addition, they could also be a 
useful standard tool for vaccine trial evaluation. It was previously reported that the magnitude 
and breadth of detectable responses were enhanced when subtype B PTE peptides were used, 
compared to consensus B peptides, during early HIV infection in subtype B-infected 
individuals (Malhotra et al., 2007). Here, the magnitude of the response detected was 
significantly higher in Gag when PTE peptides were used compared to consensus peptides, 
but this was not the case for Nef. The breadth of responses was however similar when the two 
sets of reagents were used, both in Gag and Nef. Further analyses in Nef revealed that the 
magnitude and breadth of responses were similar in CRF02_AG and non-AG-infected 
individuals. It appeared that since Gag was more homogenous than Nef (more patients were 
infected with CRF02_AG in Gag), this resulted in the increase in magnitude detected, most 
likely because there were less mismatches between the peptides and the virus. The result in 
Nef suggests that epitopes from minor circulating viruses are underrepresented in the PTE 
peptide set. The overall similarity of breadth between PTE and consensus peptides 
underscores the fact that there are fewer characterised epitopes from viruses circulating in 
Cameroon present in Los Alamos HIV databases. These findings therefore suggest that PTE 
peptides should be optimised to include more epitopes from minor subtypes. Therefore, if a 
mosaic approach for an HIV vaccine is pursued, or the use of PTE peptides for vaccine testing 
is pursued, additional mosaic sequences may need to be included for highly diverse epidemics 
such as that in Cameroon. 
There were several limitations to this work that could be addressed in future studies. 
Characterisation of HIV diversity with intra- and inter-gene recombinants was performed for 
only two genes, namely gag and nef. Therefore, they do not represent an accurate picture of 
the extent of the recombination across the full genome. Further recombination analyses will 
be performed with the nine full length genome sequences generated here, as well as other 
published sequences. This may provide some insights into the early HIV-1 group M ancestral 
sequences. T cell characterisation was investigated using one function, namely the production 
of IFN-γ. It is possible that T cell responses producing other cytokines (such as MIP-1β) were 
missed. Furthermore, HLA typing was not performed on the study participants. This would 
have permitted the prediction of epitopes within reactive peptides, which would be useful to 
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update the HIV immunology database. In addition, HIV typing in gag and nef was performed 
using bulk PCR, which limited the analyses that could be performed on reactive peptide 
variants and autologous virus sequences. Finally, blood samples used in this study were 
drawn from HIV-infected blood donors, and no information was available on how long they 
had been infected, and whether they were in the acute or chronic phase of infection.  
The work presented in this thesis offered some strengths. These included the large 
number of participants enrolled in the cohort (n=57), which allowed for the analysis of two 
sub-groupings (CRF02_AG and non-AG-infected individuals). Furthermore, all gag and nef 
sequences generated have been deposited in the Los Alamos HIV sequence database, and 
could prove to be useful in generating a consensus sequence or for designing or updating the 
PTE group M peptide set.   
In conclusion, the study described in this thesis provides novel data on HIV diversity 
in Cameroon, where under-sampled divergent viruses are still circulating, and on T cell 
immune responses influenced by the viral diversity present in the country. Moreover, despite 
the central nature of consensus group M Gag and Nef peptide reagents, as well as the greater 
number of variants included in consensus group M PTE peptide sets, their use to evaluate 
HIV-specific T cell responses may be limited due to mismatches with particular HIV 
subtypes. These data suggest that developing a vaccine for a highly diverse epidemic is 
extremely challenging, and that a globally relevant vaccine may not provide sufficient 
coverage across different epidemics. 
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APPENDICES 
Appendix A ELISPOT assay with consensus group M peptides 
Table A1 Peptide pool and matrix configuration for Consensus M peptides 
 
The pooled peptides were arranged in 12 Gag pools and five Nef pools and 12 Matrix pools. Pools were tested in duplicate and matrices in single 
wells. 
POOLS 1 2 3 4 5 6 7 8 9 10 11 12
Gag 1-12 13-24 25-33 34-45 46-57 58-69 70-81 82-93 94-95 96-107 108-119 120-129
Nef 1-12 13-24 25-36 37-48 49-53
MATRIX Matrix 1 Matrix 2 Matrix 3 Matrix 4 Matrix 5 Matrix 6 Matrix 7 Matrix 8 Matrix 9 Matrix 10 Matrix 11 Matrix 12
Gag Pool 1 Gag 1 Gag 2 Gag 3 Gag 4 Gag 5 Gag 6 Gag 7 Gag 8 Gag 9 Gag 10 Gag 11 Gag 12
Gag Pool 2 Gag 13 Gag 14 Gag 15 Gag 16 Gag 17 Gag 18 Gag 19 Gag 20 Gag 21 Gag 22 Gag 23 Gag 24
Gag Pool 3 Gag 25 Gag 26 Gag 27 Gag 28 Gag 29 Gag 30 Gag 31 Gag 32 Gag 33
Gag Pool 4 Gag 34 Gag 35 Gag 36 Gag 37 Gag 38 Gag 39 Gag 40 Gag 41 Gag 42 Gag 43 Gag 44 Gag 45
Gag Pool 5 Gag 46 Gag 47 Gag 48 Gag 49 Gag 50 Gag 51 Gag 52 Gag 53 Gag 54 Gag 55 Gag 56 Gag 57
Gag Pool 6 Gag 58 Gag 59 Gag 60 Gag 61 Gag 62 Gag 63 Gag 64 Gag 65 Gag 66 Gag 67 Gag 68 Gag 69
Gag Pool 7 Gag 70 Gag 71 Gag 72 Gag 73 Gag 74 Gag 75 Gag 76 Gag 77 Gag 78 Gag 79 Gag 80 Gag 81
Gag Pool 8 Gag 82 Gag 83 Gag 84 Gag 85 Gag 86 Gag 87 Gag 88 Gag 89 Gag 90 Gag 91 Gag 92 Gag 93
Gag Pool 9 Gag 94 Gag 95
Gag Pool 10 Gag 96 Gag 97 Gag 98 Gag 99 Gag 100 Gag 101 Gag 102 Gag 103 Gag 104 Gag 105 Gag 106 Gag 107
Gag Pool 11 Gag 108 Gag 109 Gag 110 Gag 111 Gag 112 Gag 113 Gag 114 Gag 115 Gag 116 Gag 117 Gag 118 Gag 119
Gag Pool 12 Gag 120 Gag 121 Gag 122 Gag 123 Gag 124 Gag 125 Gag 126 Gag 127 Gag 128 Gag 129
Nef Pool 1 Nef 1 Nef 2 Nef 3 Nef 4 Nef 5 Nef 6 Nef 7 Nef 8 Nef 9 Nef 10 Nef 11 Nef 12
Nef Pool 2 Nef 13 Nef 14 Nef 15 Nef 16 Nef 17 Nef 18 Nef 19 Nef 20 Nef 21 Nef 22 Nef 23 Nef 24
Nef Pool 3 Nef 25 Nef 26 Nef 27 Nef 28 Nef 29 Nef 30 Nef 31 Nef 32 Nef 33 Nef 34 Nef 35 Nef 36
Nef Pool 4 Nef 37 Nef 38 Nef 39 Nef 40 Nef 41 Nef 42 Nef 43 Nef 44 Nef 45 Nef 46 Nef 47 Nef 48
Nef Pool 5 Nef 49 Nef 50 Nef 51 Nef 52 Nef 53
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Table A2 ELISPOT plate layout for testing Consensus M peptides 
 
This table shows the ELISPOT layout utilised for those individuals screened for consensus group M Gag and Nef and HIV-specific T cell 
responses. Subsequent confirmatory assays were performed on single predicted reactive peptides. 
1 2 3 4 5 6 7 8 9 10 11 12
A
Gag Pool 1 Gag Pool 5 Gag Pool 9 Nef Pool 1 Nef Pool 5 Matrix 7 Cells+Media QC Cells+Media
B
Gag Pool 1 Gag Pool 5 Gag Pool 9 Nef Pool 1 Nef Pool 5 Matrix 8 Cells+Media QC Cells+Media
C
Gag Pool 2 Gag Pool 6 Gag Pool 10 Nef Pool 2 Matrix 1 Matrix 9 Cells+Media QC Cells+Media
D
Gag Pool 2 Gag Pool 6 Gag Pool 10 Nef Pool 2 Matrix 2 Matrix 10 Cells+Media QC CEF
E
Gag Pool 3 Gag Pool 7 Gag Pool 11 Nef Pool 3 Matrix 3 Matrix 11 CEF QC CEF
F
Gag Pool 3 Gag Pool 7 Gag Pool 11 Nef Pool 3 Matrix 4 Matrix 12 CEF QC CEF
G
Gag Pool 4 Gag Pool 8 Gag Pool 12 Nef Pool 3 Matrix 5 Media PHA QC PHA
H
Gag Pool 4 Gag Pool 8 Gag Pool 12 Nef Pool 4 Matrix 6 Media PHA QC PHA
Initials Start Time End Time Initials
PtID Coating ab Blocking : :
Secondary ab O/N incubation : :
Cells/well Streptavidin 2nd Ab : :
NovaRed Streptavidin : :
QC ID Blocking media Nova Red : :
FCS Plate Number
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Appendix A3. The relationship between infecting viral sequences and peptide amino 













Figure A3 The relationship between infecting viral sequences and peptide amino acid 
sequences. Amino acid distances between infecting viral sequences and consensus M peptide 
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Appendix A4 T cell responses to Gag and Nef consensus M reagents in a multiclade 

















Figure A4 T cell responses to Gag and Nef consensus M reagents. HIV-specific T cells were 
detected in 57 individuals from Cameroon (white symbols) and 44 from South Africa (black symbols) 
using the IFN-γ ELISPOT assay. (A) The frequency of responders, (B) the total magnitude of 
responses, and (C) the breadth of responses to Consensus M Gag and Nef peptides in Cameroonian 
and South African infected individuals. The number of responding peptides represents the minimum 
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Appendix B ELISPOT assay using PTE peptides 
Table B1 Peptide pool configuration for the PTE peptide set in Gag  
Pool #                                                                                                                                                                                                                                                                                                                                                                                                                 Peptides in pool
1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
2 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
3 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96
4 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128
5 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160
6 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192
7 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224
8 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256
9 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288
10 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320
11 1 2 3 4 33 34 35 36 65 66 67 97 98 99 129 130 131 161 162 163 193 194 195 225 226 227 257 258 259 289 290 291
12 5 6 7 8 37 38 39 68 69 70 100 101 102 132 133 134 164 165 166 196 197 198 228 229 230 260 261 262 292 293 294 295
13 9 10 11 12 40 41 42 71 72 73 103 104 105 135 136 137 167 168 169 199 200 201 231 232 233 263 264 265 296 297 298 299
14 13 14 15 16 43 44 45 74 75 76 106 107 108 138 139 140 170 171 172 202 203 204 234 235 236 266 267 268 300 301 302 303
15 17 18 19 20 46 47 48 77 78 79 109 110 111 141 142 143 173 174 175 205 206 207 237 238 239 269 270 271 304 305 306 307
16 21 22 23 24 49 50 51 80 81 82 112 113 114 144 145 146 176 177 178 208 209 210 240 241 242 272 273 274 308 309 310 311
17 25 26 27 28 52 53 54 83 84 85 115 116 117 147 148 149 179 180 181 211 212 213 243 244 245 275 276 277 312 313 314 315
18 29 30 31 32 55 56 57 86 87 88 118 119 120 150 151 152 182 183 184 214 215 216 246 247 248 278 279 280 316 317 318 319
19 58 59 60 61 89 90 91 92 121 122 123 124 153 154 155 156 185 186 187 188 217 218 219 220 249 250 251 252 281 282 283 320
20 62 63 64 93 94 95 96 125 126 127 128 157 158 159 160 189 190 191 192 221 222 223 224 253 254 255 256 284 285 286 287 288
21 1 5 9 13 33 37 62 68 71 74 93 103 106 109 138 141 144 173 176 179 208 211 214 243 246 249 278 281 284 289 292 320
22 2 6 10 14 38 58 63 65 72 75 94 104 107 110 139 142 145 174 177 180 209 212 215 244 247 250 279 282 285 290 293 296
23 3 7 11 34 39 43 64 66 73 76 100 111 112 143 146 147 178 181 182 213 216 217 248 251 253 257 283 286 297 300 304 308
24 4 8 12 15 35 40 44 46 67 69 77 101 105 108 140 148 153 175 183 189 205 210 218 240 252 254 275 280 287 309 312 316
25 16 17 29 36 41 45 55 70 78 80 89 97 102 113 132 135 149 167 170 185 206 219 221 241 245 255 258 276 288 291 294 317
26 18 21 25 42 47 59 81 83 90 95 98 114 118 125 129 133 136 164 171 184 199 202 220 234 237 256 259 260 277 295 298 318
27 19 22 26 30 48 49 56 60 84 91 96 99 115 126 130 134 137 168 172 186 203 207 222 225 228 242 261 263 266 301 313 319
28 20 23 27 31 50 52 57 61 79 85 92 119 121 127 131 150 157 161 165 190 196 200 204 226 235 238 262 264 267 299 310 314
29 24 28 32 51 53 82 86 116 120 122 128 151 154 158 162 166 169 187 193 197 201 223 227 229 231 239 265 268 269 302 305 315
30 54 87 88 117 123 124 152 155 156 159 160 163 188 191 192 194 195 198 224 230 232 233 236 270 271 272 273 274 303 306 307 311
31 1 10 23 32 38 40 61 73 74 77 87 108 110 128 146 149 159 170 184 186 207 220 221 225 229 232 257 272 277 290 292 314
32 2 7 15 25 36 37 42 69 71 76 88 105 107 111 145 150 154 172 185 190 194 196 222 237 242 245 269 273 284 315 316 320
33 3 6 31 41 43 54 56 67 68 72 90 106 114 123 139 141 147 175 187 191 195 210 223 226 239 255 260 263 267 310 313 317
34 4 11 22 39 46 52 59 75 79 80 86 101 103 117 130 155 158 161 171 177 203 206 214 228 250 256 265 276 286 289 303 318
35 5 12 21 34 47 53 60 78 82 83 93 100 104 127 140 142 152 176 180 188 193 204 216 230 231 252 264 266 288 291 293 319
36 8 9 16 28 33 44 63 81 85 91 109 115 120 121 134 135 160 174 178 183 199 215 217 227 235 253 258 262 270 295 297 311
37 13 17 24 35 45 48 57 65 92 96 102 112 116 125 136 144 151 163 165 182 202 205 224 233 243 251 259 261 282 296 300 312
38 14 19 27 49 55 58 66 84 94 97 118 124 131 132 137 153 164 169 181 192 197 209 211 236 238 246 268 281 287 298 304 309
39 18 26 29 50 62 70 95 99 113 119 122 129 138 143 156 166 167 173 189 198 201 208 213 234 240 244 275 279 283 299 301 306
40 20 30 51 64 89 98 126 133 148 157 162 168 179 200 212 218 219 241 247 248 249 254 271 274 278 280 285 294 302 305 307 308
Peptides were arranged in pools using the Deconvolution program (Mario Roederer, Vaccine Research Center, NIH). There were a total of 320 
peptides arranged in 40 pools; each pool consisted of 32 peptides and each peptide appeared four times.  Pools were tested singly. 
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Table B2 Peptide pool configuration for the PTE peptide set in Nef  
Pool #
1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
2 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
3 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
4 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
5 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
6 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
7 121 122 123 124 125 126 127
8 1 2 3 21 22 23 41 42 43 61 62 63 81 82 101 102 121 122
9 4 5 6 24 25 26 44 45 46 64 65 83 84 103 104 123 124
10 7 8 9 27 28 29 47 48 49 66 67 85 86 105 106 125 126
11 10 11 12 30 31 32 50 51 52 68 69 87 88 107 108 127
12 13 14 15 33 34 35 53 54 55 70 71 89 90 109 110
13 16 17 18 36 37 38 56 57 58 72 73 91 92 111 112
14 19 20 39 40 59 60 74 75 76 93 94 95 113 114 115
15 77 78 79 80 96 97 98 99 100 116 117 118 119 120
16 1 4 7 21 24 27 44 47 50 68 70 77 89 91 109 111
17 2 5 8 22 25 30 45 48 51 66 69 78 90 92 110 112
18 3 6 9 23 26 31 46 49 52 67 71 79 87 93 101 116
19 10 13 19 28 32 33 41 56 59 61 64 72 83 94 105 117
20 11 14 16 29 34 39 42 53 57 65 74 80 84 95 106 118 121 127
21 12 15 20 35 36 40 43 54 58 62 73 85 88 96 103 113 125
22 17 37 55 60 63 75 81 86 97 102 104 107 119 123 126
23 18 38 76 82 98 99 100 108 114 115 120 122 124
Peptides in pool
 
Peptides were arranged in pools using the Deconvolution program (Mario Roederer, Vaccine Research Center, NIH). There were a total of 120 
peptides arranged in 23 pools; each pool consisted of seven to 20 peptides and each peptide appeared three times.  Pools were tested singly. 
Appendices Page 173 
 
Table B3 ELISPOT plate layout for PTE peptide set  
 
This table shows the ELISPOT layout utilised for those individuals screened for PTE Gag and Nef and HIV-specific T cell responses.  Subsequent 
confirmatory assays were performed on single predicted reactive peptides.      
1 2 3 4 5 6 7 8 9 10 11 12
A
Gag Pool 1 Gag Pool 9 Gag Pool 17 Gag Pool 25 Gag Pool 33 Nef Pool 1 Nef Pool 9 Nef Pool 17 Media QC Cells+Media
B
Gag Pool 2 Gag Pool 10 Gag Pool 18 Gag Pool 26 Gag Pool 34 Nef Pool 2 Nef Pool 10 Nef Pool 18 Cells+MediaQC Cells+Media
C
Gag Pool 3 Gag Pool 11 Gag Pool 19 Gag Pool 27 Gag Pool 35 Nef Pool 3 Nef Pool 11 Neff Pool 19 Cells+MediaQC Cells+Media
D
Gag Pool 4 Gag Pool 12 Gag Pool 20 Gag Pool 28 Gag Pool 36 Nef Pool 4 Nef Pool 12 Nef Pool 20 Cells+MediaQC Cells + CEF
E
Gag Pool 5 Gag Pool 13 Gag Pool 21 Gag Pool 29 Gag Pool 37 Nef pool 5 Nef Pool 13 Nef Pool 21 Cells + CEF QC Cells + CEF
F
Gag Pool 6 Gag Pool 14 Gag Pool 22 Gag Pool 30 Gag Pool 38 Nef Pool 6 Nef Pool 14 Nef Pool 22 Cells + CEF QC Cells + CEF
G
Gag Pool 7 Gag Pool 15 Gag Pool 23 Gag Pool 31 Gag Pool 39 Nef Pool 7 Nef Pool 15 Nef Pool 23 Cells + PHA QC Cells + PHA
H
Gag Pool 8 Gag Pool 16 Gag Pool 24 Gag Pool 32 Gag Pool 40 Nef Pool 8 Nef Pool 16 Media Cells + PHA QC Cells + PHA
Initials Start Time End Time Initials
PtID Coating ab Blocking : :
Secondary ab O/N incubation : :
Cells/well Streptavidin 2nd Ab : :
NovaRed Streptavidin : :
QC ID Blocking media Nova Red : :
FCS Plate Number
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Appendix B4. The correlation between the consensus and PTE ELISPOT responses 
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Figure B4 The correlation between the consensus and PTE ELISPOT responses when exactly 
matched peptides, or peptides shifted by one amino acid, between the two sets were compared PBMC 
(A) and when PBMC were stimulated with the CEF control peptide pool (B).  
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